Therapeutic Goods (Poisons Standard—June 2023) Instrument 2023
I, Benjamin Noyen, as delegate of the Secretary of the Department of Health and Aged Care, make the following instrument.
Dated 25 May 2023
Benjamin Noyen
Assistant Secretary
Regulatory Engagement Branch
Health Products Regulation Group
Department of Health and Aged Care
Contents
Reader’s guide i
Introduction i
Classification iii
Principles of scheduling iv
Reading the schedules v
Availability of poisons vii
Appendices viii
Appendix A (General exemptions) viii
Appendix B (Substances considered not to require control by scheduling) ix
Appendix C (blank) ix
Appendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8) ix
Appendix E (First aid instructions for poisons) ix
Appendix F (Warning statements and general safety directions for poisons) x
Appendix G (Dilute preparations) x
Appendix H (Schedule 3 medicines permitted to be advertised) x
Appendix I (blank) x
Appendix J (Conditions for availability and use of certain poisons included in Schedule 7) x
Appendix K (Human medicines required to be labelled with a sedation warning) x
Appendix L (Requirements for dispensing labels for medicines) x
Appendix M (blank) x
Poisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons xi
Part 1—Preliminary and interpretation 1
1 Name. 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Repeal and transitional provisions............................................................................................ 1
5 Reader’s guide and Index......................................................................................................... 2
6 Definitions................................................................................................................................ 2
7 References to substances........................................................................................................ 10
8 References to concentration, strength or quantity of substances............................................. 11
9 References to boiling or distillation temperatures................................................................... 11
10 References to standards........................................................................................................ 11
Part 2—Controls on substances 12
Division 1—Preliminary 12
11 Application of Part 2............................................................................................................ 12
12 Preparations containing poisons included in different schedules.......................................... 12
Division 2—Labels 13
Subdivision A—General 13
13 General requirements............................................................................................................ 13
14 Immediate wrapper............................................................................................................... 13
Subdivision B—Primary packs and immediate containers 13
15 Primary packs and immediate containers.............................................................................. 13
16 Signal words........................................................................................................................ 14
17 Cautionary statement—possession without authority illegal................................................. 14
18 Cautionary statement—keep out of reach of children........................................................... 15
19 Cautionary statement—fire and explosion hazard................................................................. 15
20 Cautionary statement—burns skin and throat....................................................................... 15
21 Cautionary statements for aqueous solution of paraquat....................................................... 16
22 Cautionary statement—read safety directions....................................................................... 16
23 Cautionary statement—flammable........................................................................................ 17
24 Cautionary statement—for animal treatment only................................................................. 17
25 Cautionary statement—do not swallow................................................................................ 17
26 Approved name and quantity, proportion or strength........................................................... 17
27 Statement—an anticholinesterase compound........................................................................ 18
28 Directions for use................................................................................................................. 18
29 Safety directions................................................................................................................... 19
30 Warning statements.............................................................................................................. 19
31 First aid................................................................................................................................ 20
32 Name and address of manufacturer or distributor................................................................. 20
33 Warning statements and sedation warnings for certain medicines for human use................. 21
Subdivision C—Statements of quantity, proportion or strength 21
34 Statements of quantity, proportion or strength...................................................................... 21
Subdivision D—Exemptions from labelling requirements 22
35 Selected containers and measure packs................................................................................. 22
36 Ampoules, pre‑filled syringes and injection vials................................................................. 23
37 Transport containers and wrappings..................................................................................... 23
38 Dispensary, industrial, laboratory and manufacturing poisons............................................. 23
39 Exemptions from label requirements in certain circumstances.............................................. 24
40 Dispensed medicines............................................................................................................ 24
41 Gas cylinders........................................................................................................................ 24
42 Paints.................................................................................................................................... 24
43 Camphor and naphthalene.................................................................................................... 25
Subdivision E—Prohibitions 25
44 Prohibitions.......................................................................................................................... 25
Division 3—Containers 27
45 General requirements............................................................................................................ 27
46 Containers for poisons other than poisons included in Schedule 5....................................... 27
47 Containers for poisons included in Schedule 5..................................................................... 27
48 Approved containers............................................................................................................ 28
49 Child‑resistant closures........................................................................................................ 28
50 Poisons included in Schedule 8............................................................................................ 30
51 Exemptions........................................................................................................................... 30
52 Camphor and naphthalene.................................................................................................... 31
53 Prohibitions—use of containers for poisons........................................................................ 31
Division 4—Storage 32
54 General storage requirements............................................................................................... 32
Division 5—Disposal 33
55 General disposal requirements.............................................................................................. 33
Division 6—Record keeping 34
56 General record‑keeping requirements................................................................................... 34
Division 7—Advertising 35
57 General advertising requirements......................................................................................... 35
Division 8—Supply, prescribing, possession or use 36
58 Poisons included in Schedule 2............................................................................................ 36
59 Poisons included in Schedule 3............................................................................................ 36
60 Poisons included in Schedule 4............................................................................................ 37
61 Poisons included in Schedules 5 and 6................................................................................. 37
62 Poisons included in Schedule 7............................................................................................ 37
63 Poisons included in Schedule 10.......................................................................................... 38
64 Poisons included in Schedule 4 or 8 and Appendix D......................................................... 38
65 Hawking............................................................................................................................... 39
Division 9—Paints and tinters 40
66 General requirements............................................................................................................ 40
67 Definition of first group paint.............................................................................................. 40
68 Definition of second group paint......................................................................................... 41
Schedule 1—Blank 42
Schedule 2—Pharmacy medicines 43
Schedule 3—Pharmacist only medicines 61
Schedule 4—Prescription only medicines and prescription animal remedies 70
Schedule 5—Caution 173
Schedule 6—Poisons 207
Schedule 7—Dangerous poisons 261
Schedule 8—Controlled drugs 274
Schedule 9—Prohibited substances 279
Schedule 10—Substances of such danger to health as to warrant prohibition of supply and use 287
Appendix A—General exemptions 293
1 Exempt preparations and products........................................................................................ 293
Appendix B—Substances considered not to require control by scheduling 296
1 Reasons for including substances in the table in clause 3..................................................... 296
2 Areas of use in relation to substances included in the table in clause 3................................. 296
3 Substances exempt in certain uses........................................................................................ 298
Appendix C—Blank 306
Appendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8 307
1 Poisons available for human use only from or on the prescription or order of an authorised medical practitioner 307
2 Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist 307
3 Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act....................................................................................................................... 308
4 Poisons available only from or on the order of a specialist physician................................... 308
5 Poisons for which possession without authority is illegal.................................................... 308
6 Poisons available for human use only from or on the prescription or order of a specialist physician 309
7 Poisons available for human use only from or on the prescription or order of a dermatologist 310
8 Poison available for initial treatment of a patient only if authorised by certain health practitioners 310
9 Poisons which must be stored in a locked container to prevent unauthorised access............ 310
Appendix E—First aid instructions for poisons 311
1 Standard statements for first aid instructions........................................................................ 311
2 Poisons information centre contact information in statements.............................................. 312
3 First aid instructions for poisons.......................................................................................... 312
Appendix F—Warning statements and general safety directions for poisons 323
1 Warning statements.............................................................................................................. 323
2 Safety directions—general.................................................................................................... 327
3 Poisons information centre contact information in statements.............................................. 329
4 Poisons that must be labelled with warning statements and safety directions....................... 329
Appendix G—Dilute preparations 344
1 Substances exempt at or below certain concentrations.......................................................... 344
Appendix H—Schedule 3 medicines permitted to be advertised 346
1 Schedule 3 medicines permitted to be advertised.................................................................. 346
Appendix I—Blank 348
Appendix J—Conditions for availability and use of certain poisons included in Schedule 7 349
1 Conditions for supply of certain poisons included in Schedule 7......................................... 349
Appendix K—Human medicines required to be labelled with a sedation warning 352
1 Human medicines required to be labelled with a sedation warning....................................... 352
Appendix L—Requirements for dispensing labels for medicines 357
1 General................................................................................................................................. 357
2 Additional warning statements for certain human medicines................................................ 357
Appendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist 360
Index 361
Reader’s guide
Introduction
This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989 (the Act), and is a compilation of decisions made under section 52D of the Act. This instrument should be read in conjunction with the Scheduling Policy Framework (the SPF) of the Australian Health Ministers’ Advisory Council. Further information on the scheduling amendments and the SPF can be viewed on the Therapeutic Goods Administration’s website (www.tga.gov.au). Refer to section 6 for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine).
This instrument serves 2 key purposes.
Firstly, this instrument contains the decisions of the Secretary of the Department of Health and Aged Care or the Secretary’s delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes.
Secondly, this instrument includes provisions for labelling, containers, storage, disposal, record‑keeping, supply and possession of poisons in general which are intended to be adopted for use in each jurisdiction of Australia. Other government agencies may also impose controls on certain products.
The requirements for labelling and containers in this instrument are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation.
Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in this instrument as they are covered by labelling requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time. Note, however that this exemption does not extend to controls on supply of these poisons.
This instrument is presented with a view to promoting uniform:
· scheduling of poisons throughout Australia; and
· signal headings on labels for poisons throughout Australia; and
· labelling and packaging requirements for poisons throughout Australia; and
· additional controls on the availability and use of poisons in Australia.
The various Commonwealth Acts, legislative instruments and other documents, which integrate with this instrument include the following:
· the Act;
· the Agricultural and Veterinary Chemicals Code Act 1994;
· the Agricultural and Veterinary Chemicals Code Regulations 1995;
· the Therapeutic Goods Order No. 91 ‑ Standard for labels of prescription and related medicines;
· the Therapeutic Goods Order No. 92 ‑ Standard for labels of non‑prescription medicines;
· the Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017;
· the Therapeutic Goods Order No. 95 ‑ Child‑resistant packaging requirements for medicines 2017 (TGO 95);
· the Therapeutic Goods (Standard for Nicotine Vaping Products) (TGO 110) Order 2021;
· the Therapeutic Goods (Medicines Advisory Statements) Specification 2021 – Schedule 1 Required Advisory Statements for Medicine Labels No. 6 (RASML).
Classification
Poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with each relevant State or Territory authority.
| Schedule | Title | Description |
| Schedule 1 | Blank | This Schedule is intentionally blank. |
| Schedule 2 | Pharmacy medicines | Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person. |
| Schedule 3 | Pharmacist only medicines | Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription. |
| Schedule 4 | Prescription only medicines and prescription animal remedies | Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription. |
| Schedule 5 | Caution | Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label. |
| Schedule 6 | Poisons | Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label. |
| Schedule 7 | Dangerous poisons | Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply. |
| Schedule 8 | Controlled drugs | Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence. |
| Schedule 9 | Prohibited substances | Substances which may be abused or misused, the manufacture, possession, supply or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. |
| Schedule 10 (previously Appendix C) | Substances of such danger to health as to warrant prohibition of supply and use | Substances which are prohibited for the purpose or purposes listed for each poison. |
Principles of scheduling
Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.
This instrument lists poisons in 10 Schedules according to the degree of control recommended to be exercised over their availability to the public.
Poisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls.
For some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7. Products for domestic use must not include poisons listed in Schedule 7.
Schedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this instrument, the method by which it is implemented in the States and Territories may vary.
Schedule 10 (previously Appendix C) contains a list of substances or preparations, the supply or use of which should be prohibited because of their known dangerous properties.
Substances in products which have been considered for scheduling, but have been exempted from this instrument, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).
Reading the schedules
Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result, they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.
Firstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned below. Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.
Secondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the 2 different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.
Where exceptions are included in an entry, these have been emphasised by printing the word “except” in bold type.
Where the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this instrument do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply.
Where a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (“reverse scheduling”), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.
Where a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.
It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise (see section 7).
It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, and toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison. However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply.
Finally, when using this instrument to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A, B and the Index. In this process, if the poison is not found under its “approved name” it may be shown under a group term such as:
| Group | Example |
| the parent acid of salts | “oxalic acid” to find sodium oxalate |
| the radical of a salt | “chromates” to find potassium chromate |
| the element | “arsenic” to find arsenic trioxide |
| a chemical group with similar toxicological or pharmacological activity | “hydrocarbons, liquid” to find kerosene |
| a pharmacological group | “anabolic steroidal agents” to find “androsterone” |
Availability of poisons
The purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability.
These Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons. Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.
Inclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It does not:
· indicate that the poison is available; or
· indicate that it is has been approved or is efficacious for any use that may be specified in a Schedule; or
· negate any obligation for registration of therapeutic goods, or agricultural or veterinary chemical product containing that poison.
Appendices
Some substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this instrument. The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them.
| Appendix | Title | Purpose/controls imposed |
| Appendix A | General exemptions | List of preparations and products exempted from this instrument. |
| Appendix B | Substances considered not to require control by scheduling | List of poisons exempted from scheduling. |
| Appendix C | Appendix is intentionally left blank | See Schedule 10. |
| Appendix D | Additional controls on possession or supply of poisons included in Schedule 4 or 8 | List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply. |
| Appendix E | First aid instructions for poisons | First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
| Appendix F | Warning statements and general safety directions for poisons | Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
| Appendix G | Dilute preparations | Concentration cut‑offs for specified poisons, below which the requirements of this instrument do not apply |
| Appendix H | Schedule 3 medicines permitted to be advertised | List of medicines included in Schedule 3 that are permitted to be advertised to the public. |
| Appendix I | Appendix is intentionally left blank | |
| Appendix J | Conditions for availability and use of Schedule 7 poisons | List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use. |
| Appendix K | Human medicines required to be labelled with a sedation warning | List of poisons in medicines for human use required to be labelled with a warning regarding their sedation potential. |
| Appendix L | Requirements for dispensing labels for medicines | Requirements applying to labels attached to medicines at the time of dispensing. |
| Appendix M | Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist Appendix is intentionally left blank and is reserved for future use. | |
Appendix A (General exemptions)
Appendix A lists preparations and products that are exempted from this instrument.
Appendix B (Substances considered not to require control by scheduling)
Substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times.
Inclusion in Appendix B indicates that a decision has been taken not to include substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list (that is, there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non‑hazardous, but have not been considered in relation to the need for scheduling).
Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:
· the toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;
· the use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or
· the public access was limited such that scheduling was inappropriate or unnecessary.
The list of substances included in Appendix B was developed from scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”.
Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.
Applications are considered for scheduling. Applications for inclusion in Appendix B will not be accepted.
Appendix C (blank)
Appendix C is intentionally blank.
Appendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8)
Appendix D lists poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply.
Appendix E (First aid instructions for poisons)
Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. Standard statements have been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in Appendix E may be varied provided that the intent is not changed.
The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non‑toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.
The First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self‑evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.
Appendix F (Warning statements and general safety directions for poisons)
It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.
Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. Warning statements and safety directions have been prepared as a guide for this purpose.
The wording of warning statements and safety directions specified in Appendix F may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.
Appendix G (Dilute preparations)
Appendix G lists concentration cut‑offs for specified substances, below which the requirements of this instrument do not apply.
Appendix H (Schedule 3 medicines permitted to be advertised)
Appendix H lists medicines included in Schedule 3 that are permitted to be advertised to the public.
Appendix I (blank)
Appendix I is intentionally blank.
Appendix J (Conditions for availability and use of certain poisons included in Schedule 7)
All poisons included in Appendix J are not to be available except to authorised or licensed persons.
The use of a poison may be restricted for a particular purpose. Controls recommended for the Schedule 7 poisons included in Appendix J may be implemented through poisons controls or other State or Territory legislation.
Appendix K (Human medicines required to be labelled with a sedation warning)
Medicines for human use that contain a poison included in Appendix K are required to be labelled with a warning regarding their sedation potential.
Appendix L (Requirements for dispensing labels for medicines)
Appendix L sets out the requirements for labels attached to medicines at the time of dispensing.
Appendix M (blank)
Appendix M is intentionally blank and is reserved for future use.
Poisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons
Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.
Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:
1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
2. calls must be logged and submitted for incorporation into the official collection of poisoning data.
Part 1—Preliminary and interpretation
1 Name
(1) This instrument is the Therapeutic Goods (Poisons Standard—June 2023) Instrument 2023.
(2) This instrument may also be cited as the Standard for the Uniform Scheduling of Medicines and Poisons No. 40.
Note: This instrument is the current Poisons Standard for the purposes of the Act until a document is prepared in substitution for it (see sections 52A and 52D of the Act).
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 June 2023. | 1 June 2023 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989.
4 Repeal and transitional provisions
Repeal
(1) The Therapeutic Goods (Poisons Standard—February 2023) Instrument 2023 is repealed.
Saving—things done under the repealed instrument
(2) If:
(a) a thing was done for a particular purpose under the Therapeutic Goods (Poisons Standard—February 2023) Instrument 2023 as in force immediately before that instrument was repealed; and
(b) the thing could be done for that purpose under this instrument;
the thing has effect for the purposes of this instrument as if it had been done for that purpose under this instrument.
(3) Without limiting subsection (2), a reference in that subsection to a thing being done includes a reference to an approval, authorisation, certificate, exemption, requirement or other instrument being given, made, granted or issued.
5 Reader’s guide and Index
(1) The Reader’s guide is not part of this instrument.
(2) The Index is not part of this instrument.
6 Definitions
Note 1: The following expressions used in this instrument are defined in the Act:
(a) current Poisons Standard;
(b) poison;
(c) Register;
(d) Secretary;
(e) supply;
(f) therapeutic goods.
Note 2: The definition of poison in the Act is as follows:
poison means an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury and includes any ingredient, compound, material or preparation referred to in a schedule to the current Poisons Standard.
In this instrument:
Act means the Therapeutic Goods Act 1989.
agricultural chemical means:
(a) a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly:
(i) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing; or
(ii) destroying a plant; or
(iii) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity; or
(iv) modifying an effect of another agricultural chemical; or
(v) attracting a pest for the purpose of destroying it; or
(b) an active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be an agricultural chemical product;
but does not include a veterinary chemical.
agricultural chemical product has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.
animal means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs.
animal feed premix means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.
appropriate authority: each of the following is an appropriate authority:
(a) each person who is the head of the body (however described) in a State or Territory that is responsible for the administration of matters relating to health in that State or Territory;
(b) the Deputy Secretary of the Department with responsibility for the part of the Department known as the Therapeutic Goods Administration, or their delegate;
(c) the Chief Executive Officer of the Australian Pesticides and Veterinary Medicines Authority, or their delegate.
approved name means:
(a) for a poison that is for human therapeutic use—the name for the poison in the Australian Approved Names List within the meaning of the Therapeutic Goods Regulations 1990; or
(b) for a poison that is for animal or agricultural use—the name approved for use by the Australian Pesticides and Veterinary Medicines Authority under the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994; or
(c) for any other poison—the name for the poison mentioned in the first‑occurring of the following paragraphs that applies to the poison:
(i) the name used for the poison in this instrument;
(ii) the name recommended by Standards Australia as the common name for the poison;
(iii) the English name given to the poison by the International Organization for Standardization;
(iv) the name given to the poison by the British Standards Institution;
(v) the English name given to the poison by the European Committee for Standardization (CEN);
(vi) the international non‑proprietary name recommended for the poison by the World Health Organization;
(vii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the International Cosmetic Ingredient Dictionary & Handbook published by the Personal Care Products Council of America;
(viii) the accepted scientific name or the name descriptive of the true nature and origin of the poison.
Australian Dangerous Goods Code means the Australian Code for the Transport of Dangerous Goods by Road & Rail, published by the National Transport Commission, as existing from time to time.
Note: The Australian Dangerous Goods Code could in 2022 be viewed on the Commission’s website (www.ntc.gov.au).
authorised prescriber means any of the following:
(a) a dental practitioner;
(b) a medical practitioner;
(c) a veterinarian;
(d) a person for whom an authorisation, given for the purposes of this paragraph by an appropriate authority, is in effect.
blood means whole blood extracted from human donors.
blood components means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.
child‑resistant closure means:
(a) a closure that complies with the requirements for a child‑resistant closure in Australian Standard AS 1928‑2007, Child‑resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD); or
(b) a closure that complies with the requirements for child‑resistant closures specified in Therapeutic Goods Order No. 95 ‑ Child‑resistant packaging requirements for medicines 2017 (TGO 95); or
(c) a closure that is taken to comply with the requirements mentioned in paragraph (b) under Therapeutic Goods (Standard for Nicotine Vaping Products) (TGO 110) Order 2021; or
(d) in the case of a can fitted with a press‑on lid, a lid of the design known as “double tight” or “triple tight”.
Note: See also the definition of non‑access packaging.
child‑resistant packaging means packaging that:
(a) complies with the requirements of Australian Standard AS 1928‑2007, Child resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD); or
(b) is reclosable and complies with the requirements of at least one of the following:
(i) the International Organization for Standardization Standard ISO 8317:2015, Child‑resistant packaging—Requirements and testing procedures for reclosable packages;
(ii) the British Standards Institution Standard BS EN ISO 8317:2004, Child‑resistant packaging—Requirements and testing procedures for reclosable packages;
(iii) the Canadian Standards Association Standard CSA Z76.1‑06, Reclosable Child‑Resistant Packages;
(iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, Poison prevention packaging standards and Section 1700.20, Testing procedure for special packaging, as in force from time to time; or
(c) a closure that complies with the requirements for child‑resistant packaging specified in Therapeutic Goods Order No. 95 ‑ Child‑resistant packaging requirements for medicines 2017 (TGO 95); or
(d) a closure that is taken to comply with the requirements mentioned in paragraph (c) under Therapeutic Goods (Standard for Nicotine Vaping Products) (TGO 110) Order 2021; or
(e) is in the form of blister or strip packaging:
(i) in which a unit of use is individually protected until the time of release; and
(ii) that complies with section 3 (Requirements for non‑reclosable packages) of Australian Standard AS 1928‑2001, Child‑resistant packages.
Note: See also the definition of non‑access packaging.
compounded in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.
cosmetic means a substance or preparation intended for placement in contact with any external part of the human body, including:
(a) the mucous membranes of the oral cavity; and
(b) the teeth;
with a view to:
(c) altering the odours of the body; or
(d) changing its appearance; or
(e) cleansing it; or
(f) maintaining it in good condition; or
(g) perfuming it; or
(h) protecting it.
debitterised neem seed oil means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.
dental practitioner means a person who is registered, in a State or internal Territory, as a dental practitioner (other than a dental therapist, dental hygienist, dental prosthetist or oral health therapist).
dermal use means application to the skin primarily for localised effect.
designated solvent means the following:
(a) acetone;
(b) dimethylformamide;
(c) N‑(N‑dodecyl)‑2‑pyrrolidone;
(d) hydrocarbons, liquid;
(e) methanol when included in Schedule 5;
(f) methyl ethyl ketone;
(g) methyl isoamyl ketone;
(h) methyl isobutyl ketone;
(i) N‑methyl‑2‑pyrrolidone;
(j) N‑(N‑octyl)‑2‑pyrrolidone;
(k) phenyl methyl ketone;
(l) styrene;
(m) tetrachloroethylene;
(n) 1,1,1‑trichloroethane.
dispensing label, for a substance for therapeutic use, means the label attached to the immediate container of the substance at the time of dispensing.
Note: See section 40 and Appendix L.
distributor means a person who imports or supplies a poison.
divided preparation means a preparation manufactured and packed as discrete pre‑measured dosage units prior to supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.
dosage unit means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.
drug means a poison intended for human or animal therapeutic use.
essential oils means:
(a) products obtained from natural raw materials by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation; or
(b) oils of equivalent composition to products mentioned in paragraph (a) that are derived through synthetic means; or
(c) prepared mixtures of oils of equivalent composition to products mentioned in paragraph (a) that comprise a mixture of synthetic and natural components.
external in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.
first group paint: see section 67.
free formaldehyde includes all hydrated and non‑hydrated formaldehyde present in aqueous solution, including methylene glycol and formaldehyde released from formaldehyde donors.
graphic material means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.
hand sanitiser preparation means an antimicrobial skin care product that:
(a) consists of, contains or generates one or more antimicrobial active substances; and
(b) is represented in any way to be, or is likely to be taken to be (whether because of the way in which it is presented or for any other reason):
(i) for use on hands when soap and water are not available; and
(ii) applied to the hands without rinsing off; and
(iii) intended to destroy, deter, render harmless, prevent the action of, or otherwise exert a controlling effect on any microbes on the skin.
hawking means to supply (including peddle or distribute or cause to be distributed) in a public place.
height in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.
hemp seed oil means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa.
immediate container includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.
immediate wrapper means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.
internal use means administration:
(a) orally, except for topical effect in the mouth; or
(b) for absorption and the production of a systemic effect:
(i) by way of a body orifice other than the mouth; or
(ii) parenterally, other than by application to unbroken skin.
label:
(a) means a written statement on a container of a poison; and
(b) in relation to therapeutic goods, includes a display of printed information about the product:
(i) on, or attached to, the goods; or
(ii) on, or attached to, a container or primary pack in which the goods are supplied; or
(iii) supplied with such a container or pack.
main label, for a container of poison, means:
(a) the part of the label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and
(b) if there are 2 or more labels:
(i) the label or the part of the label where the product name is more or most conspicuously shown; or
(ii) if the product name is equally more or most conspicuously displayed on more than one of those labels—each of the labels on which the product name is equally more or most conspicuously displayed.
manufacturer of a poison means a person who manufactures, produces, or packs a poison.
marker dyes or pigments means any product that is added to a liquid used in agricultural or veterinary chemicals to identify or distinguish treated from untreated objects, land or organisms by temporarily imparting colour on the relevant object, land or organism through, for example, spot‑ or boom‑spraying.
measure pack means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.
medical practitioner means a person who is registered, in a State or internal Territory, as a medical practitioner.
medicine means any poison for therapeutic use.
midwife means a person who is registered, in a State or internal Territory, as a midwife.
non‑access packaging, for a product that is not intended for human therapeutic use, means packaging that complies with the requirements of AS 4710‑2001, Packages for chemicals not intended for access or contact with their contents by humans.
Note: See also the definitions of child‑resistant closure and child‑resistant packaging.
non‑volatile content in relation to a paint or tinter means that portion of a paint or tinter determined to be the non‑volatile content by Method 301.1 of Australian Standard AS 1580‑301.1‑2005, Paints and related materials – Methods of test – Non‑volatile content by mass.
nurse means a person who is registered, in a State or internal Territory, as a nurse.
oromucosal use means administration to the oral mucosa, specifically the oral cavity and/or the pharynx.
paint includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use.
pesticide means any substance or mixture of substances used or intended to be used:
(a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or
(b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non‑agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.
pharmacist means a person who is registered, in a State or internal Territory, as a pharmacist.
primary pack, in relation to a poison, means the pack in which the poison and its immediate container or immediate wrapper or measure pack are presented for supply.
product sample means a packed poison supplied directly to a consumer:
(a) free of charge or for a nominal charge; and
(b) as a mechanism to promote the supply of the product; and
(c) in the form of:
(i) a small pack produced specifically for the purposes of promotion; or
(ii) a normal commercial pack that in other circumstances could be purchased by the consumer.
public place means any place where members of the public are lawfully entitled, invited or permitted to be present in their capacity as members of the public.
Note: Examples of a public place include a street, road, footway, court, alley or thoroughfare that the public may use in any residential premises or to get from door to door, place to place or house to house.
required advisory statements for medicine labels means the Therapeutic Goods (Medicines Advisory Statements) Specification 2021.
restricted flow insert means a restriction:
(a) that is fitted or moulded in the neck of a container; and
(b) that cannot readily be removed from the container by manual force; and
(c) that limits the delivery of the contents of the container to drops each of which is not more than 200 microlitres.
second group paint: see section 68.
selected container means:
(a) an injection vial having a nominal capacity of 10 ml or less; or
(b) a single use syringe; or
(c) any other container for substances for therapeutic use having a nominal capacity of 10 ml or less.
solid includes powder.
substance has the same meaning as in Part 6‑3 of the Act.
Note 1: In general terms, that definition covers an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury to persons or animals.
Note 2: See also section 7.
therapeutic use means use in or in connection with:
(a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals; or
(b) influencing, inhibiting or modifying a physiological process in human beings or animals; or
(c) testing the susceptibility of human beings or animals to a disease or ailment; or
(d) influencing, controlling or preventing conception in human beings or animals; or
(e) testing for pregnancy in human beings or animals; or
(f) the replacement or modification of parts of the anatomy in human beings or animals.
tinter means any pigment or admixture of pigment with other substances, in powder, semi‑solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.
topical use means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.
toy means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of 14 years.
transdermal use means application to the skin primarily for systemic effect.
veterinarian means a person who is registered under the law of a State or Territory as a veterinarian, a veterinary practitioner or a veterinary surgeon.
veterinary chemical means:
(a) a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly:
(i) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest; or
(ii) curing or alleviating an injury suffered by the animal; or
(iii) modifying the physiology of the animal:
(A) so as to alter its natural development, productivity, quality or reproductive capacity; or
(B) so as to make it more manageable; or
(iv) modifying the effect of another veterinary chemical; or
(b) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a); or
(c) any active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be a veterinary chemical product;
but does not include an agricultural chemical.
veterinary chemical product has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.
7 References to substances
In this instrument, unless the contrary intention appears, a reference to a substance includes the following:
(a) that substance prepared from natural sources or artificially;
(b) if the substance is a plant (other than a plant included in Schedule 8 or 9)—that plant or any part of that plant when packed or prepared for therapeutic use;
(c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative;
(d) every alkaloid of the substance and every salt of such an alkaloid;
(e) every stereoisomer of the substance and every salt of such a stereoisomer;
(f) every recombinant form of the substance;
(g) a preparation or admixture containing any proportion of the substance.
Note: Part 2 (controls on substances) does not apply in relation to certain substances (see section 11).
8 References to concentration, strength or quantity of substances
In this instrument, for a reference to a concentration, strength or quantity of a substance:
(a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance; and
(b) the expression “1%” means:
(i) in the case of a liquid preparation, 1 g of the substance per 100 mL of the preparation; or
(ii) in the case of a solid, semi‑solid or pressurised spray aerosol preparation, 1 g of the substance per 100 g of the preparation; and
(iii) any expression of greater or lesser percentages shall have a corresponding meaning; and
(c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine.
9 References to boiling or distillation temperatures
In this instrument, a reference to a boiling or distillation temperature means that temperature at an atmospheric pressure of 101.325 kPa (760 mm of mercury).
10 References to standards
A reference in this instrument to an Australian standard, an international standard or a standard of a foreign country is a reference to that standard as it exists from time to time.
Part 2—Controls on substances
Division 1—Preliminary
11 Application of Part 2
This Part applies to a substance or preparation included in a schedule to this instrument, other than the following:
(a) a preparation or product included in the table in clause 1 of Appendix A;
(b) a substance included in the table in clause 3 of Appendix B when used in an area, sub‑area or sub‑sub‑area of use specified in the table in relation to that substance;
(c) a substance included in the table in clause 1 of Appendix G at a concentration not exceeding the concentration specified in that table in relation to that substance;
(d) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8;
(e) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022, published by the Australian Pesticides and Veterinary Medicines Authority, as existing from time to time.
Note: For paragraph (e), the Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022 is a legislative instrument that could in 2023 be accessed at www.legislation.gov.au.
12 Preparations containing poisons included in different schedules
(1) If a preparation contains 2 or more poisons, the provisions relating to each of the schedules in which those poisons are included apply to the preparation.
(2) However, if it is not possible to comply both with a provision relating to one of those schedules and with a provision relating to another of those schedules, the provision relating to the more restrictive schedule applies, unless a contrary intention is indicated in the schedules or relevant State or Territory legislation.
(3) The Schedules listed in order of greatest to least restrictiveness are 9, 10, 8, 4, 7, 3, 2, 6, 5.
Note: Schedule 1 is not currently in use.
Division 2—Labels
Subdivision A—General
13 General requirements
(1) A poison must not be supplied unless it is labelled in accordance with this Division.
(2) Any word, expression or statement required by this instrument to be written on a label or container must be written:
(a) on the outside face of the label or container; and
(b) in English; and
(c) in durable characters; and
(d) in a colour or colours to provide a distinct contrast to the background colour; and
(e) in letters at least 1.5 mm in height.
(3) Paragraph (2)(e) does not apply to a word, expression or statement on a container which has a capacity of 20 ml or less, or on the label of such a container if:
(a) an appropriate authority approves the use of smaller letters; and
(b) the letters are at least 1 mm in height.
(4) The label must be printed on, or securely attached to:
(a) the outside of the immediate container; and
(b) if the immediate container is enclosed in a primary pack—the outside of that primary pack.
14 Immediate wrapper
If a poison is enclosed in an immediate wrapper:
(a) the poison must be contained in a primary pack labelled in accordance with section 15; and
(b) the immediate wrapper must be conspicuously labelled with:
(i) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and
(ii) the approved name of the poison; and
(iii) a statement of the quantity, proportion or strength of the poison in accordance with section 34.
Subdivision B—Primary packs and immediate containers
15 Primary packs and immediate containers
This Subdivision sets out how the primary pack and immediate container of a poison must be labelled.
16 Signal words
(1) The signal word or words for the poison, as shown in the following table, must be written:
(a) on the first line or lines of the main label; and
(b) in bold‑face sans serif capital letters of uniform thickness; and
(c) subject to subsection (3), in letters at least half the height of the largest letter or numeral on the label; and
(d) with nothing else other than the following written on the same line or lines:
(i) if the poison is included in Schedule 5—a class label as specified in the Australian Dangerous Goods Code or a statement of the principal hazard of the poison;
(ii) if the poison is not included in Schedule 5—a class label as specified in the Australian Dangerous Goods Code.
| Signal word or words for poisons |
| Item | For a poison included in the following schedule … | that is to be used for the following purpose … | the signal word or words are … |
| 1 | Schedule 2 | for any purpose | PHARMACY MEDICINE |
| 2 | Schedule 3 | for any purpose | PHARMACIST ONLY MEDICINE |
| 3 | Schedule 4 | for human use | PRESCRIPTION ONLY MEDICINE |
| 4 | Schedule 4 | for animal use | PRESCRIPTION ANIMAL REMEDY |
| 5 | Schedule 5 | for any purpose | CAUTION |
| 6 | Schedule 6 | for any purpose | POISON |
| 7 | Schedule 7 | for any purpose | DANGEROUS POISON |
| 8 | Schedule 8 | for any purpose | CONTROLLED DRUG |
(2) For the purposes of paragraph (1)(c), the largest letter or numeral does not include:
(a) a single letter or numeral which is larger than other lettering on the label; or
(b) an affix forming part of the trade name for the poison; or
(c) in the case of a poison for therapeutic use—numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.
(3) For the purposes of paragraph (1)(c), the letters need not be larger than:
(a) 6 mm on labels for packages having a nominal capacity of 2 L or less; or
(b) 15 mm on labels for packages having a nominal capacity of more than 2 L.
17 Cautionary statement—possession without authority illegal
If the poison is included in Schedule 8, the cautionary statement:
POSSESSION WITHOUT AUTHORITY ILLEGAL
must be written:
(a) on a separate line or lines immediately below the signal words required by section 16; and
(b) in bold‑face sans serif capital letters of uniform thickness; and
(c) in letters at least four‑tenths the height of the letters used for the signal words; and
(d) with no other statement written on the same line or lines.
18 Cautionary statement—keep out of reach of children
The cautionary statement:
KEEP OUT OF REACH OF CHILDREN
must be written:
(a) on a separate line or lines:
(i) immediately below the signal word or words required by section 16; or
(ii) if the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by section 17—immediately below that statement; and
(b) in bold‑face sans serif capital letters of uniform thickness; and
(c) in letters at least four‑tenths the height of the letters used for the signal word or words; and
(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.
19 Cautionary statement—fire and explosion hazard
(1) If the poison is a dry chlorinating compound containing more than 10% of available chlorine, the cautionary statement:
FIRE AND EXPLOSION HAZARD
must be written:
(a) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and
(b) in bold‑face sans serif capital letters of uniform thickness; and
(c) in letters at least four‑tenths the height of the letters used for the signal word or words; and
(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.
(2) This section does not apply to a preparation certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code.
20 Cautionary statement—burns skin and throat
If the poison is an alkaline salt in a dishwashing machine product, the cautionary statement:
BURNS SKIN AND THROAT
must be written:
(a) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and
(b) in bold‑face sans serif capital letters of uniform thickness; and
(c) in letters at least four‑tenths the height of the letters used for the signal word; and
(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines of the main label.
21 Cautionary statements for aqueous solution of paraquat
If the poison is an aqueous solution of paraquat, the cautionary statements:
CAN KILL IF SWALLOWED
DO NOT PUT IN DRINK BOTTLES
KEEP LOCKED UP
must be written:
(a) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and
(b) in bold‑face sans serif capital letters of uniform thickness; and
(c) in letters at least four‑tenths the height of the letters used for the signal words; and
(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same lines of the main label.
22 Cautionary statement—read safety directions
(1) If safety directions are required on the label by section 29, the following cautionary statement:
READ SAFETY DIRECTIONS BEFORE OPENING OR USING
or the following cautionary statement:
READ SAFETY DIRECTIONS
must be written:
(a) on a separate line or lines:
(i) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; or
(ii) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and
(b) in bold‑face sans serif capital letters of uniform thickness; and
(c) in letters at least four‑tenths the height of the letters used for the signal word or words; and
(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.
(2) This section does not apply to a medicine for human use that is labelled in accordance with the required advisory statements for medicine labels.
23 Cautionary statement—flammable
If the poison meets the criteria for a “flammable liquid” in the Australian Dangerous Goods Code, the cautionary statement:
FLAMMABLE
must be written on the main label in bold‑face sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the Australian Dangerous Goods Code.
24 Cautionary statement—for animal treatment only
If the poison is only for the treatment of animals, the cautionary statement:
FOR ANIMAL TREATMENT ONLY
must be written on the main label in bold‑face sans serif capital letters of uniform thickness.
25 Cautionary statement—do not swallow
If the poison is included in Schedule 5 and is intended for any purpose other than internal or pesticidal use, the cautionary statement:
DO NOT SWALLOW
must be written in sans serif capital letters on the main label or as part of the directions for use.
26 Approved name and quantity, proportion or strength
(1) The approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with section 34 must be:
(a) if the poison is for human therapeutic use—written on the main label in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or
(b) if the poison is not for human therapeutic use—written in bold‑face sans serif capital letters on the main label, unless:
(i) a list of approved names is required; and
(ii) it is impractical to include the list on the main label; and
(iii) it is included on another part of the label in accordance with an authorisation given by an appropriate authority.
(2) If the poison is included in Schedule 5 and is referred to in column 1 of an item of the following table, the appropriate name in column 2 of that item may be used as the approved name.
| Appropriate names for poisons |
| Item | Column 1
Poison | Column 2
Appropriate name |
| 1 | Alkaline salts | Alkaline salts |
| 2 | Amines for use as curing agents for epoxy resins (unless separately specified in the Schedules) | Aliphatic amines or aromatic amines |
| 3 | Epoxy resins, liquid | Liquid epoxy resins |
| 4 | Hydrocarbons, liquid | Liquid hydrocarbons |
| 5 | Quaternary ammonium compounds | Quaternary ammonium compound(s) |
(3) If a poison contains a mixture of designated solvents in excess of 25% of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25%, the approved names of those solvents may be expressed as follows:
(a) where the designated solvent is a liquid hydrocarbon—as “liquid hydrocarbons”;
(b) where the designated solvent is a ketone—as “ketones”;
(c) in any other case—as “solvents” or “other solvents”.
27 Statement—an anticholinesterase compound
(1) If the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, the following expression:
AN ANTICHOLINESTERASE COMPOUND
must be written immediately below the approved name or the list of declared contents on the label.
(2) This section does not apply to:
(a) dazomet, mancozeb, metiram, propineb, thiram, tri‑allate, zineb or ziram; or
(b) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or
(c) an organophosphorus compound or carbamate contained in a pressurised spray pack for household use.
28 Directions for use
If the poison is prepared, packed or sold for a specific purpose, it must be labelled with clear and adequate directions for use, unless:
(a) it is a medicine for human use that is labelled in accordance with:
(i) Therapeutic Goods Order No. 91 ‑ Standard for labels of prescription and related medicines; or
(ii) Therapeutic Goods Order No. 92 ‑ Standard for labels of non‑prescription medicines; or
(b) it is in an agricultural or veterinary chemical product labelled in compliance with the Agricultural and Veterinary Chemicals Code Act 1994; or
(c) it is included in Schedule 4 or 8; or
(d) all of the following apply:
(i) it is impractical to include such directions on the label;
(ii) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”;
(iii) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label;
(iv) the insert is enclosed in the primary pack.
29 Safety directions
(1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each safety direction required for the poison by that clause, grouped together as a distinct section of the label and prefaced by the words:
SAFETY DIRECTIONS
written in bold‑face capital letters.
(2) This section does not apply to the following:
(a) a poison that:
(i) is a medicine for human use; and
(ii) is labelled in accordance with the required advisory statements for medicine labels;
(b) a poison that:
(i) is an agricultural chemical or a veterinary chemical; and
(ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.
30 Warning statements
(1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each warning statement required for the poison by that clause, grouped together:
(a) if safety directions are included on the label—immediately after the words “SAFETY DIRECTIONS”; or
(b) if there are no safety directions—immediately preceding the directions for use.
(2) This section does not apply to the following:
(a) a poison that:
(i) is a medicine for human use; and
(ii) is labelled in accordance with the required advisory statements for medicine labels;
(b) a poison that:
(i) is an agricultural chemical or a veterinary chemical; and
(ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.
31 First aid
(1) If the poison is included in the table in clause 3 of Appendix E, it must be labelled with each statement required for the poison by clause 3 of Appendix E:
(a) grouped together and prefaced by the following words:
FIRST AID
written in bold‑face capital letters; or
(b) if a primary pack contains 2 or more immediate containers of poisons each requiring different first aid instructions:
(i) written on each immediate container as specified in paragraph (a); and
(ii) replaced on the primary pack with the statement:
FIRST AID: See inner packs.
(2) This section does not apply to the following:
(a) a poison that:
(i) is for human internal use; and
(ii) is included in Schedule 3, 4 or 8;
(b) a poison that:
(i) is a medicine for human use; and
(ii) is labelled in accordance with the required advisory statements for medicine labels;
(c) a poison that:
(i) is an agricultural chemical or a veterinary chemical; and
(ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.
32 Name and address of manufacturer or distributor
(1) The poison must be labelled with the name and address of its manufacturer or distributor. The address:
(a) must be a physical address in Australia; and
(b) must not be a post office, cable, telegraphic or code address.
(2) However, if the manufacturer or distributor is a company incorporated under the law of a State or Territory, or a firm registered under a law of a State or Territory dealing with business names, the name and address may be:
(a) the registered name of the corporation or firm, or its branch or division; and
(b) the city or town in which a registered office of the company or firm is situated.
33 Warning statements and sedation warnings for certain medicines for human use
Warning statements for certain medicines
(1) A dispensed medicine for human use containing a poison included in column 1 of the table in clause 2 of Appendix L must be clearly labelled with each warning statement required for the poison by that clause.
Sedation warning for certain medicines
(2) A dispensed medicine for human use containing a poison included in Appendix K must be clearly labelled with a warning statement set out in item 39, 40 or 90 of the table in clause 1 of Appendix F.
Subdivision C—Statements of quantity, proportion or strength
34 Statements of quantity, proportion or strength
(1) The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:
(a) if the poison is for human therapeutic use—the manner required by the standards for the goods specified in orders made under subsection 10(1) of the Act;
(b) if the poison is for a purpose or purposes other than human therapeutic use—as follows:
(i) if the poison is in a pressurised spray aerosol preparation—as the mass of the poison per stated mass of the preparation;
(ii) if the poison is a liquid in a liquid preparation—as the mass or volume of the poison per stated volume of the preparation;
(iii) if the poison is a liquid in a solid or semi‑solid preparation—as the mass or volume of the poison per stated mass of the preparation;
(iv) if the poison is a solid or semi‑solid in a liquid preparation—as the mass of the poison per stated volume of the preparation;
(v) if the poison is a solid or semi‑solid in a solid or semi‑solid preparation—as the mass of the poison per stated mass of the preparation;
(vi) if the poison is a gas in a liquid preparation—as the mass of the poison per stated volume of the preparation;
(vii) if the poison is a gas in a solid or semi‑solid preparation—as the mass of the poison per stated mass of the preparation;
(viii) if the poison is a gas in a gaseous preparation—as the mass of the poison per stated mass of the preparation;
(c) if the poison is a solution of a mineral acid, the proportion of the acid (un‑neutralised by any bases present in the preparation) in a preparation may be expressed as the un‑neutralised mass of the acid per stated mass of the preparation;
(d) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:
(i) “contains not more than 10 per cent of (insert name of the metal)”;
(ii) “contains not more than 30 per cent of (insert name of the metal)”;
(iii) “contains more than 30 per cent of (insert name of the metal)”;
(e) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5% of the product;
(f) if the poison is a lead‑based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non‑volatile content of the paint;
(g) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.
(2) In paragraph (1)(g):
derivative includes alkaloid.
Note: For requirements to state the quantity, proportion or strength of a poison, see subparagraph 14(b)(iii), section 26 and sub‑subparagraphs 35(b)(ii)(B) and 36(1)(b)(ii)(A) and (2)(b)(iii)(B).
Subdivision D—Exemptions from labelling requirements
35 Selected containers and measure packs
The requirements of Subdivision B do not apply to an immediate container of poison that is a measure pack or a selected container (other than an ampoule, a pre‑filled syringe or an injection vial to which subsections 36(1) or (2) applies) if:
(a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or
(b) the immediate container is:
(i) packed in a primary pack labelled in accordance with Subdivision B; and
(ii) labelled with:
(A) the signal word or words for the poison as shown in the table in subsection 16(1); and
(B) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and
(C) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and
(D) if the poison is only for the treatment of animals—the cautionary statement:
FOR ANIMAL TREATMENT ONLY
written in sans serif capital letters.
36 Ampoules, pre‑filled syringes and injection vials
(1) The requirements of Subdivision B do not apply to a selected container of poison or an ampoule of poison (other than an ampoule to which subsection (2) applies) when:
(a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or
(b) the selected container or ampoule is:
(i) packed in a primary pack labelled in accordance with Subdivision B; and
(ii) labelled with:
(A) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and
(B) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and
(C) if the poison is only for the treatment of animals—the cautionary statement:
FOR ANIMAL TREATMENT ONLY
written in sans serif capital letters.
(2) The requirements of Subdivision B do not apply to a selected container of poison that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:
(a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or
(b) the poison is not therapeutic goods and all of the following apply:
(i) the ampoule is packed in a primary pack labelled in accordance with Subdivision B;
(ii) the strip is labelled in accordance with this section;
(iii) the ampoule is labelled with:
(A) the approved name of the poison or the trade name of the poison; and
(B) the quantity, proportion or strength of the poison in accordance with section 34.
37 Transport containers and wrappings
The labelling requirements of this instrument do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.
38 Dispensary, industrial, laboratory and manufacturing poisons
The labelling requirements of this instrument do not apply to a poison that:
(a) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and
(b) is labelled in accordance with requirements under applicable jurisdictional work health and safety laws, as in force from time to time.
39 Exemptions from label requirements in certain circumstances
(1) A requirement specified in Subdivision B or section 35 or 37 does not apply to a poison if an appropriate authority has granted a labelling exemption under this subsection in relation to that requirement for the poison.
(2) A labelling exemption granted by an appropriate authority under subsection (1) remains in force:
(a) if the exemption relates to a product that is indicated for the treatment or prevention of the coronavirus known as COVID‑19:
(i) for the period specified in the exemption; or
(ii) if no period is specified—until revoked by the appropriate authority; or
(b) in any other case:
(i) for the period, specified in the exemption, that is 12 months or less from the date of commencement of the exemption; or
(ii) if no period is specified—12 months from the date of commencement of the exemption.
(3) For the avoidance of doubt, this section does not apply to an authorisation given under subparagraph 28(d)(iii).
40 Dispensed medicines
Unless otherwise specified in relevant State or Territory legislation and subject to section 33, the labelling requirements of this instrument do not apply to a medicine that:
(a) is:
(i) supplied by an authorised prescriber; or
(ii) supplied on and in accordance with a prescription written by an authorised prescriber; or
(iii) prepared and supplied by a pharmacist for an individual patient; and
(b) is labelled in accordance with the requirements of clause 1 of Appendix L.
41 Gas cylinders
The requirements of paragraph 16(1)(d) and paragraphs 18(d) and 22(1)(d) do not apply to a cylinder containing a poison that is a compressed gas.
42 Paints
The requirements of Subdivision B do not apply to:
(a) a paint (other than a paint for therapeutic or cosmetic use) that contains only poisons included in Schedule 5; or
(b) a first group paint or second group paint that is labelled with:
(i) the word “WARNING”, written in bold‑face sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and
(ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold‑face sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and
(iii) the appropriate warnings required for the paint by clause 4 of Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and
(iv) the name and proportion of the first group or second group poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non‑volatile content” or “in the dried film” of the paint; or
(c) a tinter which contains only poisons included in Schedule 5; or
(d) a tinter that contains a poison mentioned in a table in section 67 or 68, if:
(i) the tinter is labelled with the name and proportion of the poison; and
(ii) if the poison is a metal or metal salt—the proportion is expressed as the metallic element present as “calculated on the non‑volatile content” or “in the dried film”.
43 Camphor and naphthalene
The labelling requirements of paragraph 13(2)(d) and Subdivision B do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:
(a) complies with section 52; and
(b) is sold or supplied in a primary pack labelled in accordance with section 13 and Subdivision B.
Subdivision E—Prohibitions
44 Prohibitions
(1) A label used in connection with a poison must not include:
(a) any reference to this instrument, or any comment on, reference to, or explanation of any expression required by this instrument that directly or by implication contradicts, qualifies or modifies such expression; or
(b) any expression or device suggesting or implying that the poison is safe, harmless, non‑toxic, non‑poisonous, or is recommended or approved by a government or government authority unless required by legislation; or
(c) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or
(d) any trade name or description that:
(i) represents any single constituent of a compound preparation; or
(ii) misrepresents the composition or any property or quality of the poison; or
(iii) gives any false or misleading indication of origin or place of manufacture of the poison.
(2) A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure any of the ribs or any expression required by this instrument to be written or embossed on the container or pack.
Division 3—Containers
45 General requirements
A poison must not be supplied unless the requirements of this Division for the immediate container for the poison are met.
46 Containers for poisons other than poisons included in Schedule 5
(1) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of 2 L or less, the container must comply with Australian Standard AS 2216‑1997, Packaging for poisonous substances.
(2) Despite subsection (1), a poison included in Schedule 6 that is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216‑1997, Packaging for poisonous substances, if:
(a) other safety factors are not diminished; and
(b) the container has a restricted flow insert and a child‑resistant closure.
(3) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of more than 2 L:
(a) the container must comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216‑1997, Packaging for poisonous substances; and
(b) the word “POISON” must be embossed, or indelibly written in a colour in distinct contrast to the background colour, on the side or shoulder of the container, in sans serif capital letters the height of which is at least one thirty‑second part of the length, height or width of the container, whichever is the greatest.
47 Containers for poisons included in Schedule 5
(1) The container in which a poison included in Schedule 5 is supplied must:
(a) comply with the container requirements of subsection 46(1) or (3); or
(b) comply with subsection (2).
(2) A container complies with this subsection if:
(a) it is readily distinguishable from a container in which food (including a condiment) or drink is sold; and
(b) it complies with subsection 1.4 (General Requirements) of Australian Standard AS 2216‑1997, Packaging for poisonous substances, excluding paragraph 1.4.3; and
(c) it is securely closed and, except when containing a preparation for use on one occasion only, is capable of being re‑closed to prevent spillage of its contents; and
(d) the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” is:
(i) embossed or indelibly written on the container; or
(ii) printed on a label that complies with subsection (3) that is attached to the container.
(3) For the purposes of subparagraph (2)(d)(ii), the label must be a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.
(4) Despite subsection (1), the following poisons included in Schedule 5:
(a) methylated spirit(s);
(b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;
(c) petrol;
(d) toluene;
(e) xylene;
must not be supplied in a bottle or jar having a nominal capacity of 2 L or less, unless the immediate container complies with the container requirements of subsection 46(1).
48 Approved containers
Despite subsections 46(1) and (3) and section 47, a poison may be packed in a container that does not comply with the tactile identification requirements of AS2216‑1997 (Packaging for poisonous substances) or the requirements of paragraph 46(3)(b) or 47(2)(d) if:
(a) other safety factors are not diminished; and
(b) the container is for a specific purpose; and
(c) an appropriate authority has approved the use of the container for that purpose.
49 Child‑resistant closures
(1) If a poison specified in column 1 of an item of the following table is supplied in a container having a nominal capacity specified in column 2 of the item, it must be closed with a child‑resistant closure that:
(a) is appropriate for the container and the poison; and
(b) will retain its child‑resistant properties for the expected life of the poison.
| Poisons that must be closed with a child‑resistant closure |
| Item | Column 1
Poison | Column 2
Nominal capacity of container |
| 1 | Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine tablets | All sizes |
| 2 | Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine liquids, solids or gels | 5 L/kg or less |
| 3 | Alkaline salts included in Schedule 5, when packed and labelled as a food additive | 2.5 L or less |
| 4 | Anise oil when included in Schedule 5 | 200 mL or less |
| 5 | Basil oil when included in Schedule 5 | 200 mL or less |
| 6 | Bay oil when included in Schedule 6 | 200 mL or less |
| 7 | Cajuput oil when included in Schedule 6 | 200 mL or less |
| 8 | Cassia oil when included in Schedule 5 | 200 mL or less |
| 9 | Cineole when included in Schedule 6 | 2 L or less |
| 10 | Cinnamon bark oil when included in Schedule 5 | 200 mL or less |
| 11 | Cinnamon leaf oil when included in Schedule 6 | 200 mL or less |
| 12 | Clove oil when included in Schedule 6 | 200 mL or less |
| 13 | CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) when included in Schedule 6, when presented in a wipe | All sizes |
| 14 | Essential oils when included in Schedule 6 because of their natural camphor component | 200 mL or less |
| 15 | Ethylene glycol when included in Schedule 6 | 5 L or less |
| 16 | Ethylene glycol when included in Schedule 5 in preparations containing more than 50% of ethylene glycol | 5 L or less |
| 17 | Eucalyptus oil when included in Schedule 6 | 2 L or less |
| 18 | Eugenol when included in Schedule 6 | 200 mL or less |
| 19 | Fennel oil when included in Schedule 5 | 200 mL or less |
| 20 | Hydrocarbons, liquid, when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid | 5 L or less |
| 21 | Hydrochloric acid when included in Schedule 6 | 5 L or less |
| 22 | Leptospermum scoparium oil (manuka oil) when included in Schedule 6 | 200 mL or less |
| 23 | Marjoram oil when included in Schedule 5 | 200 mL or less |
| 24 | Melaleuca oil (tea‑tree oil) when included in Schedule 6 | 200 mL or less |
| 25 | Methylated spirit excluding preparations or admixtures | 5 L or less |
| 26 | Methyl salicylate and preparations containing more than 50% of methyl salicylate | 200 mL or less |
| 27 | Nicotine in liquid preparations when included in Schedule 4. | All sizes |
| 28 | Nutmeg oil when included in Schedule 5 | 200 mL or less |
| 29 | Oil of turpentine | 5 L or less |
| 30 | Paracetamol included in Schedule 4, when packed and labelled for the treatment of animals | All sizes |
| 31 | Pennyroyal oil when included in Schedule 6 | 200 mL or less |
| 32 | Potassium hydroxide as such | 2.5 L or less |
| 33 | Potassium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs | 5 L or less |
| 34 | D‑Pulegone when included in Schedule 6 | 200 mL or less |
| 35 | Sage oil (Dalmatian) when included in Schedule 6 | 200 mL or less |
| 36 | Sodium hydroxide as such | 2.5 L or less |
| 37 | Sodium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs | 5 L or less |
| 38 | Thujone when included in Schedule 6 | 200 mL or less |
| 39 | Thyme oil when included in Schedule 5 | 200 mL or less |
(2) This section does not apply to a poison included in therapeutic goods that are packaged in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act.
50 Poisons included in Schedule 8
(1) If a poison included in Schedule 8 is supplied, it must be packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.
(2) This paragraph does not apply to the supply of a poison included in Schedule 8:
(a) by an authorised prescriber or other authorised supplier; or
(b) by a pharmacist on the prescription of an authorised prescriber; or
(c) by a pharmacist employed at a hospital, on the written requisition of:
(i) a medical practitioner or dental practitioner; or
(ii) the nurse or midwife in charge of the ward in which the poison is to be used or stored; or
(d) by a nurse or midwife on the direction in writing of an authorised prescriber.
51 Exemptions
(1) Subsections 46(1) and (3) and section 47 do not apply to the immediate container of a poison prepared, packed and sold:
(a) for human internal or animal internal use; or
(b) as a solid or semi‑solid preparation for human external or animal external use; or
(c) as a paint, other than a paint for therapeutic or cosmetic use; or
(d) in containers having a nominal capacity of 15 mL or less; or
(e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or
(f) solely for dispensary, industrial, laboratory or manufacturing purposes.
(2) Section 49 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.
(3) The tactile identification or embossing required by subsections 46(1) and (3) and section 47 or Australian Standard AS 2216‑1997, Packaging for poisonous substances, do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.
52 Camphor and naphthalene
(1) The container requirements of subsection 46(1) do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device:
(a) in normal use, prevents removal or ingestion of its contents; and
(b) is incapable of reacting with the poison; and
(c) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and
(d) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it.
(2) Camphor or naphthalene must not be supplied in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents.
53 Prohibitions—use of containers for poisons
(1) A poison must not be supplied in a container that is embossed or indelibly marked with the name of another poison.
(2) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply a poison for internal use.
(3) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply food (including a condiment) or drink.
(4) A poison must not be supplied in a container that is not readily distinguishable from a container in which food (including a condiment) or drink is sold.
Division 4—Storage
54 General storage requirements
Poisons included in Schedule 2
(1) A poison included in Schedule 2 that is stored at premises for supply to the public must be stored in such a way that public access to advice from a pharmacist is available if required.
Poisons included in Schedules 3 and 4
(2) A poison included in Schedule 3 or 4 that is stored at premises for supply to the public must be stored in a part of the premises to which the public does not have access.
Poisons included in Schedule 6
(3) A poison included in Schedule 6 that is stored at premises for supply by way of retail sale must be stored in such a way as to prevent access by children.
Poisons included in Schedule 7
(4) A poison included in Schedule 7 that is stored at premises for supply by retail sale must be stored in an area of the premises, and in a manner, that allows physical access only by the following:
(a) the owner of the retail establishment;
(b) an employee of the owner;
(c) a person who is legally permitted to purchase the poison and is under the supervision of the owner or an employee of the owner.
Division 5—Disposal
55 General disposal requirements
A poison included in Schedule 5, 6 or 7 must not be disposed of in any place or manner that constitutes or is likely to constitute a risk to public health or safety.
Note: Controls on the disposal of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.
Division 6—Record keeping
56 General record‑keeping requirements
(1) If a poison included in Schedule 7 is supplied, a record of the following must be kept:
(a) the name and address of the supplier and of the purchaser;
(b) the date of the order and supply;
(c) the approved name or trade name of the poison;
(d) the quantity supplied or sold;
(e) if an authorisation is required for purchase of the poison under the law of the jurisdiction in which the purchaser purchases the poison—proof that the purchaser has the required authorisation.
(2) The records mentioned in subsection (1) must be kept for at least 5 years.
Note: Controls on record keeping for the supply of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.
Division 7—Advertising
57 General advertising requirements
Poisons included in Schedule 3, 4 and 8
(1) A reference to a poison included in:
(a) Schedule 3, unless included in Appendix H; or
(b) Schedule 4; or
(c) Schedule 8;
must not be included in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.
Poisons included in Schedules 9 and 10
(2) A reference to a poison included in Schedule 9 or Schedule 10 must not be included in any advertisement.
Note: Schedule 10 includes poisons previously listed in Appendix C.
Division 8—Supply, prescribing, possession or use
58 Poisons included in Schedule 2
(1) A poison included in Schedule 2 must not be supplied by a person other than:
(a) a person who:
(i) is a pharmacist (or an assistant under the direction of a pharmacist) or a medical practitioner, dental practitioner or veterinarian; and
(ii) is acting in the lawful practice of the person’s profession; or
(b) a person who is licensed to supply the poison under the law of the jurisdiction from which the person will supply the poison.
(2) A person is not eligible to be granted a licence to supply a poison included in Schedule 2 unless:
(a) the person is carrying on the business of supplying goods by retail sale; and
(b) the premises from which the poison will be supplied is more than 25 km by the shortest practicable route from the nearest pharmacy; and
(c) if required by the law of the jurisdiction from which the person will supply the poison—the person produces evidence that the person is a fit and proper person to be so licensed.
(3) Subsection (1) does not apply to the supply of a poison included in Schedule 2 by way of wholesale dealing to:
(a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or
(b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.
59 Poisons included in Schedule 3
(1) A poison included in Schedule 3 must not be supplied by a person other than a person who:
(a) is a pharmacist, medical practitioner, dental practitioner or veterinarian; and
(b) is acting in the lawful practice of the person’s profession.
(2) The following requirements apply if a poison included in Schedule 3 is supplied:
(a) adequate instructions for use, either written or verbal, must be provided at the time of supply;
(b) the container of the poison must be labelled with:
(i) the name of the supplier or the name of the pharmacy (as applicable); and
(ii) the address from which it was supplied;
(c) if required by the law of the jurisdiction from which the supplier supplies the poison—a record of the transaction must be made in a prescription book or other approved recording system.
(3) This section does not apply to the supply of a poison included in Schedule 3 by way of wholesale dealing to:
(a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or
(b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.
60 Poisons included in Schedule 4
(1) A poison included in Schedule 4 must not be supplied by a person other than:
(a) a person who:
(i) is a medical practitioner, dental practitioner or veterinarian; and
(ii) is acting in the lawful practice of the person’s profession; or
(b) a pharmacist dispensing a legal prescription for the poison; or
(c) a pharmacist supplying the poison without a prescription as permitted by subsection (2).
(2) A poison included in Schedule 4 may be supplied to a person (the patient) by a pharmacist without a prescription if:
(a) the poison is not excepted from this provision by the law of the jurisdiction from which the pharmacist supplies the poison; and
(b) the patient is under medical treatment with the poison and continuation of medication is essential; and
(c) the quantity supplied does not exceed 3 days’ medication; and
(d) the pharmacist is satisfied that an emergency exists.
(3) Subsection (1) does not apply to the supply of a poison included in Schedule 4 by way of wholesale dealing to:
(a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or
(b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.
61 Poisons included in Schedules 5 and 6
(1) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in any manner unless the recipient has the opportunity to refuse at the time of supply.
(2) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in an unsolicited manner (for example by post or by attaching the sample to another product).
(3) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in a manner that does not promote disposal in accordance with Division 5.
62 Poisons included in Schedule 7
Possession or use for domestic or domestic garden purposes prohibited
(1) A poison included in Schedule 7 must not be possessed or used for domestic or domestic garden purposes.
Supply for domestic or domestic garden purposes prohibited
(2) A poison included in Schedule 7 must not be supplied for domestic or domestic garden purposes.
Supply of liquid preparations containing paraquat
(3) A poison included in Schedule 7 that is a liquid preparation containing paraquat must not be supplied unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell.
Supply if authorisation required by appropriate authority
(4) A poison included in Schedule 7 for which an authorisation to purchase, possess or use is required by the appropriate authority must not be supplied unless the purchaser produces the required authorisation.
Product samples prohibited
(5) A product sample containing a poison included in Schedule 7 must not be supplied.
Supply of poisons included in Appendix J
(6) A poison included in Schedule 7 that is included in the table in clause 1 of Appendix J may be supplied only in accordance with that clause.
63 Poisons included in Schedule 10
A poison included in Schedule 10 must not be possessed, supplied or used for a purpose indicated in relation to that poison in Schedule 10.
Note: Schedule 10 includes poisons previously listed in Appendix C.
64 Poisons included in Schedule 4 or 8 and Appendix D
(1) This section applies to a poison included in Schedule 4 or 8.
Supply or prescribing
(2) A poison included in a table in clause 1, 2, 3, 4, 6 or 7 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with the clause that contains the table.
(3) A poison referred to in clause 8 or 10 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with clause 8 or 10 (as applicable) of Appendix D.
Possession
(4) A poison included in the table in clause 5 of Appendix D must not be possessed by a person without authority under the law of the jurisdiction in which the possession occurs.
Storage
(5) A poison included in the table in clause 9 of Appendix D must be stored in a locked container to prevent unauthorised access.
65 Hawking
A poison included in Schedule 7 must not be supplied by way of hawking.
Note: Controls on supply by way of hawking of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.
Division 9—Paints and tinters
Note: Paints and tinters are poisons that were previously listed in Appendix I.
66 General requirements
(1) A first group paint must not be manufactured, supplied or used for application to:
(a) a roof or any surface to be used for the collection or storage of potable water; or
(b) furniture; or
(c) any fence, wall, post, gate or building (interior or exterior) other than a building that is used exclusively for industrial purposes or mining or as an oil terminal; or
(d) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.
(2) An anti‑fouling or anti‑corrosive paint containing more than 0.1% lead (the proportion of lead for the purposes of this section is calculated as a percentage of the element present in the non‑volatile content of the paint) must not be manufactured, supplied or used.
(3) A paint (other than an anti‑fouling or anti‑corrosive paint) or tinter containing more than 0.009% lead (calculated as a percentage of the element present in the non‑volatile content of the paint) must not be manufactured, supplied or used.
(4) A paint for application to toys must not be manufactured, supplied or used unless it complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012, Safety of toys Part 3: Migration of certain elements (ISO 8124‑03:2010, MOD), published jointly by, or on behalf of, Standards Australia and Standards New Zealand.
(5) A paint or tinter containing a pesticide other than a fungicide, algaecide, bactericide or antifouling agent must not be manufactured, supplied or used.
67 Definition of first group paint
A paint containing a substance mentioned in column 1 of an item in the following table in the proportion (calculated as a percentage of the element present in the non‑volatile content of the paint) specified in column 2 of the item is a first group paint.
| First group paints |
| Item | Column 1
Substance | Column 2
Proportion |
| 1 | ANTIMONY or antimony compounds other than antimony titanate pigments | more than 5% |
| 2 | BARIUM salts except barium sulfate or barium metaborate | more than 5% |
| 3 | CADMIUM or cadmium compounds | more than 0.1% |
| 4 | CHROMIUM as chromates of ammonia, barium, potassium sodium, strontium or zinc | more than 5% |
| 5 | SELENIUM or selenium compounds | more than 0.1% |
68 Definition of second group paint
A paint containing a substance mentioned in column 1 of an item in the following table in the proportion specified in column 2 of the item is a second group paint.
| Second group paints |
| Item | Column 1
Substance | Column 2
Proportion |
| 1 | DICHLOROMETHANE (methylene chloride) | more than 5% by weight |
| 2 | ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates | more than 10% by volume |
| 3 | HEXYLOXYETHANOL | more than 10% by volume |
| 4 | TOLUENE | more than 50% by volume |
| 5 | XYLENE | more than 50% by volume |
Schedule 1—Blank
Note: Schedule 1 is intentionally blank.
Schedule 2—Pharmacy medicines
Note: See section 16, subsection 54(1) and section 58.
ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) for therapeutic use.
ACETYLCYSTEINE in preparations for oral use except when labelled with a recommended daily dose of 1 g or less of acetylcysteine.
ACONITUM spp. for therapeutic use in adults:
(a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids; or
(b) in preparations for dermal use containing 0.02% or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids.
ALIMEMAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day‑night pack containing alimemazine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
except in preparations for the treatment of children under 2 years of age.
ALOXIPRIN.
AMOROLFINE in preparations for topical use except in preparations for the treatment of tinea pedis.
ANTAZOLINE in eye drops.
ASPIRIN except when:
(a) included in Schedule 4, 5 or 6; or
(b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:
(i) enclosed in a primary pack that contains 12 or less individually wrapped powders or sachets of granules; and
(ii) compliant with the requirements of the required advisory statements for medicine labels; or
(c) in tablets or capsules containing aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:
(i) either:
(A) packed in blister or strip packing; or
(B) in a container with a child-resistant closure; and
(ii) either:
(A) in a primary pack that contains not more than 25 tablets or capsules, each containing 325 mg or less of aspirin; or
(B) in a primary pack that contains not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; or
(C) in a primary pack that contains not more than 100 tablets or capsules, each containing 100 mg or less of aspirin, and that is labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and
(iii) compliant with the requirements of the required advisory statements for medicine labels.
ATROPA BELLADONNA (belladonna):
(a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or
(b) for oral use:
(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
ATROPINE (excluding atropine methonitrate) for oral use:
(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
AZELAIC ACID in dermal preparations.
AZELASTINE:
(a) in preparations for nasal use; or
(b) in topical eye preparations containing 0.05% or less of azelastine.
BECLOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of beclometasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
BENZOCAINE in preparations for topical use other than eye drops:
(a) containing 10% or less of total local anaesthetic substances, except in dermal preparations containing 2% or less of total local anaesthetic substances; or
(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10% or less of benzoyl peroxide except in preparations containing 5% or less of benzoyl peroxide.
BENZYDAMINE in preparations for topical use, except:
(a) in preparations for dermal use; or
(b) in divided topical oral preparations containing 3 mg or less of benzydamine; or
(c) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.
BEPHENIUM SALTS.
BIFONAZOLE in preparations for dermal use except:
(a) in preparations containing 1% or less of bifonazole for the treatment of the scalp; or
(b) in preparations for the treatment of tinea pedis.
BRIMONIDINE in ophthalmic preparations for adult use containing not more than 0.025% of brimonidine.
BROMHEXINE.
BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day‑night pack containing brompheniramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
except in preparations for the treatment of children under 2 years of age.
BUDESONIDE in aqueous nasal sprays delivering 64 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
CARBETAPENTANE except in preparations containing 0.5% or less of carbetapentane.
CARBOCISTEINE.
CETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:
(a) in a primary pack containing not more than 10 days’ supply; and
(b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.
CHLOPHEDIANOL.
CHLORBUTANOL for human use in topical preparations containing 5% or less of chlorbutanol except in preparations containing 0.5% or less of chlorbutanol.
CHLOROFORM in preparations for therapeutic use except:
(a) when included in Schedule 4; or
(b) in preparations containing 0.5% or less of chloroform.
CHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day‑night pack containing chlorphenamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
except in preparations for the treatment of children under 2 years of age.
CICLOPIROX:
(a) in preparations for dermal use containing 2% or less of ciclopirox except in preparations for the treatment of tinea pedis; or
(b) in preparations for application to the nails containing 8% or less of ciclopirox.
CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5% or less of total local anaesthetic substances.
CINNAMEDRINE.
CLOTRIMAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.
CREOSOTE derived from wood other than beechwood for human therapeutic use, except in preparations containing 10% or less of creosote derived from wood other than beechwood.
DATURA spp. for oral use:
(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;
except when separately specified in these Schedules.
DATURA STRAMONIUM (stramonium) for oral use when:
(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;
except for smoking or burning.
DATURA TATULA (stramonium) for oral use:
(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;
except for smoking or burning.
DELPHINIUM STAPHISAGRIA except in preparations containing 0.2% or less of Delphinium staphisagria.
DESLORATADINE in preparations for oral use.
DEXCHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day‑night pack containing dexchlorphenamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
except in preparations for the treatment of children under 2 years of age.
DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.
DIBROMOPROPAMIDINE for ophthalmic use.
DICLOFENAC when:
(a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac; or
(b) in preparations for dermal use containing 4% or less of diclofenac except in preparations for dermal use containing 2% or less of diclofenac or for the treatment of solar keratosis; or
(c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.
DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.
DIPHENHYDRAMINE in oral preparations:
(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or
(b) when combined with one or more other therapeutically active substances when:
(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(ii) in a day‑night pack containing diphenhydramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
except in preparations for the treatment of children under 2 years of age.
DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day‑night pack containing doxylamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
except in preparations for the treatment of children under 2 years of age.
DUBOISIA LEICHHARDTII for oral use:
(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
DUBOISIA MYOPOROIDES for oral use:
(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
ECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis.
ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply.
ETAFEDRINE.
ETHER for therapeutic use except:
(a) when included in Schedule 4; or
(b) in preparations containing 10% or less of ether.
ETHYLMORPHINE when:
(a) compounded with one or more other therapeutically active substances:
(i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or
(ii) in undivided preparations containing 0.25% or less of ethylmorphine; and
(b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.
ETOFENAMATE in preparations for external use.
FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply.
FELBINAC in preparations for external use.
FEXOFENADINE in preparations for oral use except in divided preparations:
(a) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
(i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and
(ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or
(b) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
(i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and
(ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or
(c) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:
(i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and
(ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.
FLUORIDES for human use:
(a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or
(b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child‑resistant closure:
(i) for therapeutic use when compliant with the requirements of the required advisory statements for medicine labels except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child‑resistant closure and compliant with the requirements of required advisory statements for medicine labels; or
(ii) for non‑therapeutic use when labelled with warnings to the following effect:
(A) Do not swallow; and
(B) Do not use [this product/insert name of product] in children 6 years of age or less;
except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child‑resistant closure and labelled with warnings to the following effect:
(C) Do not swallow; and
(D) Do not use [this product/insert name of product] in children 6 years of age or less;
except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.
FLURBIPROFEN in preparations for topical oral use when:
(a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit except when:
(i) in a primary pack containing not more than 16 dosage units; and
(ii) labelled only for the treatment of adults and children over 12 years; or
(b) in undivided preparations containing either:
(i) 0.25% or less of flurbiprofen per dose; or
(ii) 10 mg or less of flurbiprofen per dose;
except when:
(iii) in a primary pack containing not more than 15 mL; and
(iv) labelled only for the treatment of adults 18 years and over.
FLUTICASONE PROPIONATE (excluding derivatives) in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
FOLIC ACID for human therapeutic use except:
(a) when included in Schedule 4; or
(b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.
FOLINIC ACID for human therapeutic use except:
(a) when included in Schedule 4; or
(b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.
FORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
(a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or
(b) in other preparations containing 0.2% or less of free formaldehyde.
GELSEMIUM SEMPERVIRENS.
GLUTARAL for human therapeutic use.
GUAIFENESIN in a modified release dosage form of 1200 mg or less of guaifenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.
HEXACHLOROPHENE in preparations for human use containing 3% or less of hexachlorophene except:
(a) in preparations for use on infants, as specified in Schedule 4; or
(b) in preparations for cosmetic use, as specified in Schedule 6; or
(c) in other preparations containing 0.75% or less of hexachlorophene.
HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use:
(a) for dermal use in preparations containing 0.5% or less of hydrocortisone, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
(b) for dermal use in preparations containing 1% or less of hydrocortisone, in packs containing 15 g or less of such preparations, containing an antifungal substance and no other therapeutically active constituent:
(i) for the treatment of tinea (tinea pedis, tinea cruris, tinea corporis) and other fungal skin infections; and
(ii) not labelled for the treatment of children under 12 years of age; or
(c) for rectal use in preparations containing 0.5% or less of hydrocortisone, when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:
(i) in undivided preparations in packs of 35 g or less; or
(ii) in packs containing 12 or less suppositories.
HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2% or less of hydroquinone except:
(a) in hair preparations containing 0.3% or less of hydroquinone; or
(b) in cosmetic nail preparations containing 0.02% or less of hydroquinone.
HYOSCINE:
(a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or
(b) for oral use:
(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.
HYOSCYAMINE:
(a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or
(b) for oral use:
(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.
HYOSCYAMUS NIGER for oral use:
(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;
except in a pack containing 0.03 mg or less of total solanaceous alkaloids.
IBUPROFEN in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen, when:
(a) in liquid preparations that are sold in the manufacturer’s original pack containing 8 g or less of ibuprofen; or
(b) in divided immediate release preparations:
(i) each containing 400 mg or less of ibuprofen in a primary pack containing not more than 12 dosage units; and
(ii) that are labelled not for the treatment of children under 12 years; or
(c) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units except when:
(i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and
(ii) packed in blister or strip packaging or in a container with a child-resistant closure; and
(iii) in a primary pack containing not more than 25 dosage units; and
(iv) compliant with the requirements of the required advisory statements for medicine labels; and
(v) not labelled for the treatment of children 6 years or under; and
(vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.
INDANAZOLINE.
INDOMETACIN in preparations for external use containing 1% or less of indometacin.
IODINE:
(a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or
(b) in preparations for human external therapeutic use containing more than 2.5% of available iodine (excluding salts, derivatives or iodophors);
except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.
IPRATROPIUM in preparations for nasal use.
IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1% or less of total iron oxides) for human internal use except:
(a) when included in Schedule 4; or
(b) when labelled with a recommended daily dose of 24 mg or less of iron:
(i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or
(ii) in divided preparations:
(A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or
(B) containing 5 mg or less of iron per dosage unit.
ISOCONAZOLE for human use in dermal preparations.
ISOPROPAMIDE in preparations for dermal use containing 2% or less of isopropamide.
KETOCONAZOLE in preparations for dermal use except:
(a) in preparations containing 1% or less of ketoconazole for the treatment of the scalp; or
(b) in preparations for the treatment of tinea pedis.
KETOTIFEN for ophthalmic use in preparations containing 0.025% or less of ketotifen.
LANSOPRAZOLE in oral preparations 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.
LEVOCABASTINE in topical eye or nasal preparations.
LEVOCETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
(a) in a primary pack containing not more than 5 days’ supply; and
(b) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.
LIDOCAINE in preparations for topical use other than eye drops:
(a) containing 10% or less of total local anaesthetic substances, except:
(i) in dermal preparations containing 2% or less of total local anaesthetic substances; or
(ii) in aqueous sprays for oromucosal use containing 0.6% or less of total local anaesthetic substances; or
(b) in divided preparations containing 200 mg or less of total local anaesthetic substances, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
LINDANE in preparations for human external therapeutic use containing 2% or less of lindane.
LITHIUM in preparations for dermal use containing 1% or less of lithium except:
(a) when present as an excipient at 0.25% or less of lithium; or
(b) in preparations containing 0.01% or less of lithium.
LOBELIA INFLATA except for smoking or burning.
LOBELINE except in preparations for smoking or burning.
LODOXAMIDE in preparations for ophthalmic use.
LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less except in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.
LORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis when:
(a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and
(b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.
MACROGOLS in preparations for oral use as a liquid concentrate for laxative use.
MEBENDAZOLE for human therapeutic use.
MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.
MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.
MEPYRAMINE for dermal use.
MERCUROCHROME in preparations for external use containing 2% or less of mercurochrome except when included in Schedule 6.
MERCURY for external use in preparations containing 0.5% or less of mercury.
METHOXAMINE in preparations for external use except in preparations containing 1% or less of methoxamine.
METHOXYPHENAMINE.
METHYLEPHEDRINE.
MICONAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.
MINOXIDIL in preparations for dermal use containing 5% or less of minoxidil.
MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.
NAPHAZOLINE.
NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.
NICLOSAMIDE for human therapeutic use.
NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply.
NOSCAPINE.
NYSTATIN in dermal preparations.
OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.
OXETACAINE (oxethazaine) in preparations for internal use.
OXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis.
OXYMETAZOLINE.
OXYQUINOLINE and its non‑halogenated derivatives for human therapeutic use, except in preparations for external use containing 1% or less of such substances.
PAPAVERINE except when included in Schedule 4.
PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.
PARACETAMOL for therapeutic use:
(a) in liquid preparations for oral use containing a maximum of 10 g of paracetamol per container; or
(b) when combined with ibuprofen in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided doses in a primary pack containing no more than 12 dosage units per pack; or
(c) in tablets or capsules enclosed in a primary pack containing not more than 100 tablets or capsules; or
(d) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine pack and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or
(e) in individually wrapped powders or sachets of granules enclosed in a primary pack containing not more than 50 wrapped powders or sachets of granules; or
(f) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules intended only as a bulk medicine pack and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or
(g) in other preparations except:
(i) when included in Schedule 3 or 4; or
(ii) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:
(A) enclosed in a primary pack that contains not more than 10 such powders or sachets of granules;
(B) compliant with the requirements of the required advisory statements for medicine labels;
(C) not labelled for the treatment of children 6 years of age or less; and
(D) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin; or
(iii) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:
(A) packed in blister or strip packaging or in a container with a child‑resistant closure;
(B) in a primary pack containing not more than 20 tablets or capsules;
(C) compliant with the requirements of the required advisory statements for medicine labels;
(D) not labelled for the treatment of children 6 years of age or less; and
(E) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin.
PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
(a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or
(b) in other preparations containing 0.2% or less of free formaldehyde.
PHEDRAZINE.
PHENAZONE for human external use.
PHENIRAMINE:
(a) in eye drops; or
(b) when combined with one or more other therapeutically active substances in oral preparations when:
(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(ii) in a day‑night pack containing pheniramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
except in preparations for the treatment of children under 2 years of age.
PHENOL, or any homologue boiling below 220°C, for human therapeutic use except:
(a) when included in Schedule 4; or
(b) in preparations for external use containing 1% or less of phenol and in preparations for external use containing 3% or less of cresols and xylenols and other homologues of phenol.
PHENYLEPHRINE except:
(a) when included in Schedule 4; or
(b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or
(c) in topical eye or nasal preparations containing 1% or less of phenylephrine.
PHOLCODINE:
(a) in liquid preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or
(b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.
PIPERAZINE for human therapeutic use.
PODOPHYLLOTOXIN in preparations containing 0.5% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.
POTASSIUM CHLORATE for therapeutic use except in preparations containing 10% or less of potassium chlorate.
PRILOCAINE in preparations for dermal use containing 10% or less of total local anaesthetic substances.
PROCYCLIDINE in preparations containing 5% or less of procyclidine for dermal use.
PROMETHAZINE in oral preparations:
(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or
(b) when combined with one or more other therapeutically active substances when:
(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(ii) in a day‑night pack containing promethazine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
except in preparations for the treatment of children under 2 years of age.
PROPAMIDINE for ophthalmic use.
PYRANTEL for human therapeutic use.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10% of such substances.
PYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels.
RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.
RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days’ supply except:
(a) in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units; or
(b) in divided preparations for oral use containing 300 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units.
SALICYLAMIDE except when included in Schedule 4.
SELENIUM in preparations for human therapeutic use except:
(a) for topical use containing 3.5% or less of selenium sulfide;
(b) when included in Schedule 4; or
(c) for oral use with a recommended daily dose of 150 micrograms or less.
SILVER for therapeutic use except:
(a) in solutions for human oral use containing 0.3% or less of silver when compliant with the requirements of the required advisory statements for medicine labels; or
(b) in other preparations containing 1% or less of silver.
SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.
SODIUM NITRITE for therapeutic use (excluding when present as an excipient).
SQUILL except in preparations containing 1% or less of squill.
SULCONAZOLE in preparations for dermal use.
TERBINAFINE for dermal use except in preparations for the treatment of tinea pedis.
TETRACAINE in preparations for topical use other than eye drops, containing 10% or less of total local anaesthetic substances except in dermal preparations containing 2% or less of total local anaesthetic substances.
TETRACHLOROETHYLENE for human therapeutic use.
TETRYZOLINE.
THIABENDAZOLE for human therapeutic use.
TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.
TRAMAZOLINE.
TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:
(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b) in a day‑night pack containing triprolidine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
except in preparations for the treatment of children under 2 years of age.
TUAMINOHEPTANE.
TYMAZOLINE.
XYLOMETAZOLINE.
ZINC CHLORIDE for human dermal use except in preparations containing 5% or less of zinc chloride.
Schedule 3—Pharmacist only medicines
Note: See sections 16 and 31, subsections 54(2) and 57(1) and section 59.
ADAPALENE in topical preparations containing 0.1% or less of adapalene for the treatment of acne vulgaris in adults and in children over 12 years of age.
ADRENALINE in preparations containing 1% or less of adrenaline except in preparations containing 0.02% or less of adrenaline unless packed and labelled for injection.
ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of alclometasone in packs containing 30 g or less of the preparation.
ALIMEMAZINE:
(a) in solid oral preparations except when included in Schedule 2; or
(b) in liquid oral preparations containing 10 mg or less of alimemazine per 5 mL;
except in preparations for the treatment of children under 2 years of age.
AMINOPHYLLINE in liquid oral preparations containing 2% or less of aminophylline.
AMYL NITRITE when in preparations for human therapeutic use and packaged in containers with child‑resistant closures.
ASTODRIMER SODIUM except in a condom lubricant.
AZATADINE in oral preparations.
BILASTINE in divided oral preparations containing 20 mg or less of bilastine for the treatment of adults and adolescents 12 years of age and older.
BROMPHENIRAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age.
BUCLIZINE in oral preparations.
BUTOCONAZOLE in preparations for vaginal use.
CANNABIDIOL in oral, oromucosal and sublingual preparations included in the Register when:
(a) the cannabidiol is either plant derived or, when synthetic, only contains the (‑)‑CBD enantiomer; and
(b) the cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and
(c) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation and of which tetrahydrocannabinol (THC) can only comprise 1% of the total cannabinoid content; and
(d) the maximum recommended daily dose is 150 mg or less of cannabidiol; and
(e) packed in blister or strip packaging or in a container fitted with a child‑resistant closure; and
(f) in packs containing not more than 30 days’ supply; and
(g) for persons aged 18 years and over.
CHLORAMPHENICOL for ophthalmic use only.
CHLORBUTANOL in preparations for human use except:
(a) when included in Schedule 2; or
(b) in preparations containing 0.5% or less of chlorbutanol.
CHLORPHENAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age.
CICLOPIROX in preparations for dermal use and for application to the nails except:
(a) when included in Schedule 2; or
(b) in preparations for the treatment of tinea pedis.
CIMETIDINE in a primary pack containing not more than 14 days’ supply.
CLEMASTINE in preparations for oral use.
CLOBETASONE (clobetasone‑17‑butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of clobetasone in packs containing 30 g or less of the preparation.
CLOTRIMAZOLE in preparations for vaginal use.
CYCLIZINE in divided preparations for oral use in primary packs containing 6 dosage units or less.
CYPROHEPTADINE in oral preparations.
DEXCHLORPHENAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age.
DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units except when included in Schedule 2.
DIHYDROCODEINE when indicated for cough suppression and compounded with one or more other therapeutically active substances:
(a) in divided preparations containing 10 mg or less of dihydrocodeine per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or
(b) in undivided preparations containing 0.25% or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine.
DIIODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.
DIMENHYDRINATE in oral preparations except when included in Schedule 2.
DIMETHINDENE in oral preparations.
DIPHENHYDRAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age.
DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate.
DITHRANOL for therapeutic use.
DOXYLAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age.
ECONAZOLE in preparations for vaginal use.
ELETRIPTAN for oral use in tablets containing 40 mg or less per tablet and when in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.
ERYTHRITYL TETRANITRATE for therapeutic use.
FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).
FLAVOXATE.
FLUCONAZOLE in single‑dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.
FLUORIDES for human topical use:
(a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child‑resistant closure except when included in or expressly excluded from Schedule 2; or
(b) in non‑liquid preparations containing 5500 mg/kg or less of fluoride ion except:
(i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the required advisory statements for medicine labels; or
(ii) in preparations for non‑therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:
(A) Do not swallow; and
(B) Do not use [this product/name of product] in children six years of age or less; or
(iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.
GLUCAGON.
GLYCERYL TRINITRATE:
(a) in preparations for oral use; or
(b) in preparations for rectal use.
GLYCOPYRRONIUM except when included in Schedule 4.
HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1% or less of hydrocortisone:
(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
(b) for dermal use, in packs containing 2 g or less of such preparations, containing no other therapeutically active constituent other than aciclovir (5% w/w or less) in adults and adolescents (12 years of age and older); or
(c) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:
(i) in undivided preparations, in packs of 35 g or less; or
(ii) in packs containing 12 or less suppositories;
except when included in Schedule 2.
HYOSCINE BUTYLBROMIDE in undivided preparations for oral use with a recommended single dose not exceeding 20 mg of hyoscine butylbromide in a pack containing 100 mg or less of hyoscine butylbromide when labelled for adults and children 6 years and over.
IBUPROFEN when:
(a) either:
(i) in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units; or
(ii) in a modified release dosage form, each containing 600 mg of ibuprofen, in a primary pack containing not more than 32 dosage units; and
(b) labelled:
(i) with a recommended daily dose of 1200 mg or less of ibuprofen; and
(ii) not for the treatment of children under 12 years;
except when:
(c) included in Schedule 2; or
(d) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:
(i) ibuprofen is the only therapeutically active constitutent, other than phenylephrine or when combined with an effervescent agent; and
(ii) packed in a blister or strip packaging or in a container with a child-resistant closure; and
(iii) in a primary pack containing not more than 25 dosage units; and
(iv) compliant with the requirements of the required advisory statements for medicine labels; and
(v) not labelled for the treatment of children 6 years or under; and
(vi) when combined with phenylephrine—not labelled for the treatment of children under 12 years.
INOSITOL NICOTINATE.
ISOCONAZOLE in preparations for vaginal use.
ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.
KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.
LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.
LEVONORGESTREL for emergency post‑coital contraception.
MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.
MAGNESIUM SULFATE for human therapeutic use in divided oral preparations except when containing 1.5 g or less of magnesium sulfate per recommended daily dose.
MALATHION in preparations for human external use except in preparations containing 2% or less of malathion.
MANNITYL HEXANITRATE for therapeutic use.
MELATONIN in:
(a) modified release tablets containing 2 mg or less of melatonin for monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep for adults aged 55 or over, in packs containing not more than 30 tablets; or
(b) immediate release preparations containing 5 mg or less of melatonin for the treatment of jet lag in adults 18 years and over, in a primary pack containing no more than 10 dosage units.
MEPYRAMINE in oral preparations.
METHDILAZINE in oral preparations.
METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.
MICONAZOLE for human use in topical preparations:
(a) for the treatment of oral candidiasis; or
(b) for vaginal use.
MOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.1% or less of mometasone in packs containing 15 g or less.
NALOXONE when used for the treatment of opioid overdose.
NAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment of children under 12 years of age.
NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit except:
(a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
(b) nicotinamide.
NICOTINYL ALCOHOL except in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.
NYSTATIN in preparations for topical use except when included in Schedule 2.
OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.
ORLISTAT in oral preparations for weight‑control purposes containing 120 mg or less of orlistat per dosage unit.
OXICONAZOLE in preparations for vaginal use.
PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.
PARACETAMOL:
(a) when combined with ibuprofen in a primary pack containing 30 dosage units or less except when included in Schedule 2; or
(b) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing not more than 100 tablets or capsules; or
(c) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or
(d) in liquid preparations for oral use except when in Schedule 2.
PHENIRAMINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age.
PODOPHYLLOTOXIN in preparations containing 1% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.
PROMETHAZINE in oral preparations except:
(a) when included in Schedule 2; or
(b) in preparations for the treatment of children under 2 years of age.
PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight‑control purposes) when supplied in a primary pack:
(a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or
(b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).
RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.
RIZATRIPTAN when in divided oral preparations containing 5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of migraine symptoms.
SALBUTAMOL as the only therapeutically active substance:
(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
(b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose; and
where supply is limited:
(c) for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise‑induced asthma and other stimuli known to induce bronchospasm; or
(d) for the treatment of a person with a record of previous supply from a pharmacy; or
(e) to persons authorised under a law of a State or Territory to use or supply salbutamol in the practice of their profession; or
(f) for use in institutional first aid; and
where paragraph (c) or (d) applies—supply is limited to one primary pack of salbutamol per person being treated.
SALICYLIC ACID in preparations for dermal use except in preparations containing 40% or less of salicylic acid.
SANTONIN.
SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.
SULFACETAMIDE in preparations for ophthalmic use containing 10% or less of sulfacetamide.
SUMATRIPTAN when in divided oral preparations containing 50 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.
TERBUTALINE as the only therapeutically active substance:
(a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or
(b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.
THEOPHYLLINE in liquid oral preparations containing 2% or less of theophylline.
TIOCONAZOLE in preparations for vaginal use.
TRIAMCINOLONE for buccal use in preparations containing 0.1% or less of triamcinolone in a pack of 5 g or less.
TRIPROLIDINE in oral preparations except:
(a) when included in Schedule 2; or
(b) for the treatment of children under 2 years of age.
ULIPRISTAL for emergency post‑coital contraception.
VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose except in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.
ZOLMITRIPTAN when in divided oral preparations containing 2.5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.
Schedule 4—Prescription only medicines and prescription animal remedies
Note 1: See sections 16, 28, 31 and 49, subsections 54(2) and 57(1) and section 60.
Note 2: Substances marked # are listed in Appendix D.
ABACAVIR.
ABATACEPT.
ABIRATERONE ACETATE.
ABCIXIMAB.
ABEMACICLIB.
ACALABRUTINIB.
ACAMPROSATE CALCIUM.
ACARBOSE.
ACEBUTOLOL.
ACEPROMAZINE.
ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.
ACETARSOL.
ACETAZOLAMIDE.
ACETOHEXAMIDE.
ACETYL ISOVALERYLTYLOSIN.
ACETYLCARBROMAL.
ACETYLCHOLINE.
ACETYLCYSTEINE except:
(a) when included in Schedule 2; or
(b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.
ACETYLDIGITOXIN.
ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.
ACETYLSTROPHANTHIDIN.
ACICLOVIR except in preparations containing 5% or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.
ACIPIMOX.
# ACITRETIN.
ACLIDINIUM BROMIDE.
ACOKANTHERA OUABAIO.
ACOKANTHERA SCHIMPERI.
ACONITUM spp. except:
(a) when included in Schedule 2; or
(b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or
(c) in preparations for dermal use in adults containing 0.02% or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.
ACRIVASTINE.
ADALIMUMAB.
ADAPALENE except when included in Schedule 3.
ADEFOVIR.
ADENOSINE for human therapeutic use in preparations for injection.
ADIPHENINE.
ADONIS VERNALIS.
ADRAFINIL.
ADRENALINE except:
(a) when included in Schedule 3; or
(b) in preparations containing 0.02% or less of adrenaline unless packed and labelled for injection.
ADRENOCORTICAL HORMONES except when separately specified in these Schedules.
AFAMELANOTIDE.
AFATINIB DIMALEATE.
AFLIBERCEPT.
AGALSIDASE.
AGLEPRISTONE.
AGOMELATINE.
ALANYLGLUTAMINE.
ALATROFLOXACIN MESILATE.
ALBENDAZOLE except:
(a) when included in Schedule 5 or 6; or
(b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.
ALCLOFENAC.
ALCLOMETASONE except when included in Schedule 3.
ALCURONIUM.
ALDESLEUKIN.
ALDOSTERONE.
ALECTINIB.
# ALEFACEPT.
ALEMTUZUMAB.
ALENDRONIC ACID.
ALFACALCIDOL.
ALFUZOSIN.
ALGLUCERASE.
ALGLUCOSIDASE.
ALIMEMAZINE except when included in Schedule 2 or 3.
ALIROCUMAB.
ALISKIREN.
ALKYL NITRITES except when separately specified in these schedules.
ALLERGENS for therapeutic use.
ALLOPURINOL.
ALLYLESTRENOL.
ALOGLIPTIN.
ALOSETRON.
ALPELISIB.
ALPHA1‑PROTEINASE INHIBITOR (HUMAN).
ALPHADOLONE.
ALPHAXALONE.
ALPRENOLOL.
ALPROSTADIL.
ALSEROXYLON.
ALTEPLASE.
ALTRENOGEST.
ALTRETAMINE (hexamethylmelamine).
AMANTADINE.
AMBENONIUM CHLORIDE.
# AMBRISENTAN.
AMBUCETAMIDE.
AMBUTONIUM BROMIDE.
AMCINONIDE.
AMIFAMPRIDINE.
AMIFOSTINE.
AMIKACIN.
AMILORIDE.
AMINOCAPROIC ACID.
AMINOGLUTETHIMIDE.
5‑AMINOLEVULINIC ACID.
AMINOMETRADINE.
AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.
AMINOPHYLLINE except when included in Schedule 3.
AMINOPTERIN.
4‑AMINOPYRIDINE for therapeutic use.
AMINOREX.
AMINOSALICYLIC ACID.
AMIODARONE.
AMIPHENAZOLE.
AMISOMETRADINE.
AMISULPRIDE.
AMITRIPTYLINE.
AMLODIPINE.
AMMI VISNAGA.
AMMONIUM BROMIDE for therapeutic use.
AMOBARBITAL when packed and labelled for injection.
AMODIAQUINE.
AMOROLFINE except:
(a) when included in Schedule 2; or
(b) in preparations for the treatment of tinea pedis.
AMOXAPINE.
AMOXICILLIN.
AMPHOMYCIN.
AMPHOTERICIN B.
AMPICILLIN.
AMPRENAVIR.
AMRINONE.
AMSACRINE.
AMYL NITRITE except when included in Schedule 3.
AMYLOCAINE.
# ANABOLIC STEROIDAL AGENTS.
ANAGRELIDE.
ANAKINRA.
ANASTROZOLE.
ANCESTIM.
ANCROD and its immunoglobulin antidote.
ANDEXANET ALFA.
ANECORTAVE.
# ANDROGENIC STEROIDAL AGENTS.
# ANDROISOXAZOLE.
# ANDROSTANOLONE.
# ANDROSTENEDIOL.
# ANDROSTENEDIONE.
ANGIOTENSIN AMIDE.
ANIDULAFUNGIN.
ANIRACETAM.
ANISTREPLASE.
ANTAZOLINE except when included in Schedule 2.
ANTIBIOTIC SUBSTANCES except:
(a) when separately specified in these Schedules; or
(b) nisin.
ANTIGENS for human therapeutic use except when separately specified in this Schedule.
ANTIHISTAMINES except:
(a) when included in Schedule 2 or 3; or
(b) when separately specified in this Schedule.
ANTIMONY for therapeutic use except when separately specified in these Schedules.
ANTISERA (immunosera) for human use by injection except when separately specified in these Schedules.
# AOD‑9604 (CAS No. 221231‑10‑3).
APALUTAMIDE.
APIXABAN.
APOCYNUM spp.
APOMORPHINE.
APRACLONIDINE.
APRAMYCIN.
APREMILAST.
APREPITANT.
APROTININ.
ARBUTIN (BETA) in oral preparations except herbal preparations containing 500 mg or less beta‑arbutin per recommended daily dose.
ARECOLINE.
ARIPIPRAZOLE.
ARMODAFINIL.
ARSENIC for human therapeutic use except when separately specified in these Schedules.
ARTEMETHER.
ARTICAINE.
ASCIMINIB.
ASENAPINE.
ASFOTASE ALFA.
ASPARAGINASE.
ASPIRIN when:
(a) combined with caffeine, paracetamol or salicylamide; or
(b) combined with any derivative of the substances mentioned in paragraph (a); or
(c) for injection.
ASTEMIZOLE.
ASUNAPREVIR.
# ATAMESTANE.
ATAZANAVIR.
ATENOLOL.
ATEZOLIZUMAB.
ATIPAMEZOLE.
ATOMOXETINE.
ATORVASTATIN.
ATOSIBAN.
ATOVAQUONE.
ATRACURIUM BESILATE.
ATROPA BELLADONNA (belladonna) except when included in Schedule 2.
ATROPINE except when included in Schedule 2.
ATROPINE METHONITRATE.
AURANOFIN.
AUROTHIOMALATE SODIUM.
AVACOPAN.
AVATROMBOPAG.
AVELUMAB.
AVILAMYCIN except:
(a) in animal feed premixes containing 15% or less of avilamycin activity; or
(b) in animal feeds containing 50 mg/kg or less of avilamycin activity.
AVIPTADIL.
AXITINIB.
AVOPARCIN.
AZACITIDINE.
AZACYCLONOL.
AZAPERONE.
AZAPROPAZONE.
AZARIBINE.
AZATADINE except when included in Schedule 3.
AZATHIOPRINE.
AZELAIC ACID except:
(a) when included in Schedule 2; or
(b) in preparations containing 1% or less of azelaic acid for non‑human use.
AZELASTINE except when included in Schedule 2.
AZITHROMYCIN.
AZLOCILLIN.
AZTREONAM.
BACAMPICILLIN.
BACITRACIN.
BACLOFEN.
BALOXAVIR MARBOXIL.
BALSALAZIDE.
BAMBERMYCIN (flavophospholipol) except:
(a) when included in Schedule 6; or
(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
BAMBUTEROL.
BAMETHAN.
BAMIPINE.
BARBITURATES except when separately specified in these Schedules.
BARICITINIB.
BASILIXIMAB.
BAZEDOXIFENE.
BECAPLERMIN.
BECLAMIDE.
BECLOMETASONE except when included in Schedule 2.
BELATACEPT.
BELIMUMAB.
BELUMOSUDIL.
BELZUTIFAN.
BEMEGRIDE.
BENACTYZINE.
BENAZEPRIL.
BENDAMUSTINE.
BENDROFLUAZIDE.
BENETHAMINE PENICILLIN.
BENORYLATE.
BENOXAPROFEN.
BENPERIDOL.
BENRALIZUMAB.
BENSERAZIDE.
BENZATHINE PENICILLIN.
BENZILONIUM.
BENZOCAINE except:
(a) when included in Schedule 2; or
(b) in dermal preparations containing 2% or less of total local anaesthetic substances; or
(c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
# BENZODIAZEPINE derivatives except when separately specified in these Schedules.
BENZOYL PEROXIDE in preparations for human therapeutic use except:
(a) when included in Schedule 2; or
(b) in preparations for external use containing 5% or less of benzoyl peroxide.
BENZPHETAMINE.
BENZTHIAZIDE.
BENZATROPINE.
BENZYDAMINE except:
(a) when included in Schedule 2; or
(b) in preparations for dermal use; or
(c) in divided topical oral preparations containing 3 mg or less of benzydamine; or
(d) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.
BENZYLPENICILLIN.
BEPRIDIL.
BERACTANT.
BESIFLOXACIN.
BETAHISTINE.
BETAMETHASONE.
BETAXOLOL.
BETHANECHOL CHLORIDE.
BETHANIDINE.
BEVACIZUMAB.
BEVANTOLOL.
# BEXAROTENE.
BEZAFIBRATE.
BEZLOTOXUMAB.
BICALUTAMIDE.
BICTEGRAVIR.
BIFONAZOLE except:
(a) when included in Schedule 2; or
(b) in preparations for dermal use containing 1% or less of bifonazole for the treatment of the scalp; or
(c) in preparations for dermal use for the treatment of tinea pedis.
BILASTINE except when included in Schedule 3.
BIMATOPROST.
BINIMETINIB.
BIPERIDEN.
BISMUTH COMPOUNDS for cosmetic use, except:
(a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per or less; or
(b) bismuth oxychloride.
BISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth.
BISOPROLOL.
BIVALIRUDIN.
BLEOMYCIN.
BLINATUMOMAB.
BOCEPREVIR.
# BOLANDIOL.
# BOLASTERONE.
# BOLAZINE.
# BOLDENONE (dehydrotestosterone).
# BOLENOL.
# BOLMANTALATE.
BORON, including boric acid and borax, for human therapeutic use except:
(a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose; or
(b) in preparations for dermal use containing 0.35% or less of boron, which are not for paediatric or antifungal use; or
(c) when present as an excipient.
BORTEZOMIB.
# BOSENTAN.
BOSUTINIB.
BOTULINUM TOXINS for human use except when separately specified in these Schedules.
BRENTUXIMAB VEDOTIN.
BRETYLIUM TOSILATE.
BREXPIPRAZOLE.
BRIGATINIB.
BRIMONIDINE except when included in Schedule 2.
BRINZOLAMIDE.
BRIVARACETAM.
# BROMAZEPAM.
BROMIDES, inorganic, for therapeutic use except when separately specified in these Schedules.
BROMOCRIPTINE.
BROMOFORM for therapeutic use.
BROMPHENIRAMINE except when included in Schedule 2 or 3.
BROMVALETONE.
BRUGMANSIA spp.
BUCLIZINE except when included in Schedule 3.
BUDESONIDE except when included in Schedule 2.
BUFEXAMAC.
BUMETANIDE.
BUPHENINE.
BUPIVACAINE except when included in Schedule 5.
BUPROPION.
BUSERELIN.
BUSPIRONE.
BUSULPHAN.
BUTACAINE.
BUTAMBEN except in dermal preparations containing 2% or less of total local anaesthetic substances.
BUTOCONAZOLE except when included in Schedule 3.
BUTRACONAZOLE.
BUTYLCHLORAL HYDRATE.
BUTYL NITRITE.
CABAZITAXEL.
CABERGOLINE.
CABOTEGRAVIR.
CABOZANTINIB.
CADMIUM COMPOUNDS for human therapeutic use.
CAFFEINE for internal therapeutic use except:
(a) in divided preparations when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or
(b) in undivided preparations with a concentration of less than 5% of caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine.
CALCIFEDIOL for human internal therapeutic use except in preparations containing 10 micrograms or less of calcifediol per recommended daily dose.
CALCIPOTRIOL.
CALCITONIN.
CALCITONIN SALMON.
CALCITRIOL.
CALCIUM CARBIMIDE for therapeutic use.
CALCIUM HYDROXYLAPATITE in preparations for injection or implantation:
(a) for tissue augmentation; or
(b) for cosmetic use.
CALCIUM POLYSTYRENE SULPHONATE.
CALOTROPIS GIGANTEA.
CALOTROPIS PROCERA.
# CALUSTERONE.
CAMPHORATED OIL for therapeutic use.
CAMPHOTAMIDE.
CANAGLIFLOZIN.
CANAKINUMAB.
CANDESARTAN CILEXETIL.
CANDICIDIN.
CANINE TICK ANTI‑SERUM.
CANNABIDIOL in preparations for therapeutic use or analytical and scientific research where:
(a) cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and
(b) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation;
except when:
(c) included in Schedule 3; or
(d) in hemp seed oil at a concentration of 75 mg/kg or less.
CANTHARIDIN.
CAPECITABINE.
CAPREOMYCIN.
CAPTODIAME.
CAPTOPRIL.
CAPURIDE.
CARAMIPHEN.
CARBACHOL.
CARBAMAZEPINE.
CARBARYL for human therapeutic use.
CARBAZOCHROME.
CARBENICILLIN.
CARBENOXOLONE for internal use.
CARBETOCIN.
CARBIDOPA.
CARBIMAZOLE.
CARBOCROMEN.
CARBOPLATIN.
CARBOPROST.
CARBROMAL.
CARBUTAMIDE.
CARBUTEROL.
CARFILZOMIB.
CARGLUMIC ACID (N‑carbamoyl‑L‑glutamic acid).
CARINDACILLIN.
CARIPRAZINE.
CARISOPRODOL.
CARMUSTINE.
CARNIDAZOLE.
CARPROFEN.
CARVEDILOL.
CASIRIVIMAB.
CASPOFUNGIN.
CATHINE.
CATUMAXOMAB.
CEDAZURIDINE.
CEFACETRILE.
CEFACLOR.
CEFADROXIL.
CEFALEXIN.
CEFALORIDINE.
CEFALOTIN.
CEFAMANDOLE.
CEFAPIRIN.
CEFAZOLIN.
CEFEPIME.
CEFETAMET.
CEFIXIME.
CEFODIZIME.
CEFONICID.
CEFOPERAZONE.
CEFOTAXIME.
CEFOTETAN.
CEFOTIAM.
CEFOVECIN for veterinary use.
CEFOXITIN.
CEFPIROME.
CEFPODOXIME.
CEFQUINOME.
CEFTAROLINE FOSAMIL.
CEFSULODIN.
CEFTAZIDIME.
CEFTIBUTEN.
CEFTIOFUR.
CEFTRIAXONE.
CEFUROXIME.
CELECOXIB.
CELIPROLOL.
CENEGERMIN.
CEPHAELIS ACUMINATA (ipecacuanha) except in preparations containing 0.2% or less of emetine.
CEPHAELIS IPECACUANHA except in preparations containing 0.2% or less of emetine.
CEPHALONIUM.
CEPHRADINE.
CERITINIB.
CERIVASTATIN.
CERLIPONASE ALFA.
CERTOLIZUMAB PEGOL.
CERULETIDE.
CETIRIZINE except
(a) when included in Schedule 2; or
(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:
(i) in a primary pack containing not more than 10 days’ supply; and
(ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.
CETRORELIX.
CETUXIMAB.
CHENODEOXYCHOLIC ACID.
CHLORAL FORMAMIDE.
CHLORAL HYDRATE except in preparations for topical use containing 2% or less of chloral hydrate.
CHLORALOSE except when included in Schedule 6.
CHLORAMBUCIL.
CHLORAMPHENICOL except when included in Schedule 3.
# CHLORANDROSTENOLONE.
CHLORAZANIL.
CHLORCYCLIZINE.
# CHLORDIAZEPOXIDE.
CHLORMERODRIN.
CHLORMETHIAZOLE.
CHLORMEZANONE.
CHLOROFORM for use in anaesthesia.
# 4‑CHLOROMETHANDIENONE.
2‑(4‑CHLOROPHENYL)‑(1,2,4)TRIAZOLO[5,1‑A]ISOQUINOLINE.
CHLOROQUINE.
CHLOROTHIAZIDE.
CHLOROTRIANISENE.
# CHLOROXYDIENONE.
CHLORPHENAMINE except when included in Schedule 2 or 3.
CHLORPHENTERMINE.
CHLORPROMAZINE.
CHLORPROPAMIDE.
CHLORPROTHIXENE.
CHLORQUINALDOL for human topical use.
CHLORTALIDONE.
CHLORTETRACYCLINE except when included in Schedule 5.
CHLORZOXAZONE.
CHOLERA VACCINE.
CHOLIC ACID.
CHYMOPAPAIN for human therapeutic use.
CICLACILLIN.
CICLESONIDE.
CICLOPIROX except:
(a) when included in Schedule 2 or 3; or
(b) in preparations for the treatment of tinea pedis.
CICLOSPORIN.
CIDOFOVIR.
CILASTATIN.
CILAZAPRIL.
CILGAVIMAB.
CILOSTAZOL.
CIMETIDINE except when included in Schedule 3.
CIMICOXIB.
CINACALCET.
CINCHOCAINE except when included in Schedule 2.
CINNARIZINE.
CINOXACIN.
CIPROFLOXACIN.
CISAPRIDE.
CISATRACURIUM BESILATE.
CISPLATIN.
CITALOPRAM.
# CJC‑1295 (CAS No. 863288‑34‑0).
CLADRIBINE.
CLANOBUTIN.
CLARITHROMYCIN.
CLAVULANIC ACID.
CLEMASTINE except when included in Schedule 3.
CLEMIZOLE.
CLENBUTEROL.
CLEVIDIPINE.
CLIDINIUM BROMIDE.
CLINDAMYCIN.
CLIOQUINOL and other halogenated derivatives of oxyquinoline for human topical use except when separately specified in this Schedule.
CLOBAZAM.
CLOBETASOL.
CLOBETASONE (clobetasone‑17‑butyrate) except when included in Schedule 3.
CLOCORTOLONE.
CLODRONIC ACID (includes sodium clodronate).
CLOFARABINE.
CLOFAZIMINE.
CLOFENAMIDE.
CLOFIBRATE.
# CLOMIFENE.
CLOMIPRAMINE.
CLOMOCYCLINE.
# CLONAZEPAM.
CLONIDINE.
CLOPAMIDE.
CLOPIDOGREL.
CLOPROSTENOL.
# CLORAZEPATE.
CLOREXOLONE.
CLORPRENALINE.
# CLOSTEBOL (4‑chlorotestosterone).
CLOTRIMAZOLE except:
(a) when included in Schedule 2, 3 or 6; or
(b) in preparations for dermal use for the treatment of tinea pedis.
CLOXACILLIN.
# CLOZAPINE.
COBALT for human therapeutic use except as dicobalt edetate in preparations for the treatment of cyanide poisoning.
COBICISTAT.
COBIMETINIB.
CODEINE when compounded with one or more other therapeutically active substances:
(a) in divided preparations containing 30 mg or less of codeine per dosage unit; or
(b) in undivided preparations containing 1% or less of codeine.
CO‑DERGOCRINE.
COLCHICINE.
COLCHICUM AUTUMNALE.
COLESTIPOL.
COLESTYRAMINE for human therapeutic use.
COLFOSCERIL PALMITATE for human therapeutic use.
COLISTIN.
COLLAGEN in preparations for injection or implantation:
(a) for tissue augmentation; or
(b) for cosmetic use.
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.
COLURACETAM.
CONVALLARIA KEISKI.
CONVALLARIA MAJALIS.
COPPER COMPOUNDS for human use except:
(a) when separately specified in these Schedules; or
(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or
(c) in other preparations containing 5% or less of copper compounds.
# CORIFOLLITROPIN ALFA.
CORONILLA spp.
CORTICOSTERONE.
CORTICOTROPHIN.
CORTISONE.
CO‑TRIMOXAZOLE.
COUMARIN for therapeutic use (excluding when present as an excipient).
CRISABOROLE.
CRIZOTINIB.
CROFELEMER.
CUPRIMYXIN.
CURARE.
CYCLANDELATE.
CYCLIZINE except when included in Schedule 3.
CYCLOBENZAPRINE.
# CYCLOFENIL.
CYCLOHEXIMIDE.
CYCLOPENTHIAZIDE.
CYCLOPENTOLATE.
CYCLOPHOSPHAMIDE.
CYCLOPROPANE for therapeutic use.
CYCLOSERINE.
CYCLOTHIAZIDE.
CYCRIMINE.
CYMARIN.
CYPROHEPTADINE except when included in Schedule 3.
CYPROTERONE.
CYTARABINE.
DABRAFENIB MESILATE.
DABIGATRAN.
DACARBAZINE.
DACLATASVIR.
DACLIZUMAB.
DACTINOMYCIN.
DALFOPRISTIN.
DALTEPARIN (includes dalteparin sodium).
DANAPAROID (includes danaparoid sodium).
# DANAZOL.
DANTHRON for human use.
DANTROLENE.
DAPAGLIFLOZIN.
DAPOXETINE.
DAPSONE.
DAPTOMYCIN.
DARATUMUMAB.
# DARBEPOETIN.
DARIFENACIN.
DAROLUTAMIDE.
DARUNAVIR.
DATURA spp. except:
(a) when included in Schedule 2; or
(b) when separately specified in this Schedule.
DASABUVIR.
DASATINIB.
DATURA STRAMONIUM (stramonium) except:
(a) when included in Schedule 2; or
(b) for smoking or burning.
DATURA TATULA (stramonium) except:
(a) when included in Schedule 2; or
(b) for smoking or burning.
DAUNORUBICIN.
DEANOL for therapeutic use.
DEBRISOQUINE.
DECAMETHONIUM.
DECITABINE.
DEFERASIROX.
DEFERIPRONE.
DEFIBROTIDE.
DEFLAZACORT.
DEGARELIX.
# DEHYDROCHLOROMETHYLTESTOSTERONE.
DEHYDROCORTICOSTERONE.
DELAVIRDINE MESILATE.
DEMBREXINE except when included in Schedule 5.
DEMECARIUM.
DEMECLOCYCLINE.
DENGUE VACCINE.
DENOSUMAB.
DEOXYCHOLIC ACID.
DEOXYCORTONE.
DEOXYRIBONUCLEASE except:
(a) when separately specified in this Schedule; or
(b) for external use.
DERACOXIB.
DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT.
DESFERRIOXAMINE.
DESFLURANE.
DESIPRAMINE.
DESIRUDIN.
DESLANOSIDE.
DESLORATADINE except when included in Schedule 2.
DESLORELIN.
DESMOPRESSIN (D.D.A.V.P.).
DESOGESTREL.
DESONIDE.
DESOXYMETHASONE.
DESVENLAFAXINE.
DETOMIDINE.
DEUCRAVACITINIB.
DEUTETRABENAZINE.
DEXAMETHASONE.
DEXCHLORPHENAMINE except when included in Schedule 2 or 3.
DEXFENFLURAMINE.
DEXMEDETOMIDINE.
DEXTROMETHORPHAN (excluding its stereoisomers) except when included in Schedule 2.
# DEXTROPROPOXYPHENE:
(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or
(b) liquid preparations containing 2.5% or less of dextropropoxyphene.
DEXTRORPHAN (excluding its stereoisomers).
DIAMTHAZOLE.
DIAVERIDINE.
# DIAZEPAM.
DIAZOXIDE.
DIBENZEPIN.
DIBOTERMIN.
DIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.
DICHLORALPHENAZONE.
DICHLOROPHEN for human therapeutic use.
DICHLORPHENAMIDE.
DICLOFENAC except:
(a) when included in Schedule 2 or 3; or
(b) in preparations for dermal use unless:
(i) for the treatment of solar keratosis; or
(ii) containing more than 4% of diclofenac.
DICLOXACILLIN.
DICYCLOMINE.
DIDANOSINE.
DIENESTROL.
DIENOGEST.
DIETHAZINE.
DIETHYLCARBAMAZINE for human therapeutic use.
DIETHYLPROPION.
DIFELIKEFALIN.
DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5% of the dose of difenoxin.
DIFLORASONE.
DIFLOXACIN.
DIFLUCORTOLONE.
DIFLUNISAL.
DIGITALIS LANATA.
DIGITALIS PURPUREA.
DIGITOXIN.
DIGOXIN.
DIGOXIN‑SPECIFIC ANTIBODY FRAGMENT F (Ab).
DIHYDRALAZINE.
DIHYDROCODEINE when compounded with one or more other therapeutically active substances:
(a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine;
except when included in Schedule 3.
DIHYDROERGOTOXINE.
# DIHYDROLONE.
DIHYDROSTREPTOMYCIN.
DIHYDROTACHYSTEROL.
DIIODOHYDROXYQUINOLINE (iodoquinol) except:
(a) when included in Schedule 3; or
(b) for human internal use.
DIISOPROPYLAMINE DICHLOROACETATE.
DILTIAZEM.
DIMENHYDRINATE except when included in Schedule 2 or 3.
DIMERCAPROL.
# DIMETHANDROSTANOLONE.
# DIMETHAZINE.
DIMETHINDENE except when included in Schedule 3.
DIMETHOTHIAZINE.
DIMETHOXANATE.
DIMETHYL FUMARATE.
DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use except:
(a) when included in Schedule 6; or
(b) in in vitro test kits; or
(c) when used as a flavour component in compliance with the current Therapeutic Goods (Permissible Ingredients) determination for listed medicines.
DIMETRIDAZOLE.
DIMIRACETAM.
2,4‑DINITROCHLOROBENZENE for therapeutic use.
DINITROCRESOLS for therapeutic use except when separately specified in these Schedules.
DINITRONAPHTHOLS for therapeutic use except when separately specified in these Schedules.
DINITROPHENOLS for therapeutic use.
DINITROTHYMOLS for therapeutic use except when separately specified in these Schedules.
# DINOPROST.
# DINOPROSTONE.
DIPERODON.
DIPHEMANIL except in preparations for dermal use.
DIPHENHYDRAMINE except when included in Schedule 2 or 3.
DIPHENIDOL.
DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate except when included in Schedule 3.
DIPHENYLPYRALINE.
DIPHTHERIA TOXOID.
DIPIVEFRIN.
DIPYRIDAMOLE.
DIRITHROMYCIN.
DIRLOTAPIDE.
DIROXIMEL FUMARATE.
DISOPHENOL.
DISOPYRAMIDE.
DISTIGMINE.
DISULFIRAM for therapeutic use.
DISULPHAMIDE.
DITHIAZANINE except when included in Schedule 6.
DITIOCARB.
DOBUTAMINE.
DOCETAXEL.
DOFETILIDE.
DOLASETRON.
DOLUTEGRAVIR.
DOMPERIDONE.
DONEPEZIL.
DOPAMINE.
DOPEXAMINE.
DORAVIRINE.
DORIPENEM.
DORNASE.
DORZOLAMIDE.
DOSULEPIN.
DOXANTRAZOLE.
DOXAPRAM.
DOXAZOSIN.
DOXEPIN.
DOXORUBICIN.
DOXYCYCLINE.
DOXYLAMINE except when included in Schedule 2 or 3.
DRONEDARONE.
DROPERIDOL.
DROSPIRENONE.
# DROSTANOLONE.
DROTRECOGIN.
DUBOISIA LEICHHARDTII except when included in Schedule 2.
DUBOISIA MYOPOROIDES except when included in Schedule 2.
DULAGLUTIDE.
DULOXETINE.
DUPILUMAB.
DURVALUMAB.
DUTASTERIDE.
DYDROGESTERONE.
ECONAZOLE except:
(a) when included in Schedule 2, 3 or 6; or
(b) in preparations for dermal use for the treatment of tinea pedis.
ECOTHIOPATE (includes ecothiopate iodide).
ECTYLUREA.
ECULIZUMAB.
EDARAVONE.
EDETIC ACID for human therapeutic use except:
(a) in preparations containing 0.25% or less of edetic acid; or
(b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or
(c) in contact lens preparations.
EDOXUDINE.
EDROPHONIUM.
EFALIZUMAB.
EFAVIRENZ.
EFLORNITHINE.
ELBASVIR.
ELETRIPTAN except when included in Schedule 3.
ELEXACAFTOR.
ELOSULFASE ALFA.
ELOTUZUMAB.
ELTENAC.
ELTROMBOPAG.
ELUXADOLINE.
ELVITEGRAVIR.
EMEPRONIUM.
EMETINE except in preparations containing 0.2% or less of emetine.
EMPAGLIFLOZIN.
EMTRICITABINE.
ENALAPRIL.
ENASIDENIB.
ENCORAFENIB.
# ENESTEBOL.
ENFLURANE for therapeutic use.
ENFORTUMAB VEDOTIN.
ENFUVIRTIDE.
# ENOBOSARM.
ENOXACIN.
ENOXAPARIN.
ENOXIMONE.
ENPROSTIL.
ENROFLOXACIN.
ENTACAPONE.
ENTECAVIR.
ENTRECTINIB.
ENZALUTAMIDE.
EPHEDRA spp. except in preparations containing 0.001% or less of ephedrine.
# EPHEDRINE.
EPICILLIN.
EPINASTINE.
EPIRUBICIN.
# EPITIOSTANOL.
EPLERENONE.
# EPOETINS.
EPOPROSTENOL.
EPROSARTAN.
EPTIFIBATIDE.
ERENUMAB.
ERGOMETRINE.
ERGOT.
ERGOTAMINE.
ERGOTOXINE.
ERIBULIN MESILATE.
ERLOTINIB.
ERTAPENEM.
ERTUGLIFLOZIN.
ERYSIMUM spp.
ERYTHROMYCIN.
# ERYTHROPOIETIN.
# ERYTHROPOIETINS except when separately specified in these Schedules.
ESCITALOPRAM.
ESLICARBAZEPINE ACETATE.
ESMOLOL.
ESOMEPRAZOLE except when included in Schedule 2.
ESTETROL MONOHYDRATE.
ESTRADIOL except when included in Schedule 5.
ESTRIOL.
ESTRAMUSTINE.
ESTROGENS except when separately specified in these Schedules.
ESTRONE.
ESTROPIPATE (piperazine estrone sulfate).
ETACRYNIC ACID.
ETANERCEPT.
ETHAMBUTOL.
ETHAMIVAN.
ETHCHLORVYNOL.
ETHER for use in anaesthesia.
ETHINAMATE.
ETHINYLESTRADIOL.
ETHIONAMIDE.
# ETHISTERONE.
ETHOGLUCID.
ETHOHEPTAZINE.
ETHOPROPAZINE.
ETHOSUXIMIDE.
ETHOTOIN.
ETHOXZOLAMIDE.
ETHYL CHLORIDE for human therapeutic use.
# ETHYLDIENOLONE.
ETHYLMORPHINE when compounded with one or more other therapeutically active substances:
(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5% of ethylmorphine;
except when included in Schedule 2.
# ETHYLESTRENOL.
ETIDOCAINE.
ETIDRONIC ACID (includes etidronate disodium):
(a) for internal use; or
(b) in topical preparations except in preparations containing 1% or less of etidronic acid.
ETILEFRIN.
ETIPROSTON.
ETODOLAC.
ETOFENAMATE except when included in Schedule 2.
ETONOGESTREL.
ETOPOSIDE.
ETORICOXIB.
ETRAVIRINE.
# ETRETINATE.
ETYNODIOL.
EVEROLIMUS.
EXEMESTANE.
EXENATIDE.
EZETIMIBE.
FAMCICLOVIR except when included in Schedule 3.
FAMOTIDINE except when included in Schedule 2.
FARICIMAB.
FASORACETAM.
FEBUXOSTAT.
FELBINAC except when included in Schedule 2.
FELODIPINE.
FELYPRESSIN.
FENBUFEN.
FENCAMFAMIN.
FENCLOFENAC.
FENFLURAMINE.
FENOFIBRATE.
FENOLDOPAM.
FENOPROFEN.
FENOTEROL.
FENPIPRAMIDE.
FENPIPRANE.
FENPROPOREX.
FENPROSTALENE.
FERRIC DERISOMALTOSE.
FEXOFENADINE except:
(a) when included in Schedule 2; or
(b) in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
(i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and
(ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or
(c) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
(i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and
(ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or
(d) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:
(i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and
(ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.
FIBRINOLYSIN except for external use.
# FIBROBLAST GROWTH FACTORS.
FIDAXOMICIN.
FILGOTINIB.
FILGRASTIM.
FINASTERIDE.
FINERENONE.
FINGOLIMOD.
FIROCOXIB.
FLECAINIDE.
FLEROXACIN.
FLOCTAFENINE.
FLORFENICOL.
FLUANISONE.
FLUCLOROLONE.
FLUCLOXACILLIN.
FLUCONAZOLE except when included in Schedule 3.
FLUCYTOSINE.
FLUDARABINE.
FLUDROCORTISONE.
FLUFENAMIC ACID.
FLUMAZENIL.
FLUMETASONE.
FLUMETHIAZIDE.
FLUNISOLIDE.
FLUNIXIN MEGLUMINE.
FLUOCINOLONE.
FLUOCINONIDE.
FLUOCORTIN.
FLUOCORTOLONE.
FLUORESCEIN in preparations for injection.
FLUORIDES in preparations for human use except when included in or expressly excluded from Schedule 2 or 3.
FLUOROMETHOLONE.
FLUOROURACIL.
FLUOXETINE.
# FLUOXYMESTERONE.
FLUPENTIXOL.
FLUPHENAZINE.
FLUPROSTENOL.
FLURALANER in injectable preparations for use in companion animals.
FLURANDRENOLONE.
# FLURAZEPAM.
FLURBIPROFEN except when:
(a) included in Schedule 2; or
(b) in divided preparations for topical oral use that contain 10 mg or less of flurbiprofen per dosage unit and that are:
(i) in a primary pack containing not more than 16 dosage units; and
(ii) labelled only for the treatment of adults and children over 12 years; or
(c) in undivided preparations for topical oral use containing either:
(i) 0.25% or less of flurbiprofen per dose; or
(ii) 10 mg or less of flurbiprofen per dose; and
that are:
(iii) in a primary pack containing not more than 15 mL; and
(iv) labelled only for the treatment of adults 18 years and over.
FLUROXENE for human therapeutic use.
FLUSPIRILENE.
FLUTAMIDE.
FLUTICASONE except when included in Schedule 2.
FLUVASTATIN.
FLUVOXAMINE.
FOLIC ACID in preparations for human use for injection.
FOLINIC ACID in preparations for human use for injection.
FOLLICLE‑STIMULATING HORMONE except when separately specified in this Schedule.
# FOLLISTATIN.
# FOLLITROPIN ALFA.
# FOLLITROPIN BETA.
# FOLLITROPIN DELTA.
FOMEPIZOLE.
FOMIVIRSEN.
FONDAPARINUX.
# FORMEBOLONE.
FORMESTANE.
FORMOTEROL
FOSAMPRENAVIR.
FOSAPREPITANT.
FOSCARNET.
FOSFESTROL (diethylstilbestrol diphosphate).
FOSFOMYCIN.
FOSINOPRIL.
FOSNETUPITANT.
FOSPHENYTOIN.
FOSTEMSAVIR.
FOTEMUSTINE.
FRAMYCETIN.
FULVESTRANT.
FURALTADONE.
# FURAZABOL.
FURAZOLIDONE.
FUROSEMIDE (frusemide).
FUSIDIC ACID.
GABAPENTIN.
GALANTAMINE.
GALANTHUS spp.
GALCANEZUMAB.
GALLAMINE.
GALSULFASE.
GANCICLOVIR.
GANIRELIX.
GATIFLOXACIN.
GRAZOPREVIR.
GEFITINIB.
GEMCITABINE.
GEMEPROST.
GEMFIBROZIL.
GEMIFLOXACIN.
GEMTUZUMAB OZOGAMICIN.
GENTAMICIN.
GESTODENE.
GESTONORONE.
# GESTRINONE.
GHRH INJECTABLE PLASMID.
GILTERITINIB.
GITALIN.
GLATIRAMER ACETATE.
GLECAPREVIR.
GLIBENCLAMIDE.
GLIBORNURIDE.
GLICLAZIDE.
GLIMEPIRIDE.
GLIPIZIDE.
GLIPTINS except when separately specified in these Schedules.
GLISOXEPIDE.
GLUTATHIONE for parenteral use.
# GLUTETHIMIDE.
GLYCERYL TRINITRATE except when included in Schedule 3.
GLYCOPYRRONIUM in preparations for injection.
GLYMIDINE.
GnRH VACCINE.
GOLIMUMAB.
GONADORELIN.
GONADOTROPHIC HORMONES except when separately specified in this Schedule.
GOSERELIN.
GRAMICIDIN.
GRANISETRON.
GRAPIPRANT.
GREPAFLOXACIN.
GRISEOFULVIN.
# GROWTH HORMONE RELEASING HORMONES* (GHRHs).
# GROWTH HORMONE RELEASING PEPTIDES (GHRPs).
# GROWTH HORMONE RELEASING PEPTIDE‑6 (GHRP‑6).
# GROWTH HORMONE SECRETAGOGUES* (GHSs).
GUAIFENESIN for human therapeutic use except:
(a) when included in Schedule 2; or
(b) in oral liquid preparations containing 2% or less of guaifenesin; or
(c) in divided preparations containing 200 mg or less of guaifenesin per dosage unit.
GUANABENZ.
GUANACLINE.
GUANETHIDINE.
GUANFACINE.
GUANIDINE for therapeutic use.
GUSELKUMAB.
HACHIMYCIN.
HAEMATIN.
HAEMOPHILUS INFLUENZAE VACCINE.
HALCINONIDE.
HALOFANTRINE.
HALOFENATE.
HALOFUGINONE in preparations containing 0.1% or less of halofuginone for the treatment of animals.
HALOPERIDOL.
HALOTHANE for therapeutic use.
HEMEROCALLIS (Hemerocallis flava).
HEPARINS for internal use except when separately specified in this Schedule.
HEPATITIS A VACCINE.
HEPATITIS B VACCINE.
HETACILLIN.
HEXACHLOROPHENE:
(a) in preparations for use on infants; or
(b) in other preparations except:
(i) when included in Schedule 2 or 6; or
(ii) in preparations containing 0.75% or less of hexachlorophene.
HEXAMETHONIUM.
# HEXARELIN.
HEXETIDINE for human internal use.
HEXOBENDINE.
HEXOCYCLIUM.
HEXOPRENALINE.
HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE).
HISTAMINE for therapeutic use except in preparations containing 0.5% or less of histamine.
HMG‑CoA REDUCTASE INHIBITORS (including "statins") except when separately specified in these Schedules.
HOMATROPINE.
HUMAN CHORIONIC GONADATROPHIN except in pregnancy test kits.
HUMAN PAPILLOMAVIRUS VACCINE.
HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation.
HYDRALAZINE.
HYDRARGAPHEN.
HYDROCHLOROTHIAZIDE.
HYDROCORTISONE:
(a) for human use except when included in Schedule 2 or 3; or
(b) for the treatment of animals.
HYDROCYANIC ACID for therapeutic use.
HYDROFLUMETHIAZIDE.
HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use except:
(a) when included in Schedule 2; or
(b) in hair preparations containing 0.3% or less of hydroquinone; or
(c) in cosmetic nail preparations containing 0.02% or less of hydroquinone.
HYDROXYCARBAMIDE.
# HYDROXYCHLOROQUINE.
HYDROXYEPHEDRINE.
HYDROXYPHENAMATE.
HYDROXYPROGESTERONE.
# HYDROXYSTENOZOL.
HYDROXYZINE.
HYGROMYCIN.
HYOSCINE except when included in Schedule 2.
HYOSCYAMINE except when included in Schedule 2.
HYOSCINE BUTYLBROMIDE except when included in Schedule 2 or Schedule 3.
HYOSCYAMUS NIGER except:
(a) when included in Schedule 2; or
(b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.
HYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule.
HYPROMELLOSE in preparations for injection.
IBAFLOXACIN for veterinary use.
IBANDRONIC ACID.
IBOGAINE.
IBRITUMOMAB.
IBRUTINIB.
IBUFENAC.
IBUPROFEN except when:
(a) included in Schedule 2 or 3; or
(b) in preparations for dermal use; or
(c) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:
(i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and
(ii) packed in blister or strip packaging or in a container with a child-resistant closure; and
(iii) in a primary pack containing not more than 25 dosage units; and
(iv) compliant with the requirements of the required advisory statements for medicine labels; and
(v) not labelled for the treatment of children 6 years and under; and
(vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.
# IBUTAMOREN.
IBUTEROL.
IBUTILIDE.
ICATIBANT.
IDARUBICIN.
IDARUCIZUMAB.
IDEBENONE.
IDOXURIDINE except in preparations containing 0.5% or less of idoxuridine for dermal use.
IDURSULFASE.
IFOSFAMIDE.
ILOPROST.
IMATINIB.
IMDEVIMAB.
IMEPITOIN.
IMIDAPRIL.
IMIGLUCERASE.
IMIPENEM.
IMIPRAMINE.
IMIQUIMOD.
IMMUNOGLOBULINS for human parenteral use except when separately specified in these Schedules.
INCLISIRAN.
INDACATEROL.
INDAPAMIDE.
INDINAVIR.
INDOMETACIN except when included in Schedule 2.
INDOPROFEN.
INDORAMIN.
INFIGRATINIB.
INFLIXIMAB.
INFLUENZA AND CORYZA VACCINES:
(a) for parenteral use; or
(b) for nasal administration.
INGENOL MEBUTATE.
INOTUZUMAB OZOGAMICIN.
INSULIN DEGLUDEC.
INSULIN GLARGINE.
# INSULIN‑LIKE GROWTH FACTOR I.
# INSULIN‑LIKE GROWTH FACTORS except when separately specified in this Schedule.
INSULINS.
INTERFERONS.
INTERLEUKINS except when separately specified in these Schedules.
IODOTHIOURACIL.
# IPAMORELIN.
IPILIMUMAB.
IPRATROPIUM except when included in Schedule 2.
IPRIFLAVONE.
IPRINDOLE.
IPRONIAZID.
IRBESARTAN.
IRINOTECAN.
IRON COMPOUNDS in injectable preparations for human use.
ISAVUCONAZOLE.
ISOAMINILE.
ISOAMYL NITRITE.
ISOBUTYL NITRITE.
ISOCARBOXAZID.
ISOCONAZOLE except when included in Schedule 2, 3 or 6.
ISOETARINE.
ISOFLURANE for therapeutic use.
ISOMETHEPTENE.
ISONIAZID.
ISOPRENALINE.
ISOPRINOSINE.
ISOPROPAMIDE except when included in Schedule 2.
ISOSORBIDE DINITRATE except when included in Schedule 3.
ISOSORBIDE MONONITRATE.
# ISOTRETINOIN.
ISOXICAM.
ISOXSUPRINE.
ISRADIPINE.
ITRACONAZOLE.
IVABRADINE.
IVACAFTOR.
IVERMECTIN:
(a) for human use; or
(b) for the treatment of mange in dogs.
IVOSIDENIB.
IXABEPILONE.
IXAZOMIB.
IXEKIZUMAB.
JAPANESE ENCEPHALITIS VACCINE.
KANAMYCIN.
KETANSERIN except in topical veterinary preparations containing 0.5% or less of ketanserin.
# KETAZOLAM.
KETOCONAZOLE except:
(a) when included in Schedule 2; or
(b) in preparations for dermal use containing 1% or less of ketoconazole for the treatment of the scalp; or
(c) in preparations for dermal use for the treatment of tinea pedis.
KETOPROFEN except:
(a) in preparations for dermal use; or
(b) when included in Schedule 3.
KETOROLAC (includes ketorolac trometamol).
KETOTIFEN except when included in Schedule 2.
KHELLIN.
KITASAMYCIN except:
(a) when included in Schedule 5; or
(b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.
LABETALOL.
LACIDIPINE.
LACOSAMIDE.
LAMIVUDINE.
LAMOTRIGINE.
LANADELUMAB.
LANATOSIDES.
LANREOTIDE.
LANSOPRAZOLE except when included in Schedule 2 or 3.
LANTHANUM for therapeutic use.
LAPATINIB.
LARONIDASE.
LAROPIPRANT.
LAROTRECTINIB.
LATAMOXEF.
LATANOPROST.
LAUDEXIUM.
LAUROMACROGOLS in preparations for injection except:
(a) when present as an excipient; or
(b) when separately specified in these Schedules.
LEAD for human therapeutic use.
LEDIPASVIR.
LEFETAMINE.
LEFLUNOMIDE.
LEMBOREXANT.
LENACAPAVIR.
# LENALIDOMIDE.
LENOGRASTIM.
LENVATINIB.
LEPIRUDIN.
LEPTAZOL.
LERCANIDIPINE.
LESINURAD.
LETERMOVIR.
LETROZOLE.
LEUPRORELIN.
LEVALLORPHAN.
LEVAMISOLE:
(a) for human therapeutic use; or
(b) in preparations for the prevention or treatment of heartworm in dogs.
LEVETIRACETAM.
LEVOBUNOLOL.
LEVOBUPIVACAINE.
LEVOCABASTINE except when included in Schedule 2.
LEVOCETIRIZINE except:
(a) when included in Schedule 2; or
(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
(i) in a primary pack containing not more than 5 days’ supply; and
(ii) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.
LEVODOPA.
LEVOMEPROMAZINE.
LEVOMILNACIPRAN.
LEVONORGESTREL except when included in Schedule 3.
LEVOSIMENDAN.
LIDOCAINE except:
(a) when included in Schedules 2 or 5; or
(b) in dermal preparations containing 2% or less of total local anaesthetic substances per dosage unit; or
(c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.
LIDOFLAZINE.
LIFITEGRAST.
LINACLOTIDE.
LINAGLIPTIN.
LINCOMYCIN.
LINDANE for human therapeutic use except when included in Schedule 2.
LINEZOLID.
LIOTHYRONINE.
LIPEGFILGRASTIM.
LIRAGLUTIDE.
LISINOPRIL.
LISURIDE.
LITHIUM for therapeutic use except:
(a) when included in Schedule 2; or
(b) when present as an excipient in preparations for dermal use containing 0.25% or less of lithium; or
(c) in preparations containing 0.01% or less of lithium.
LIXISENATIDE.
LODOXAMIDE except when included in Schedule 2.
LOFEXIDINE.
LOGIPARIN for internal use.
LOMEFLOXACIN.
LOMUSTINE.
LOPERAMIDE except:
(a) when included in Schedule 2; or
(b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.
LOPINAVIR.
# LOPRAZOLAM.
LORACARBEF.
LORATADINE except:
(a) when included in Schedule 2; or
(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, when:
(i) in a primary pack containing 10 dosage units or less; and
(ii) labelled with a recommended daily dose not exceeding 10 mg of loratadine.
# LORAZEPAM.
LORLATINIB.
# LORMETAZEPAM.
LOSARTAN.
LOTEPREDNOL.
LOXAPINE.
LUMACAFTOR.
LUMEFANTRINE.
LUMIRACOXIB.
LURASIDONE.
LURBINECTEDIN.
LUSPATERCEPT.
# LUTEINISING HORMONE except in ovulation test kits.
LYMECYCLINE.
MACITENTAN for human use.
MAFENIDE except when included in Schedule 6.
MANDRAGORA OFFICINARUM.
MANNOMUSTINE.
MAPROTILINE.
MARAVIROC.
MARBOFLOXACIN.
MAROPITANT.
MAVACAMTEN.
MAVACOXIB.
MAZINDOL.
MEASLES VACCINE.
MEBANAZINE.
MEBEVERINE.
MEBHYDROLIN.
# MEBOLAZINE.
MEBUTAMATE.
MECAMYLAMINE.
MECASERMIN.
MECILLINAM.
MECLOCYCLINE.
MECLOFENAMATE.
MECLOFENOXATE.
MECLOZINE except when included in Schedule 2.
# MEDAZEPAM.
MEDETOMIDINE.
MEDIGOXIN (methyldigoxin).
MEDROXYPROGESTERONE.
MEDRYSONE.
MEFENAMIC ACID except when included in Schedule 2.
MEFENOREX.
MEFLOQUINE.
MEFRUSIDE.
MEGESTROL.
MELAGATRAN.
MELANOTAN II.
MELATONIN for human use except when included in Schedule 3.
MELENGESTROL except when included in Schedule 6.
MELOXICAM except when included in Schedule 6.
MELPHALAN.
MEMANTINE.
MENINGOCOCCAL VACCINE.
MENINGOCOCCAL GROUP B VACCINE.
MENOTROPHIN.
MEPACRINE.
MEPENZOLATE.
MEPHENESIN.
MEPHENTERMINE.
MEPINDOLOL.
# MEPITIOSTANE.
MEPIVACAINE.
MEPROBAMATE.
MEPTAZINOL.
MEPYRAMINE except when included in Schedule 2 or 3.
MEQUITAZINE.
MERCAPTAMINE for human therapeutic use.
MERCAPTOMERIN.
MERCAPTOPURINE.
MERCUROCHROME except when included in Schedule 2 or 6.
MERCURY for cosmetic or therapeutic use except:
(a) when separately specified in these Schedules; or
(b) in a sealed device which prevents access to the mercury.
MEROPENEM.
MERSALYL.
# MESABOLONE.
MESALAZINE.
MESNA.
# MESTANOLONE (androstalone).
# MESTEROLONE.
MESTRANOL.
# METANDIENONE.
METARAMINOL.
# METENOLONE.
METERGOLINE.
METFORMIN.
METHACHOLINE.
METHACYCLINE.
METHALLENESTRIL.
# METHANDRIOL.
METHANTHELINIUM.
METHAZOLAMIDE.
METHDILAZINE except when included in Schedule 3.
# METHENOLONE.
METHICILLIN.
METHIMAZOLE.
METHISAZONE.
METHIXENE.
METHOCARBAMOL.
METHOHEXITONE.
METHOIN.
METHOTREXATE.
METHOXAMINE except:
(a) when included in Schedule 2; or
(b) in preparations for external use containing 1% or less of methoxamine.
METHOXSALEN.
METHOXYFLURANE.
METHSUXIMIDE.
METHYCLOTHIAZIDE.
METHYL AMINOLEVULINATE.
#METHYLANDROSTANOLONE.
# METHYLCLOSTEBOL.
METHYLDOPA.
METHYLENE BLUE in preparations for injection.
METHYLERGOMETRINE.
METHYLMERCURY for therapeutic use.
METHYLNALTREXONE.
METHYLPENTYNOL.
METHYLPHENOBARBITAL.
METHYLPHENYLPIRACETAM.
METHYLPREDNISOLONE.
METHYLROSANILINIUM CHLORIDE for human use except when used as a dermal marker.
METHYL SALICYLATE in preparations for internal therapeutic use.
# METHYLTESTOSTERONE.
METHYLTHIOURACIL.
# METHYLTRIENOLONE.
METHYPRYLONE.
METHYSERGIDE.
METOCLOPRAMIDE except when included in Schedule 3.
METOLAZONE.
METOPROLOL.
# METRIBOLONE.
METRIFONATE (trichlorfon) for human therapeutic use.
METRONIDAZOLE.
METYRAPONE.
MEXILETINE.
MEZLOCILLIN.
MIANSERIN.
MIBEFRADIL.
# MIBOLERONE.
MICAFUNGIN.
MICONAZOLE except:
(a) when included in Schedule 2, 3 or 6; or
(b) in preparations for dermal use for the treatment of tinea pedis.
# MIDAZOLAM.
MIDOSTAURIN.
MIDODRINE.
MIFEPRISTONE.
MIGALASTAT.
MIGLITOL.
MIGLUSTAT.
MILBEMYCIN OXIME except when included in Schedule 5.
MILNACIPRAN.
MILRINONE.
MINOCYCLINE.
MINOXIDIL except when included in Schedule 2.
MIRABEGRON.
MIRTAZAPINE.
MISOPROSTOL.
MITOBRONITOL.
MITOMYCIN.
MITOTANE.
MITOXANTRONE.
MITRATAPIDE.
MIVACURIUM CHLORIDE.
MOBOCERTINIB.
MOCLOBEMIDE.
MODAFINIL.
MOLGRAMOSTIM.
MOLINDONE.
MOLNUPIRAVIR.
MOMETASONE except when included in Schedule 2 or Schedule 3.
MONENSIN except:
(a) when included in Schedule 5 or 6; or
(b) in animal feeds containing 360 mg/kg or less of antibiotic substances.
MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use except in cosmetic nail preparations containing 0.02% or less of monobenzone or alkyl ethers of hydroquinone.
MONOCLONAL ANTIBODIES for therapeutic use except:
(a) in diagnostic test kits; or
(b) when separately specified in these Schedules.
MONOETHANOLAMINE in preparations for injection.
MONTELUKAST.
MOPERONE.
MORAZONE.
MORICIZINE.
MOTRAZEPAM.
MOTRETINIDE.
MOXIDECTIN in preparations for injection containing 10% or less of moxidectin except when included in Schedule 5 or 6.
MOXIFLOXACIN.
MOXONIDINE.
MUMPS VACCINE.
MUPIROCIN.
MURAGLITAZAR.
MUROMONAB.
MUSTINE (nitrogen mustard).
MYCOPHENOLIC ACID (includes mycophenolate mofetil).
NABUMETONE.
NADOLOL.
NADROPARIN.
NAFARELIN.
NAFTIDROFURYL.
NALBUPHINE.
NALIDIXIC ACID.
NALMEFENE.
NALORPHINE.
NALOXEGOL.
NALOXONE except when in Schedule 3.
NALTREXONE.
# NANDROLONE.
NAPROXEN except when included in Schedule 2 or 3.
NARASIN except:
(a) when included in Schedule 6; or
(b) in animal feeds containing 100 mg/kg or less of antibiotic substances.
NARATRIPTAN.
NATALIZUMAB.
NATAMYCIN except for use as a food additive.
NATEGLINIDE.
NEBACUMAB.
NEBIVOLOL.
NEBRACETAM.
NEDOCROMIL.
NEFAZODONE.
NEFIRACETAM.
NEFOPAM.
NELFINAVIR (includes nelfinavir mesilate).
NEOMYCIN.
NEOSTIGMINE.
NEPAFENAC.
NERATINIB.
NERIUM OLEANDER.
NESIRITIDE.
NETILMICIN.
NETUPITANT.
NEVIRAPINE.
NIALAMIDE.
NICARDIPINE.
NICERGOLINE.
NICOFURANOSE.
NICORANDIL.
# NICOTINE in preparations for human use except:
(a) in preparations for oromucosal or transdermal administration for human therapeutic use as an aid in withdrawal from tobacco smoking; or
(b) in tobacco prepared and packed for smoking.
NICOTINIC ACID for human therapeutic use except:
(a) when separately specified in these Schedules; or
(b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
(c) nicotinamide.
NICOUMALONE.
NIFEDIPINE.
NIFENAZONE.
NIKETHAMIDE.
NILOTINIB.
NILUTAMIDE.
NIMESULIDE.
NIMODIPINE.
NIMORAZOLE.
NINTEDANIB.
NIRAPARIB.
NIRIDAZOLE.
NIRMATRELVIR.
NISOLDIPINE.
NITISINONE.
# NITRAZEPAM.
NITRENDIPINE.
NITRIC OXIDE for human therapeutic use.
NITROFURANTOIN.
NITROFURAZONE.
NITROUS OXIDE for therapeutic use.
NITROXOLINE.
NIVOLUMAB.
NIZATIDINE except when included in Schedule 2.
NOMEGESTROL.
NOMIFENSINE.
NORADRENALINE.
# 19‑NORANDROSTENEDIOL.
# 19‑NORANDROSTENEDIONE.
# NORANDROSTENOLONE.
# NORBOLETHONE.
# NORCLOSTEBOL.
NORELGESTROMIN.
# NORETHANDROLONE.
NORETHISTERONE.
NORFLOXACIN.
NORGESTREL.
NORIBOGAINE.
NORMAL HUMAN IMMUNOGLOBULIN.
# NORMETHANDRONE.
NORTRIPTYLINE.
NOVOBIOCIN.
NOXIPTYLINE.
NUSINERSEN.
NYSTATIN except when included in Schedule 2 or 3.
OBETICHOLIC ACID.
OCLACITINIB.
OCRELIZUMAB.
OCRIPLASMIN.
OCTAMYLAMINE.
OCTATROPINE.
OCTREOTIDE.
OCTYL NITRITE.
OFATUMUMAB.
OFLOXACIN.
OLANZAPINE.
OLAPARIB.
OLARATUMAB.
OLEANDOMYCIN except:
(a) when included in Schedule 5; or
(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
OLEANDRIN.
OLMESARTAN.
OLODATEROL.
OLOPATADINE.
OLSALAZINE.
OMALIZUMAB.
OMBERACETAM.
OMBITASVIR.
OMEGA‑3‑ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post‑myocardial infarction and/or hypertriglyceridaemia.
OMEPRAZOLE except when included in Schedule 2 or 3.
ONASEMNOGENE ABEPARVOVEC.
ONDANSETRON.
OPICAPONE.
OPIPRAMOL.
ORBIFLOXACIN.
ORCIPRENALINE.
ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:
(a) when separately specified in these Schedules; or
(b) in preparations containing 2% or less of malathion for external use.
ORLISTAT except when included in Schedule 3.
ORNIDAZOLE.
ORNIPRESSIN.
ORPHENADRINE.
ORTHOPTERIN.
OSELTAMIVIR.
OSILODROSTAT.
OSIMERTINIB.
OUABAIN.
# OVANDROTONE.
# OXABOLONE.
OXACILLIN.
OXALIPLATIN.
# OXANDROLONE.
OXAPROZIN.
# OXAZEPAM.
OXCARBAZEPINE.
OXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.
OXETACAINE (oxethazaine) except when included in Schedule 2.
OXICONAZOLE except:
(a) when included in Schedule 2 or 3; or
(b) in preparations for the treatment of tinea pedis.
OXIRACETAM.
OXITROPIUM.
OXOLAMINE.
OXOLINIC ACID.
OXPRENOLOL.
OXYBUPROCAINE.
OXYBUTYNIN.
# OXYMESTERONE.
# OXYMETHOLONE.
OXYPHENBUTAZONE.
OXYPHENCYCLIMINE.
OXYPHENONIUM.
OXYTETRACYCLINE except when included in Schedule 5.
OXYTOCIN.
OZANIMOD.
PACLITAXEL.
PALBOCICLIB.
PALIFERMIN.
PALIPERIDONE.
PALIVIZUMAB.
PALONOSETRON.
PAMAQUIN.
PAMIDRONIC ACID (includes pamidronate disodium).
PANCREATIC ENZYMES except:
(a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or
(b) when separately specified in these Schedules.
PANCURONIUM.
PANITUMUMAB.
PANOBINOSTAT.
PANTOPRAZOLE except when included in Schedule 2 or 3.
PAPAVERINE in preparations for injection.
PARACETAMOL:
(a) when combined with aspirin or salicylamide or any derivative of these substances except when separately specified in these Schedules; or
(b) when combined with ibuprofen in a primary pack containing more than 30 dosage units; or
(c) in modified release tablets or capsules containing more than 665 mg paracetamol; or
(d) in non‑modified release tablets or capsules containing more than 500 mg paracetamol; or
(e) in individually wrapped powders or sachets of granules each containing more than 1000 mg paracetamol; or
(f) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules except in Schedule 2 or Schedule 3; or
(g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules except when included in Schedule 2; or
(h) for injection; or
(i) for the treatment of animals.
PARALDEHYDE.
PARAMETHADIONE.
PARAMETHASONE.
PARECOXIB.
PARICALCITOL.
PARITAPREVIR.
PAROMOMYCIN.
PAROXETINE.
PASIREOTIDE.
PATIROMER SORBITEX CALCIUM.
PATISIRAN.
PAZOPANIB.
PECAZINE.
PEFLOXACIN.
PEGAPTANIB.
PEGASPARGASE.
PEGCETACOPLAN.
PEGFILGRASTIM.
PEGINTERFERON.
PEGVALIASE.
PEGVISOMANT.
PEMBROLIZUMAB.
PEMETREXED.
PEMIGATINIB.
PEMOLINE.
PEMPIDINE.
PENBUTOLOL.
PENCICLOVIR except in preparations containing 1% or less of penciclovir for the treatment of herpes labialis in packs containing 10 g or less.
PENETHAMATE.
PENICILLAMINE.
PENTAERYTHRITYL TETRANITRATE.
PENTAGASTRIN.
PENTAMETHONIUM.
PENTAMIDINE (includes pentamidine isetionate).
PENTHIENATE.
PENTOBARBITAL when packed and labelled for injection.
PENTOLINIUM.
PENTOSAN POLYSULFATE SODIUM.
PENTOXIFYLLINE.
PERAMIVIR.
# PERAMPANEL.
PERGOLIDE.
PERHEXILINE.
PERICIAZINE.
PERINDOPRIL.
PERMETHRIN for human therapeutic use except in preparations containing 5% or less of permethrin.
PERPHENAZINE.
PERTUSSIS ANTIGEN.
PERTUZUMAB.
PHENACEMIDE.
PHENACETIN for therapeutic use (excluding when present as an excipient).
PHENAGLYCODOL.
PHENAZONE except when included in Schedule 2 or 5.
PHENAZOPYRIDINE.
PHENELZINE.
PHENETICILLIN.
PHENFORMIN.
PHENGLUTARIMIDE.
PHENINDIONE.
PHENIRAMINE except when included in Schedule 2 or 3.
PHENISATIN.
PHENOBARBITAL.
PHENOL in preparations for injection.
PHENOLPHTHALEIN for human therapeutic use.
PHENOXYBENZAMINE.
PHENOXYMETHYLPENICILLIN.
PHENSUXIMIDE.
# PHENTERMINE.
PHENTHIMENTONIUM.
PHENTOLAMINE.
PHENYLBUTAZONE.
PHENYLEPHRINE:
(a) in preparations for injection; or
(b) in preparations for human ophthalmic use containing 5% or more of phenylephrine.
PHENYLPIRACETAM.
PHENYLPROPANOLAMINE.
PHENYLTOLOXAMINE.
PHENYTOIN.
PHLEUM PRATENSE POLLEN EXTRACT (Timothy‑grass pollen extract).
PHOLCODINE:
(a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or
(b) in undivided preparations containing 2.5% or less of pholcodine;
except when included in Schedule 2.
PHOSPHODIESTERASE TYPE 5 INHIBITORS except:
(a) when separately specified in these Schedules; or
(b) when present as an unmodified, naturally occurring substance.
PHTHALYLSULFATHIAZOLE.
PHYSOSTIGMINE.
PIBRENTASVIR.
PICROTOXIN.
PILOCARPINE except in preparations containing 0.025% or less of pilocarpine.
PIMECROLIMUS.
PIMOBENDAN.
PIMOZIDE.
PINACIDIL.
PINDOLOL.
PIOGLITAZONE.
PIPECURONIUM.
PIPEMIDIC ACID.
PIPENZOLATE.
PIPER METHYSTICUM (kava) in preparations for human use except when included on the Register in preparations:
(a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:
(i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or
(ii) the amount of dried whole or peeled rhizome and/or root in the teabag does not exceed 3 g;
and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the required advisory statements for medicine labels; or
(b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome and/or root or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome and/or root; or
(c) in dermal preparations.
PIPERACILLIN.
PIPERIDINE.
PIPERIDOLATE.
PIPOBROMAN.
PIPOTHIAZINE.
PIPRADROL.
PIRACETAM.
PIRBUTEROL.
PIRENOXINE (catalin).
PIRENZEPINE.
PIRETANIDE.
PIRFENIDONE.
PIROXICAM except in preparations for dermal use.
PIRPROFEN.
PITAVASTATIN.
PITUITARY HORMONES except when separately specified in these Schedules.
PIVAMPICILLIN.
PIZOTIFEN.
PLICAMYCIN.
PLITIDEPSIN.
PLERIXAFOR.
PNEUMOCOCCAL VACCINE.
PODOPHYLLOTOXIN for human use:
(a) internally; or
(b) in preparations for the treatment of anogenital warts; or
(c) in other preparations except when included in Schedule 2 or 3.
PODOPHYLLUM EMODI (podophyllin) for human use:
(a) internally; or
(b) in preparations for the treatment of anogenital warts; or
(c) in other preparations except when included in Schedule 2 or 3.
PODOPHYLLUM PELTATUM (podophyllin) for human use:
(a) internally; or
(b) in preparations for the treatment of anogenital warts; or
(c) in other preparations except when included in Schedule 2 or 3.
POLIDEXIDE.
POLIOMYELITIS VACCINE.
POLYACRYLAMIDE in preparations for injection or implantation:
(a) for tissue augmentation; or
(b) for cosmetic use; or
(c) for veterinary use.
POLYCAPROLACTONE in preparations for injection or implantation:
(a) for tissue augmentation; or
(b) for cosmetic use.
POLYESTRADIOL.
POLYLACTIC ACID in preparations for injection or implantation:
(a) for tissue augmentation; or
(b) for cosmetic use.
POLYMYXIN.
POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, except when separately specified in these Schedules.
POLYTHIAZIDE.
POMALIDOMIDE.
PONATINIB.
PONESIMOD.
PORACTANT.
POSACONAZOLE.
POTASSIUM BROMIDE for therapeutic use.
POTASSIUM CHLORIDE in oral preparations for human therapeutic use except:
(a) when containing less than 550 mg of potassium chloride per dosage unit; or
(b) in preparations for oral rehydration therapy; or
(c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or
(d) in preparations for enteral feeding.
POTASSIUM PERCHLORATE for therapeutic use.
PRACTOLOL.
PRADOFLOXACIN.
PRALATREXATE.
PRALIDOXIME.
PRAMIPEXOLE.
PRAMIRACETAM.
PRAMOCAINE.
# PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE‑2 (GHRP‑2)).
PRALSETINIB.
PRAMPINE.
# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).
PRASUGREL.
PRAVASTATIN.
# PRAZEPAM.
PRAZIQUANTEL for human therapeutic use.
PRAZOSIN.
PREDNISOLONE.
PREDNISONE.
PREGABALIN.
PREGNENOLONE.
PRENALTEROL.
PRENYLAMINE.
PRILOCAINE except when included in Schedule 2.
PRIMAQUINE.
PRIMIDONE.
PROBENECID.
PROBUCOL.
PROCAINAMIDE.
PROCAINE.
PROCAINE BENZYLPENICILLIN.
PROCARBAZINE.
PROCHLORPERAZINE except when included in Schedule 3.
PROCYCLIDINE except when included in Schedule 2.
PROGESTERONE except when included in Schedule 5.
PROGESTOGENS except when separately specified in these Schedules.
PROGLUMIDE.
PROGUANIL.
PROLINTANE.
PROMAZINE.
PROMETHAZINE except when included in Schedule 2 or 3.
PROMOXOLANE.
PROPAFENONE.
PROPAMIDINE for therapeutic use except when included in Schedule 2.
PROPANIDID.
PROPANTHELINE.
PROPENTOFYLLINE.
# PROPETANDROL.
PROPIONIBACTERIUM ACNES for therapeutic use.
PROPOFOL.
PROPRANOLOL.
PROPYLHEXEDRINE.
PROPYLTHIOURACIL.
PROPYPHENAZONE.
PROQUAZONE.
PROSCILLARIDIN.
PROSTAGLANDINS except when separately specified in this Schedule.
PROSTIANOL.
PROTAMINE.
PROTHIONAMIDE.
PROTHIPENDYL.
PROTIRELIN.
PROTOVERATRINES.
PROTRIPTYLINE.
PROXYMETACAINE.
PRUCALOPRIDE.
PSEUDOEPHEDRINE except when included in Schedule 3.
PYRAZINAMIDE.
PYRIDINOLCARBAMATE.
PYRIDOSTIGMINE.
PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use except:
(a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the required advisory statements for medicine labels; or
(b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.
PYRIMETHAMINE.
PYROVALERONE.
PYRVINIUM.
# QUAZEPAM.
QUETIAPINE.
QUINAGOLIDE.
QUINAPRIL.
# QUINBOLONE.
QUINETHAZONE.
QUINIDINE.
QUININE for human therapeutic use except when the maximum recommended daily dose is 50 mg or less of quinine.
QUINISOCAINE (dimethisoquin).
QUINUPRISTIN.
RABEPRAZOLE except when included in Schedule 2 or 3.
RABIES VACCINE.
RACETAMS except when separately specified in these Schedules.
RACTOPAMINE except when included in Schedule 5.
RALOXIFENE.
RALTEGRAVIR.
RALTITREXED.
RAMIPRIL.
RAMUCIRUMAB.
RANIBIZUMAB.
RANITIDINE except:
(a) when included in Schedule 2; or
(b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not more than 14 dosage units; or
(c) in divided preparations for oral use containing 300mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units.
RANOLAZINE.
RAPACURONIUM.
RASAGILINE.
RASBURICASE.
RAUWOLFIA SERPENTINA.
RAUWOLFIA VOMITORIA.
RAZOXANE.
REBOXETINE.
RED YEAST RICE for human therapeutic use.
REMDESIVIR.
REGDANVIMAB.
REGORAFENIB.
REMOXIPRIDE.
REPAGLINIDE.
RESERPINE.
RESLIZUMAB.
RETAPAMULIN.
RETEPLASE.
RETIGABINE.
RIBAVIRIN.
RIBOCICLIB.
RIDAFOROLIMUS.
RIFABUTIN.
RIFAMPICIN.
RIFAMYCIN.
RIFAPENTINE.
RIFAXIMIN.
RILPIVIRINE.
RILUZOLE.
RIMEXOLONE.
RIMITEROL.
RIMONABANT.
# RIOCIGUAT.
RIPRETINIB.
RISANKIZUMAB.
RISDIPLAM.
RISEDRONIC ACID.
RISPERIDONE.
RITODRINE.
RITONAVIR.
RITUXIMAB.
RIVAROXABAN.
RIVASTIGMINE.
RIZATRIPTAN except when included in Schedule 3.
ROBENACOXIB.
ROCURONIUM.
ROFECOXIB.
ROFLUMILAST.
ROLITETRACYCLINE.
ROLZIRACETAM.
ROMIDEPSIN.
ROMIFIDINE.
ROMIPLOSTIM.
ROMOSOZUMAB.
RONIDAZOLE.
ROPINIROLE.
ROPIVACAINE.
ROSIGLITAZONE.
ROSOXACIN.
ROSUVASTATIN.
ROTIGOTINE.
# ROXIBOLONE.
ROXITHROMYCIN.
RUBELLA VACCINE.
RUBOXISTAURIN.
RUFINAMIDE.
RUPATADINE.
RUXOLITINIB.
SACITUZUMAB GOVITECAN.
SACUBITRIL.
SAFINAMIDE.
SALBUTAMOL except when included in Schedule 3.
SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.
SALINOMYCIN except:
(a) when included in Schedule 6; or
(b) in animal feeds containing 60 mg/kg or less of antibiotic substances.
SALMETEROL.
SAPROPTERIN.
SAQUINAVIR.
SARILUMAB.
SARS‑COV‑2 (COVID‑19) VACCINE.
SAXAGLIPTIN.
SCHOENOCAULON OFFICINALE (sabadilla) except in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of Schoenocaulon officinale.
SCOPOLIA CARNIOLICA for therapeutic use.
SEBELIPASE ALFA.
SECUKINUMAB.
# SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).
SELEGILINE.
SELENIUM:
(a) for human oral use with a recommended daily dose of more than 300 micrograms; or
(b) for the treatment of animals except:
(i) when included in Schedule 6 or 7; or
(ii) in solid, slow release bolus preparations containing 300 mg or less of selenium per dosage unit; or
(iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit; or
(iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or
(v) in feeds containing 1 g/tonne or less of selenium.
SELETRACETAM.
SELEXIPAG.
SELINEXOR.
SELUMETINIB.
SEMAGLUTIDE.
SERELAXIN.
SERMORELIN.
SERTINDOLE.
SERTRALINE.
SEVELAMER.
SEVOFLURANE.
SEX HORMONES and all substances having sex hormonal activity except when separately specified in these Schedules.
SIBUTRAMINE.
# SILANDRONE.
SILDENAFIL.
SILICONES for intra‑ocular use.
SILODOSIN.
SILTUXIMAB.
SILVER SULFADIAZINE.
SIMEPREVIR.
SIMVASTATIN.
SIPONIMOD.
SIROLIMUS.
SISOMICIN (sisomycin).
SITAGLIPTIN.
# SITAXENTAN.
SODIUM BROMIDE for therapeutic use.
SODIUM CELLULOSE PHOSPHATE for human internal use.
SODIUM CROMOGLYCATE except when included in Schedule 2.
SODIUM GLYCEROPHOSPHATE HYDRATE.
SODIUM MORRHUATE in preparations for injection.
SODIUM NITROPRUSSIDE for human therapeutic use.
SODIUM PHENYLBUTYRATE.
SODIUM PHOSPHATE in preparations for oral laxative use.
SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.
SODIUM SALICYLATE in preparations for internal use for the treatment of animals.
SODIUM TETRADECYLSULFATE in preparations for injection.
SODIUM ZIRCONIUM CYCLOSILICATE.
SOFOSBUVIR.
SOLASODINE.
SOLIFENACIN.
SOMAPACITAN.
SOMATOSTATIN.
SOMATOTROPIN EQUINE.
# SOMATROPIN (human growth hormone).
SONIDEGIB.
SONTOQUINE.
SORAFENIB.
SOTALOL.
SOTORASIB.
SOTROVIMAB.
SPARFLOXACIN.
SPARTEINE.
SPECTINOMYCIN.
SPIRAMYCIN.
SPIRAPRIL.
SPIRONOLACTONE.
# STANOLONE.
# STANOZOLOL.
STAVUDINE.
# STENABOLIC (SR9009) and other synthetic REV‑ERB agonists.
# STENBOLONE.
STEROID HORMONES except when separately specified in these Schedules.
STILBESTROL (diethylstilbestrol).
STIRIPENTOL.
STREPTODORNASE.
STREPTOKINASE.
STREPTOMYCIN.
STRONTIUM RANELATE.
STROPHANTHINS.
STROPHANTHUS spp.
STRYCHNINE in preparations containing 1.5% or less of strychnine for the treatment of animals.
STRYCHNOS spp. except in preparations containing 1 mg or less per litre or per kilogram of strychnine.
STYRAMATE.
SUCCIMER.
SUCROFERRIC OXYHYDROXIDE.
SUGAMMADEX.
SULBACTAM.
SULCONAZOLE except when included in Schedule 2.
SULFACETAMIDE except when included in Schedule 3 or 5.
SULFADIAZINE except when included in Schedule 5.
SULFADIMETHOXINE.
SULFADIMIDINE except when included in Schedule 5.
SULFADOXINE.
SULFAFURAZOLE.
SULFAGUANIDINE.
SULFAMERAZINE except when included in Schedule 5.
SULFAMETHIZOLE.
SULFAMETHOXAZOLE.
SULFAMETHOXYDIAZINE.
SULFAMETHOXYPYRIDAZINE.
SULFAMETROLE.
SULFAMONOMETHOXINE.
SULFAMOXOLE.
SULFAPHENAZOLE.
SULFAPYRIDINE.
SULFAQUINOXALINE.
SULFASALAZINE.
SULFATHIAZOLE except when included in Schedule 5.
SULFATROXAZOLE.
SULFINPYRAZONE.
SULFOMYXIN.
SULFONAMIDES except:
(a) when separately specified in this Schedule; or
(b) when included in Schedule 3, 5 or 6; or
(c) when packed and labelled solely for use as a herbicide.
SULFONMETHANE (sulfonal) and alkyl sulfonals.
SULINDAC.
SULTAMICILLIN.
SULTHIAME.
SUMATRIPTAN except when included in Schedule 3.
SUNIFIRAM.
SUNITINIB.
SUPROFEN.
SUTILAINS.
SUXAMETHONIUM.
SUXETHONIUM.
SUVOREXANT.
TACRINE.
TACROLIMUS.
TADALAFIL.
TAFAMIDIS.
TAFENOQUINE SUCCINATE.
TAFLUPROST.
TALAZOPARIB.
TALIGLUCERASE ALFA.
TALIMOGENE LAHERPAREPVEC.
TAMOXIFEN.
TAMSULOSIN.
TANACETUM VULGARE except in preparations containing 0.8% or less of oil of tansy.
TASONERMIN.
TAZAROTENE.
TAZOBACTAM.
# TB‑500.
T‑CELL RECEPTOR ANTIBODY.
TEDUGLUTIDE.
TEGAFUR.
TEGASEROD.
TELAPREVIR.
TELITHROMYCIN.
TEICOPLANIN.
TELBIVUDINE.
TELMISARTAN.
TELOTRISTAT ETHYL.
# TEMAZEPAM.
TEMOZOLOMIDE.
TEMSIROLIMUS.
TENECTEPLASE.
TENIPOSIDE.
TENOFOVIR.
TENOXICAM.
TEPOTINIB.
TEPOXALIN.
TERAZOSIN.
TERBINAFINE except:
(a) when included in Schedule 2; or
(b) in preparations for dermal use for the treatment of tinea pedis.
TERBUTALINE except when included in Schedule 3.
TERFENADINE.
TERIFLUNOMIDE.
# TERIPARATIDE.
TERLIPRESSIN.
TERODILINE.
TEROPTERIN.
# TESTOLACTONE.
# TESTOSTERONE except when included in Schedule 6.
TETANUS ANTITOXIN except when used for short‑term protection or treatment of tetanus in animals.
TETANUS TOXOID for human use.
TETRABENAZINE.
TETRACAINE except:
(a) when included in Schedule 2; or
(b) in dermal preparations containing 2% or less of total local anaesthetic substances.
TETRACOSACTIDE.
TETRACYCLINE except when included in Schedule 5.
TETRAETHYLAMMONIUM.
TETROXOPRIM.
TEZACAFTOR.
# THALIDOMIDE.
THENYLDIAMINE.
THEOPHYLLINE except when included in Schedule 3.
THEVETIA PERUVIANA.
THEVETIN.
THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.
THIAMBUTOSINE.
THIAZOSULFONE.
THIETHYLPERAZINE.
THIOACETAZONE.
THIOCARLIDE.
# THIOMESTERONE (tiomesterone).
THIOPENTAL.
THIOPROPAZATE.
THIOPROPERAZINE.
THIORIDAZINE.
THIOSTREPTON.
THIOTEPA.
THIOTHIXENE.
THIOURACIL.
THIOUREA for therapeutic use except in preparations containing 0.1% or less of thiourea.
# THYMOSIN BETA 4 (THYMOSIN β4).
THYMOXAMINE (includes thymoxamine hydrochloride).
THYROID except when separately specified in this Schedule.
THYROTROPHIN.
THYROXINE (includes thyroxine sodium).
TIAGABINE.
TIAMULIN.
# TIANEPTINE.
TIAPROFENIC ACID.
TIARAMIDE.
TIBOLONE.
TICAGRELOR.
TICARCILLIN.
TICLOPIDINE.
TIEMONIUM.
TIENILIC ACID.
TIGECYCLINE.
TIGILANOL TIGLATE.
TIGLOIDINE.
TILDIPIROSIN.
TILETAMINE.
TILMANOCEPT.
TILMICOSIN.
TILUDRONIC ACID (includes disodium tiludronate).
TIMOLOL.
TINIDAZOLE.
TINZAPARIN (includes tinzaparin sodium).
TIOCONAZOLE except:
(a) when included in Schedule 2 or 3; or
(b) in preparations for dermal use for the treatment of tinea pedis.
TIOGUANINE.
TIOTROPIUM.
TIPEPIDINE.
TIPIRACIL.
TIPRANAVIR.
TIRILAZAD.
TIROFIBAN.
TIRZEPATIDE.
TIXAGEVIMAB.
TOBRAMYCIN.
TOCAINIDE.
TOCERANIB.
TOCILIZUMAB.
TOFACITINIB.
TOLAZAMIDE.
TOLAZOLINE.
TOLBUTAMIDE.
TOLCAPONE.
TOLFENAMIC ACID.
TOLMETIN.
TOLONIUM.
TOLPROPAMINE.
TOLRESTAT.
TOLTERODINE.
TOLVAPTAN.
TOPIRAMATE.
TOPOTECAN.
TORASEMIDE.
TOREMIFENE.
TOXOIDS for human parenteral use except when separately specified in these Schedules.
TRABECTEDIN.
TRAMADOL.
TRANDOLAPRIL.
TRAMETINIB DIMETHYL SULFOXIDE.
TRANEXAMIC ACID except in preparations containing 3% or less of cetyl tranexamate hydrochloride for dermal cosmetic use.
TRANYLCYPROMINE.
TRASTUZUMAB.
TRASTUZUMAB DERUXTECAN.
TRASTUZUMAB EMTANSINE.
TRAVOPROST.
TRAZODONE.
# TRENBOLONE (trienbolone, trienolone) except when included in Schedule 5.
TREOSULPHAN.
TREPROSTINIL.
# TRESTOLONE.
TRETAMINE.
# TRETINOIN except the ester hydroxypinacolone retinoate in preparations for dermal use containing 0.5% or less of hydroxypinacolone retinoate.
TRIACETYLOLEANDOMYCIN.
TRIAMCINOLONE except when included in Schedule 2 or 3.
TRIAMTERENE.
TRIAZIQUONE.
# TRIAZOLAM.
TRICHLORMETHIAZIDE.
TRICHLOROACETIC ACID for human dermal use except when in preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts.
TRICHLOROETHYLENE for therapeutic use.
TRICLOFOS.
TRICYCLAMOL.
TRIDIHEXETHYL.
TRIENTINE.
TRIFAROTENE.
TRIFLUOPERAZINE.
TRIFLUPERIDOL.
TRIFLUPROMAZINE.
TRIFLURIDINE.
TRIHEXYPHENIDYL.
TRILOSTANE.
TRIMETAPHAN.
TRIMETHOPRIM.
TRIMIPRAMINE.
TRIMUSTINE.
TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.
TRIOXYSALEN.
TRIPELENNAMINE.
TRIPROLIDINE except when included in Schedule 2 or 3.
TRIPTORELIN.
TROGLITAZONE.
TROLAMINE when in preparations for tattoo removal.
TROMETAMOL in preparations for injection except in preparations containing 3% or less of trometamol.
TROPICAMIDE.
TROPISETRON.
TROVAFLOXACIN.
TROXIDONE.
TRYPTOPHAN for human therapeutic use except in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.
TUBERCULIN.
TUBOCURARINE.
TUCATINIB.
TULATHROMYCIN.
TULOBUTEROL.
TYLOSIN.
TYPHOID VACCINE.
ULIPRISTAL except when included in Schedule 3.
UMECLIDINIUM.
UNIFIRAM.
UNOPROSTONE.
UPADACITINIB.
URACIL.
URAPIDIL.
URETHANE (excluding its derivatives) for therapeutic use.
# UROFOLLITROPIN.
UROKINASE.
URSODEOXYCHOLIC ACID.
USTEKINUMAB.
VACCINES for human therapeutic use except when separately specified in this Schedule.
VACCINES for veterinary live virus except:
(a) poultry vaccines; or
(b) pigeon pox vaccine; or
(c) scabby mouth vaccine; or
(d) bovine ephemeral fever vaccine; or
(e) bovine herpesvirus‑1 vaccine.
VACCINES – PLASMID DNA for animal use except when separately specified in these Schedules.
VACCINIA VIRUS VACCINE.
VALACICLOVIR.
VALDECOXIB.
VALGANCICLOVIR.
VALNOCTAMIDE.
VALPROIC ACID.
VALSARTAN.
VANCOMYCIN.
VANDETANIB.
VARDENAFIL.
VARENICLINE.
VARICELLA VACCINE.
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN.
VASOPRESSIN.
VECURONIUM.
VEDAPROFEN.
VEDOLIZUMAB.
VELAGLUCERASE ALFA.
VELPATASVIR.
VEMURAFENIB.
VENETOCLAX.
VENLAFAXINE.
VERAPAMIL.
VERATRUM spp. except when separately specified in this Schedule.
VERICIGUAT.
VERNAKALANT.
VERTEPORFIN.
VIDARABINE.
VIGABATRIN.
VILANTEROL.
VILDAGLIPTIN.
VILOXAZINE.
VINBLASTINE.
VINCAMINE.
VINCRISTINE.
VINDESINE.
VINFLUNINE.
VINORELBINE.
VINYL ETHER for therapeutic use.
VIRGINIAMYCIN except when included in Schedule 5.
VISMODEGIB.
VISNADINE.
VITAMIN A for human therapeutic or cosmetic use except:
(a) in preparations for topical use containing 1% or less of Vitamin A; or
(b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or
(c) in preparations for parenteral nutrition replacement.
VITAMIN D for human internal therapeutic use except:
(a) in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or
(b) when included in Schedule 3.
VORAPAXAR.
VORETIGENE NEPARVOVEC.
VORICONAZOLE.
VORINOSTAT.
VORTIOXETINE.
VOSORITIDE.
VOXILAPREVIR.
WARFARIN for therapeutic use.
XAMOTEROL.
XANTHINOL NICOTINATE.
XIMELAGATRAN.
XIPAMIDE.
XYLAZINE.
YOHIMBINE.
ZAFIRLUKAST.
ZALCITABINE.
ZALEPLON.
ZANAMIVIR.
ZANUBRUTINIB.
ZERANOL except when included in Schedule 6.
ZIDOVUDINE.
ZILPATEROL.
ZIMELDINE.
ZINC COMPOUNDS for human internal use except:
(a) in preparations with a recommended daily dose of 25 mg or less of zinc; or
(b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the required advisory statements for medicine labels.
ZIPRASIDONE.
ZOLAZEPAM.
ZOLEDRONIC ACID.
ZOLMITRIPTAN except when included in Schedule 3.
ZOLPIDEM.
ZONISAMIDE.
ZOPICLONE.
ZOXAZOLAMINE.
ZUCLOPENTHIXOL.
Schedule 5—Caution
Note: See paragraph (e) of the definition of designated solvent in section 6, paragraph 7(j), sections 16 and 25, subsection 26(2) and sections 42, 46, 47, 49, 55 and 61.
ABAMECTIN
(a) in preparations, for internal use for the treatment of animals, containing 1% or less of abamectin; or
(b) in gel formulations containing 0.05% or less of abamectin in applicators containing 50 mg or less of abamectin.
ABSCISIC ACID.
ACEQUINOCYL.
ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30% of acetic acid (CH3COOH) except:
(a) when included in Schedule 2 or 6; or
(b) for therapeutic use.
ACETONE except in preparations containing 25% or less of designated solvents.
ACRIFLAVINIUM CHLORIDE in preparations for veterinary use containing 2.5% or less of acriflavinium chloride.
AFOXOLANER in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit
(a) for the treatment and prevention of flea infestations and control of ticks in dogs; or
(b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with milbemycin oxime.
AKLOMIDE.
ALBENDAZOLE for the treatment of animals, in preparations containing 12.5% or less of albendazole except in intraruminal implants each containing 3.85 g or less of albendazole.
ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:
(a) in solid orthodontic device cleaning preparations, the pH of which as an “in‑use” aqueous solution is more than 11.5; or
(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5; or
(c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
(d) in liquid or semi‑solid preparations, the pH of which is more than 11.5, unless:
(i) in food additive preparations for domestic use; or
(ii) in automatic dish washing preparations for domestic use with a pH of more than 12.5;
except when separately specified in these Schedules.
ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50% or less of alkoxylated fatty alkylamine polymer except in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.
ALLETHRIN in preparations containing 10% or less of allethrin except:
(a) in insecticidal mats; or
(b) in other preparations containing 1% or less of allethrin.
ALLOXYDIM.
ALPHA‑CYPERMETHRIN:
(a) in aqueous preparations containing 3% or less of alpha‑cypermethrin; or
(b) in other preparations containing 1.5% or less of alpha‑cypermethrin.
AMETRYN.
AMINES for use as curing agents for epoxy resins except when separately specified in these Schedules.
AMINOACRIDINE in preparations for veterinary use containing 2.5% or less of aminoacridine.
AMINOCYCLOPYRACHLOR except in preparations containing 25% or less of aminocyclopyrachlor.
AMINOPYRALID in preparations containing 22% or less of aminopyralid.
AMISULBROM.
AMITROLE.
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5% or less of ammonia except:
(a) in preparations for human internal therapeutic use; or
(b) in preparations for inhalation when absorbed in an inert solid material; or
(c) in preparations containing 0.5% or less of free ammonia.
AMMONIUM THIOCYANATE except in preparations containing 10% or less of ammonium thiocyanate.
ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins except when separately specified in these Schedules.
ANISE OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 50% or less of anise oil.
ASPIRIN for the treatment of animals, that is in divided preparations, when:
(a) packed in blister or strip packaging; or
(b) in a container with a child-resistant closure.
ATRAZINE.
AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5% or less of total limonoids, for agricultural use.
AZOXYSTROBIN.
BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas fluorescens.
BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.
BASIL OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 5% or less of methyl chavicol.
BEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFU)/mL or less of Beauveria bassiana.
BENALAXYL.
BENDIOCARB in preparations containing 2% or less of bendiocarb.
BENTAZONE.
BENZALKONIUM CHLORIDE in preparations containing 10% or less of benzalkonium chloride except in preparations containing 5% or less of benzalkonium chloride.
BENZOFENAP.
BENZOYL PEROXIDE except:
(a) when included in Schedule 2 or 4; or
(b) in preparations containing 5% or less of benzoyl peroxide.
BERGAMOT OIL except:
(a) when steam distilled or rectified; or
(b) in preparations for internal use; or
(c) in preparations containing 0.4% or less of bergamot oil; or
(d) in soaps or bath or shower gels that are washed off the skin; or
(e) in medicines for human therapeutic use when compliant with the requirements of the required advisory statements for medicine labels; or
(f) in other preparations when packed in containers labelled with the statement:
Application to the skin may increase sensitivity to sunlight.
BETACYFLUTHRIN:
(a) in aqueous preparations containing 2.5% or less of betacyfluthrin; or
(b) in solid preparations containing 8% or less of betacyfluthrin in a plastic matrix.
BICYCLOPYRONE in preparations containing 20% or less of bicyclopyrone.
BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3% or less of total bifluorides.
BIOALLETHRIN in preparations containing 10% or less of bioallethrin except in preparations containing 1% or less of bioallethrin.
BIORESMETHRIN except in preparations containing 10% or less of bioresmethrin.
BISPYRIBAC except in preparations containing 10% or less of bispyribac.
BIXAFEN.
BORIC ACID except:
(a) when included in Schedule 4; or
(b) in cosmetic hand cleaning preparations when labelled with a warning to the following effect:
NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and
if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:
NOT TO BE USED ON PEELING OR IRRITATED SKIN; or
(c) in cosmetic talc preparations containing 5% or less calculated as boric acid when labelled with a warning to the following effect:
NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and
if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:
NOT TO BE USED ON PEELING OR IRRITATED SKIN; or
(d) in cosmetic oral hygiene preparations containing 0.1% or less calculated as boric acid when labelled with a warning to the following effect:
NOT TO BE SWALLOWED. NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; or
(e) in other cosmetic preparations containing 3% or less calculated as boric acid when labelled with a warning to the following effect:
NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and
if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:
NOT TO BE USED ON PEELING OR IRRITATED SKIN; or
(f) in preparations, other than insect baits, containing 6% or less calculated as boric acid.
BORON TRIFLUORIDE in preparations containing 0.1% or less of boron trifluoride (BF3).
BROFLANILIDE in preparations containing 0.3% or less of broflanilide.
BROMUCONAZOLE in preparations containing 20% or less of bromuconazole.
BUPIVACAINE in aqueous gel preparations containing 0.5% or less of bupivacaine, for the dermal spray‑on administration to the wounds of animals.
BUPROFEZIN except in preparations containing 40% or less of buprofezin.
BUTHIDAZOLE.
BUTOXYCARBOXIM in solid preparations containing 10% or less of butoxycarboxim.
BUTRALIN.
BUTROXYDIM.
n‑BUTYL ALCOHOL in preparations containing 10% or less of n‑butyl alcohol except:
(a) in preparations containing 5% or less of n‑butyl alcohol; or
(b) in preparations for cosmetic or therapeutic use other than spray form.
CAMPHOR as a natural component in essential oils containing 10% or less of camphor except:
(a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or
(b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:
(i) KEEP OUT OF REACH OF CHILDREN; and
(ii) NOT TO BE TAKEN; or
(c) in rosemary oil, sage oil (Spanish), or lavandin oils; or
(d) in preparations containing 2.5% or less of camphor.
CARBAMIDE PEROXIDE in preparations containing 18% or less of carbamide peroxide except in preparations containing 9% or less of carbamide peroxide.
CARBARYL:
(a) in preparations containing 10% or less of carbaryl except when included in Schedule 4; or
(b) when impregnated into plastic resin material containing 20% or less of carbaryl.
CASSIA OIL except:
(a) in food additives; or
(b) in preparations for dermal use as a rubefacient containing 5% or less of cassia oil; or
(c) in other preparations containing 2% or less of cassia oil.
CHLORFENAC.
CHLORFENAPYR. in preparations containing 0.5% or less of chlorfenapyr.
CHLORFENSON.
CHLORHEXIDINE in preparations containing 3% or less of chlorhexidine except:
(a) in preparations containing 1% or less of chlorhexidine; or
(b) when in solid preparations.
CHLORINATING COMPOUNDS containing 20% or less of available chlorine, except:
(a) when separately specified in these Schedules; or
(b) sodium hypochlorite preparations with a pH of less than 11.5; or
(c) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:
WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or
(d) liquid preparations containing less than 2% of available chlorine; or
(e) other preparations containing 4% or less of available chlorine.
CHLORNIDINE.
CHLOROCRESOL except in preparations containing 3% or less of chlorocresol.
CHLORPROPHAM.
CHLORPYRIFOS:
(a) in aqueous preparations containing 20% or less of microencapsulated chlorpyrifos; or
(b) in controlled release granular preparations containing 10% or less of chlorpyrifos; or
(c) in other preparations containing 5% or less of chlorpyrifos;
except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.
CHLORSULFURON.
CHLORTETRACYCLINE in preparations:
(a) for topical application to animals for ocular use only; or
(b) containing 40% or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
CHLORTHAL‑DIMETHYL.
CINMETHYLIN.
CINNAMON BARK OIL except:
(a) in food additives; or
(b) in preparations containing 2% or less of cinnamon bark oil.
CIS‑JASMONE when prepared and packaged as an agricultural chemical except when present as a fragrance.
CLETHODIM.
CLIMBAZOLE in preparations containing 40% or less of climbazole except:
(a) in leave‑on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or
(b) in other preparations (that are not leave‑on cosmetic preparations) containing 2% or less of climbazole.
CLOFENTEZINE.
CLOPYRALID.
CLOQUINTOCET.
CLORSULON.
CLOTHIANIDIN in preparations containing 20% or less of clothianidin except in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin.
CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil except in preparations containing 25% or less of clove oil.
COPPER ACETATE in preparations containing 20% or less of copper acetate except in preparations containing 5% or less of copper acetate.
COPPER COMPOUNDS in animal feed additives containing 5% or less of copper except in preparations containing 1% or less of copper.
COPPER HYDROXIDE in preparations containing 50% or less of copper hydroxide except in preparations containing 12.5% or less of copper hydroxide.
COPPER OXIDES in preparations containing 25% or less of copper oxides except:
(a) in preparations for internal use; or
(b) in marine paints; or
(c) in other preparations containing 5% or less of copper oxides.
COPPER OXYCHLORIDE in preparations containing 50% or less of copper oxychloride except in preparations containing 12.5% or less of copper oxychloride.
COPPER SULFATE in preparations containing 15% or less of copper sulfate except:
(a) in preparations for internal use; or
(b) in other preparations containing 5% or less of copper sulfate.
COUMATETRALYL in rodenticides containing 0.05% or less of coumatetralyl.
4‑CPA.
CYANATRYN.
CYANOACRYLATE ESTERS in contact adhesives except:
(a) when labelled with the warning:
KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or
(b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:
(i) labelled with the approved name or trade name of the poison, the quantity and the warning:
Can cause eye injury. Instantly bonds skin; and
enclosed in a primary pack labelled with the warning:
KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.
CYANTRANILIPROLE.
CYANURIC ACID (excluding its salts and derivatives).
CYAZOFAMID.
CYCLOHEXANONE PEROXIDE.
CYCLOPROTHRIN except in preparations containing 10% or less of cycloprothrin.
CYCLOXYDIM.
CYFLUFENAMID.
CYFLUMETOFEN.
CYFLUTHRIN:
(a) in wettable powders containing 10% or less of cyfluthrin; or
(b) in emulsifiable concentrates containing 2% or less of cyfluthrin; or
(c) in emulsions containing 5% or less of cyfluthrin.
CYHALOFOP‑BUTYL.
CYMIAZOLE.
CYPERMETHRIN in preparations containing 10% or less of cypermethrin.
CYPHENOTHRIN in preparations containing 10% or less of cyphenothrin.
CYPROCONAZOLE except in preparations containing 10% or less of cyproconazole.
CYPRODINIL.
CYTHIOATE for the treatment of animals:
(a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child‑resistant closure; or
(b) in undivided preparations containing 5% or less of cythioate.
2,4‑D in preparations containing 20% or less of 2,4‑D.
DAMINOZIDE.
2,4‑DB.
DECOQUINATE:
DELTAMETHRIN:
(a) when impregnated in plastic resin strip material containing 4% or less of deltamethrin; or
(b) in aqueous preparations containing 5% or less of deltamethrin when no organic solvent other than a glycol is present; or
(c) in wettable granular preparations containing 25% or less of deltamethrin when packed in child‑resistant packaging each containing 3 g or less of the formulation; or
(d) in water‑dispersible tablets each containing 500 mg or less of deltamethrin in child‑resistant packaging; or
(e) in other preparations containing 0.5% or less of deltamethrin;
except:
(f) in factory prepared mosquito nets containing 1% or less deltamethrin; or
(g) in preparations containing 0.1% or less of deltamethrin.
DEMBREXINE in oral preparations for the treatment of animals.
2,4‑DES.
DIAFENTHIURON.
N,N‑DIALLYLDICHLOROACETAMIDE except in preparations containing 10% or less of N,N‑diallyldichloroacetamide.
DIAZINON in dust preparations containing 2% or less of diazinon.
DICAMBA (including its salts and derivatives) in preparations containing 20% or less of dicamba.
DICHLONE.
p‑DICHLOROBENZENE.
DICHLOROISOCYANURIC ACID containing 40% or less of available chlorine, except in:
(a) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:
WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or
(b) liquid preparations containing less than 2% of available chlorine; or
(c) other preparations containing 4% or less of available chlorine.
DICHLOROMETHANE (methylene chloride) except:
(a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10% or less of dichloromethane; or
(b) in other preparations in pressurised spray packs; or
(c) in paints and tinters containing 5% or less of dichloromethane; or
(d) in preparations for human therapeutic use.
DICHLOROPHEN for the treatment of animals.
DICHLORVOS:
(a) when impregnated in plastic resin strip material containing 20% or less of dichlorvos; or
(b) in sustained release resin pellets containing 20% or less of dichlorvos for the treatment of animals; or
(c) in pressurised spray packs containing 10 g or less of dichlorvos.
DICLOBUTRAZOL.
DICLORAN.
DICOFOL.
DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of diethanolamine except in preparations containing 5% or less of diethanolamine.
DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:
(a) in paints or paint tinters; or
(b) in toothpastes or mouthwashes containing more than 0.25% of diethylene glycol; or
(c) in other preparations containing 2.5% or less of diethylene glycol.
DIETHYLENE GLYCOL MONOBUTYL ETHER except in preparations containing 10% or less of diethylene glycol monobutyl ether.
DIETHYLTOLUAMIDE (DEET) except:
(a) in medicines for human therapeutic use containing 20% or less of diethyltoluamide, when compliant with the requirements of the required advisory statements for medicine labels; or
(b) in preparations for human use, other than medicines, containing 20% or less of diethyltoluamide, when labelled with the warning statement:
WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or
(c) in preparations other than for human use containing 20% or less of diethyltoluamide.
DIFENOCONAZOLE.
DIFLUBENZURON.
DIMETHICODIETHYLBENZALMALONATE except when included in preparations containing 10% or less of dimethicodiethylbenzalmalonate.
DIMETHIRIMOL.
DIMETHOMORPH except in preparations containing 10% or less of dimethomorph.
DIMETHYLACETAMIDE in preparations containing 20% or less of dimethylacetamide.
DIMETHYLFORMAMIDE in preparations containing 10% or less of dimethylformamide except in silicone rubber mastic containing 2% or less of dimethylformamide.
3,7‑DIMETHYL‑2,6‑OCTADIENAL and its isomers in cosmetic and household cleaning preparations except in preparations containing 5% or less of 3,7‑dimethyl‑2,6,‑octadienal isomers.
DIMPROPYRIDAZ in preparations containing 13% or less of dimpropyridaz.
DINICONAZOLE.
DINOTEFURAN except in preparations containing 1% or less of dinotefuran.
DI‑n‑PROPYL ISOCINCHOMERONATE except in preparations containing 25% or less of di‑n‑propyl isocinchomeronate.
DIPHENAMID.
DIRECT RED 254 in preparations containing 30% or less of Direct Red 254 calculated as free acid.
DITHIOPYR.
N‑(N‑DODECYL)‑2‑PYRROLIDONE in preparations containing 50% or less of N‑(N‑dodecyl)‑2‑pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N‑(N‑dodecyl)‑2‑pyrrolidone, N‑methyl‑2‑pyrrolidone or N‑(N‑octyl)‑2‑pyrrolidone except in preparations containing 25% or less of designated solvents.
DORAMECTIN for internal use for the treatment of animals, in preparations containing 2% or less of doramectin.
EMAMECTIN in preparations containing 2% or less of emamectin.
EMODEPSIDE in preparations:
(a) containing 2.5% or less of emodepside for the external treatment of animals; or
(b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.
EPOXICONAZOLE.
EPOXY RESINS, LIQUID.
EPRINOMECTIN in preparations containing 0.5% or less of eprinomectin.
ESBIOTHRIN in preparations containing 10% or less of esbiothrin except in pressurised spray packs containing 1% or less of esbiothrin.
ESFENVALERATE in preparations containing 0.1% or less of esfenvalerate.
ESTRADIOL in implant preparations for growth promotion in animals.
1,2‑ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL) OXIRANE AND N‑METHYLMETHANAMINE.
ETHER in preparations containing more than 10% of ether for use in internal combustion engines.
ETHOFUMESATE.
ETHOXYQUIN except in preparations containing 10% or less of ethoxyquin.
ETHOXYSULFURON.
ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:
(a) in paints or paint tinters; or
(b) in toothpastes or mouthwashes containing more than 0.25% of ethylene glycol; or
(c) in other preparations containing 2.5% or less of ethylene glycol.
ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use except in preparations containing 1% or less of ethyl methacrylate as residual monomer in a polymer.
ETRIDIAZOLE.
EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol except in preparations containing 25% or less of eugenol.
EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (Corymbia citriodora), except in preparations containing 40% or less of extract of lemon eucalyptus.
FENARIMOL.
FENBENDAZOLE for the treatment of animals.
FENBUCONAZOLE.
FENCHLORAZOLE‑ETHYL.
FENNEL OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of an instrument made under subsection 3(5A) of the Act relating to medicine advisory statements; or
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 5% or less of methyl chavicol.
FENOPROP.
FENOXAPROP‑ETHYL.
FENOXAPROP‑p‑ETHYL.
FENPYRAZAMINE except in preparations containing 40% or less of fenpyrazamine.
FENSON.
FENTHION:
(a) in preparations containing 25% or less of fenthion when packed in single‑use containers having a capacity of 2 mL or less; or
(b) in preparations containing 10% or less of fenthion.
FIPRONIL in preparations containing 10% or less of fipronil except in preparations containing 0.05% or less of fipronil.
FLAMPROP‑METHYL.
FLAMPROP‑M‑METHYL.
FLAZASULFURON.
FLORASULAM.
FLUAZAINDOLIZINE in preparations containing 50% or less fluazaindolizine.
FLUAZURON.
FLUBENDAZOLE for the treatment of animals.
FLUBENDIAMIDE.
FLUCHLORALIN.
FLUDIOXONIL except in preparations containing 10% or less of fludioxonil.
FLUMETHRIN:
(a) when impregnated in plastic resin strip material containing 3% or less of flumethrin; or
(b) in oil based preparations containing 1% or less of flumethrin.
FLUMICLORAC PENTYL.
FLUOPYRAM except in preparations containing 50% or less of fluopyram.
FLUORIDES in preparations containing 3% or less of fluoride ion except:
(a) in preparations for human use; or
(b) in preparations containing 15 mg/kg or less of fluoride ion.
FLURALANER except when included in Schedule 4.
FLUVALINATE in aqueous preparations containing 25% or less of fluvalinate.
FLUXAPYROXAD.
FORAMSULFURON.
FORMIC ACID (excluding its salts and derivatives) except in preparations containing 0.5% or less of formic acid.
FOSPIRATE when impregnated in plastic resin strip material containing 20% or less of fospirate.
FURALAXYL.
FURATHIOCARB in microencapsulated suspensions containing 50% or less of furathiocarb.
GAMMA‑CYHALOTHRIN in aqueous preparations containing 15% or less of microencapsulated gamma‑cyhalothrin.
GLUFOSINATE‑AMMONIUM.
GLUTARAL in preparations containing 5% or less of glutaral except:
(a) when included in Schedule 2; or
(b) in preparations containing 0.5% or less of glutaral when labelled with the statements:
(A) IRRITANT; and
(B) Avoid contact with eyes.
GLYPHOSATE.
HALOSULFURON‑METHYL.
HEXACONAZOLE except in preparations containing 5% or less of hexaconazole.
HEXAZINONE in preparations containing 25% or less of hexazinone.
HYDRAMETHYLNON in solid baits containing 2% or less of hydramethylnon in welded plastic labyrinths.
HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), except:
(a) toluene and xylene when included in Schedule 6; or
(b) benzene and liquid aromatic hydrocarbons when included in Schedule 7; or
(c) food grade and pharmaceutical grade white mineral oils; or
(d) in solid or semi‑solid preparations; or
(e) in preparations containing 25% or less of designated solvents; or
(f) in preparations packed in pressurised spray packs; or
(g) in adhesives packed in containers each containing 50 g or less of adhesive; or
(h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or
(i) in other preparations when packed in containers with a capacity of 2 mL or less.
HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of hydrochloric acid (HCl) except:
(a) in preparations containing 0.5% or less of hydrochloric acid (HCl); or
(b) for therapeutic use.
HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1% or less of hydrogen fluoride.
HYDROGEN PEROXIDE (excluding its salts and derivatives):
(a) in hair dye preparations containing 12% or less of hydrogen peroxide except in hair dyes containing 6% or less of hydrogen peroxide; or
(b) in other preparations containing 6% (20 volume) or less of hydrogen peroxide except in preparations containing 3% (10 volume) or less of hydrogen peroxide.
HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1% or less of hydrosilicofluoric acid (H2SiF6).
2‑HYDROXYETHYL METHACRYLATE except:
(a) when included in dental restorative preparations for therapeutic use; or
(b) in nail preparations when labelled “Avoid contact with skin”; or
(c) in other preparations containing 0.1% or less of 2‑hydroxyethyl methacrylate when labelled “Avoid contact with skin”.
2‑HYDROXYPROPYL METHACRYLATE in nail preparations except when labelled “Avoid contact with skin”.
IMAZALIL.
IMAZAMOX except in preparations containing 25% or less of imazamox.
IMAZAPIC except in preparations containing 25% or less of imazapic.
IMAZAPYR except in preparations containing 25% or less of imazapyr.
IMAZETHAPYR except in preparations containing 25% or less of imazethapyr.
IMIDACLOPRID in preparations containing 20% or less of imidacloprid except in preparations containing 5% or less of imidacloprid.
IMIPROTHRIN in preparations containing 50% or less of imiprothrin except in preparations containing 10% or less of imiprothrin.
INDOXACARB (includes the R and S enantiomers) in preparations containing 1% or less of indoxacarb.
3‑IODO‑2‑PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10% or less of 3‑iodo‑2‑propynyl butyl carbamate except:
(a) in aqueous preparations not for cosmetic use containing 10% or less 3‑iodo‑2‑propynyl butyl carbamate; or
(b) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3‑iodo‑2‑propynyl butyl carbamate.
IODOSULFURON‑METHYL‑SODIUM.
IPCONAZOLE in preparations containing 2% or less of ipconazole.
IRON COMPOUNDS:
(a) for the treatment of animals (excluding up to 1% of iron oxides when present as an excipient):
(i) in preparations for injection containing 20% or less of iron except in preparations containing 0.1% or less of iron; or
(ii) in other preparations containing 4% or less of iron except:
(A) in liquid or gel preparations containing 0.1% or less of iron; or
(B) in animal feeds or feed premixes; or
(b) for use as agricultural chemicals except in preparations containing 4% or less of iron.
ISOEUGENOL in preparations not intended for skin contact containing 25% or less of isoeugenol except in preparations containing 10% or less of isoeugenol.
ISOPHORONE.
ISOXABEN.
ISOXAFLUTOLE.
IVERMECTIN for use in animals:
(a) in preparations for the prophylaxis of heartworm in cats and dogs; or
(b) in intraruminal implants containing 160 mg or less of ivermectin; or
(c) in preparations containing 3.5% or less of ivermectin when packed in child‑resistant packaging or in packaging approved by the relevant registration authority; or
(d) in other preparations containing 2% or less of ivermectin.
KITASAMYCIN in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.
LAMBDA‑CYHALOTHRIN:
(a) in aqueous preparations containing 1% or less of lambda‑ cyhalothrin; or
(b) in aqueous preparations containing 10% or less of microencapsulated lambda‑cyhalothrin.
LASIODIPLODIA PSEUDOTHEOBROMAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.
LEMON OIL except:
(a) when steam distilled or rectified; or
(b) in preparations for internal use; or
(c) in preparations containing 0.05% or less of lemon oil; or
(d) in soaps or bath or shower gels that are washed off the skin; or
(e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or
(f) in other preparations when packed in containers labelled with the statement:
Application to the skin may increase sensitivity to sunlight.
LEMONGRASS OIL in cosmetic and household cleaning preparations except in preparations containing 5% or less of 3,7‑dimethyl‑2,6‑octadienal.
LEVAMISOLE in preparations containing 15% or less of levamisole for the treatment of animals except:
(a) when included in Schedule 4; or
(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.
LIDOCAINE:
(a) in aqueous gel preparations containing 4.5% or less of lidocaine, for the dermal spray‑on administration to the wounds of animals; or
(b) in injectable preparations containing 2% or less of lidocaine when packaged in a container with a tamper resistant cartridge which can only be dispensed through a rubber ring applicator for tail docking and castration of lambs; or castration of calves.
LIME OIL except:
(a) when steam distilled or rectified; or
(b) in preparations for internal use; or
(c) in preparations containing 0.5% or less of lime oil; or
(d) in soaps or bath or shower gels that are washed off the skin; or
(e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or
(f) in other preparations when packed in containers labelled with the statement:
Application to the skin may increase sensitivity to sunlight.
LINDANE in preparations containing 10% or less of lindane except when included in Schedule 2 or 4.
LOTILANER.
LUFENURON except:
(a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or
(b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.
MACROPHOMINA PHASEOLINA except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.
MADURAMICIN in animal feed premixes containing 1% or less of antibiotic substances.
MAGNESIUM CHLORATE except in preparations containing 10% or less of magnesium chlorate.
MALACHITE GREEN in preparations for veterinary use containing 10% or less of malachite green.
MALATHION in preparations containing 10% or less of malathion except:
(a) for human therapeutic use; or
(b) in dust preparations containing 2% or less of malathion.
MANCOZEB.
MANDESTROBIN except in preparations containing 25% or less of mandestrobin.
MANDIPROPAMID.
MARJORAM OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 50% or less of marjoram oil.
MCPA:
(a) in preparations containing 25% or less of MCPA (acid); or
(b) in preparations containing 50% or less of the salts and esters of MCPA.
MEBENDAZOLE for the treatment of animals:
(a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or
(b) in undivided preparations containing 25% or less of mebendazole.
MECLOFENAMIC ACID for the treatment of animals.
MECOPROP in preparations containing 2% or less of mecoprop.
MEFENPYR‑DIETHYL.
MEFENTRIFLUCONAZOLE except in preparations containing 7.5% or less of mefentrifluconazole.
MEPIQUAT.
MERCAPTAMINE in cosmetic preparations containing 6% or less of mercaptamine except in preparations containing 1% or less of mercaptamine.
MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations containing 20% or less of mercaptoacetic acid or its salts (as mercapturic acid), except in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid)
MESOTRIONE.
METAFLUMIZONE.
METALAXYL in preparations containing 35% or less of metalaxyl.
METALDEHYDE in preparations containing 2% or less of metaldehyde.
METAZACHLOR.
METHABENZTHIAZURON.
METHANOL (excluding its derivatives) in preparations containing 10 % or less of methanol except:
(a) when included in Schedule 10; or
(b) in preparations containing 2% or less of methanol; or
(c) when methanol is present only as a denaturant of ethanol.
METHENAMINE in cosmetic preparations, except in preparations containing 0.15% or less of methenamine.
METHIOCARB in pelleted preparations containing 2% or less of methiocarb.
METHIOZOLIN.
METHOXYCHLOR.
METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) except:
(a) when included in preparations or admixtures; or
(b) when packed in containers having a capacity of more than 5 L.
METHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners”.
METHYLENE BLUE in preparations for veterinary use containing 50% or less of methylene blue.
METHYL ETHYL KETONE except in preparations containing 25% or less of designated solvents.
METHYL ETHYL KETONE PEROXIDE.
METHYL ISOAMYL KETONE except in preparations containing 25% or less of designated solvents.
METHYL ISOBUTYL KETONE except in preparations containing 25% or less of designated solvents.
N‑METHYL‑2‑PYRROLIDONE:
(a) when packed in single use containers having a capacity of 2 mL or less; or
(b) in preparations containing 50% or less of N‑methyl‑2‑pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N‑methyl‑2‑pyrrolidone, N‑(N‑octyl)‑2‑pyrrolidone or N‑(N‑dodecyl)‑2‑pyrrolidone except in preparations containing 25% or less of designated solvents.
METHYL SALICYLATE in preparations containing 25% or less of methyl salicylate except:
(a) in preparations for therapeutic use; or
(b) in preparations containing 5% or less of methyl salicylate.
2‑METHYLTHIO‑4‑(2‑METHYLPROP‑2‑YL) AMINO‑6‑CYCLOPROPYLAMINO‑5‑ TRIAZINE.
METIRAM.
METOBROMURON except in preparations containing 50% or less of metobromuron.
METOFLUTHRIN:
(a) in impregnated fabric mosquito repellent preparations for use in a vaporiser containing 15 mg or less of metofluthrin per disk; or
(b) when impregnated into a polyethylene slow release matrix containing 250 mg or less of metofluthrin.
METOLACHLOR.
METRAFENONE in preparations containing 50% or less of metrafenone.
MILBEMECTIN in preparations containing 1% or less of milbemectin.
MILBEMYCIN OXIME
(a) for the prophylaxis of heartworm in dogs and cats; or
(b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with afoxolaner, in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit.
MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.
MONEPANTEL.
MONOETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of monoethanolamine except:
(a) when included in Schedule 4; or
(b) in preparations containing 5% or less of monoethanolamine.
MORANTEL in preparations containing 25% or less of morantel except in preparations containing 10% or less of morantel.
MOXIDECTIN:
(a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5% or less of moxidectin; or
(b) in preparations for external use for the treatment of cats and dogs, containing 2.5% or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or
(c) for internal use for the treatment of animals:
(i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or
(ii) in other preparations containing 2% or less of moxidectin.
MYCLOBUTANIL.
NAA except in preparations containing 25% or less of NAA.
NALED when impregnated in plastic resin strip material containing 20% or less of naled.
NAPTALAM.
NEOSCYTALIDIUM NOVAEHOLLANDIAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.
NETOBIMIN for the treatment of animals, in preparations containing 12.5% or less of netobimin.
NITRIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of nitric acid (HNO3) except in preparations containing 0.5% or less of nitric acid.
NITROSCANATE for the treatment of animals.
NONANOIC ACID:
(a) when used in a pesticide; or
(b) in other preparations except in preparations containing 10% or less of nonanoic acid.
NONOXINOL 9 in preparations containing 25% or less of nonoxinol 9 except:
(a) when labelled with the statements:
(i) IRRITANT; and
(ii) Avoid contact with eyes; or
(b) in preparations containing 12.5% or less of nonoxinol 9; or
(c) in preparations for human use.
NORBORMIDE.
NUTMEG OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 50% or less of nutmeg oil.
N‑OCTYL BICYCLOHEPTENE DICARBOXIMIDE except in preparations containing 10% or less of N‑octyl bicycloheptene dicarboximide.
N‑(N‑OCTYL)‑2‑PYRROLIDONE in preparations containing 50% or less of:
(a) N‑(N‑octyl)‑2‑pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N‑(N‑octyl)‑2‑pyrrolidone, N‑methyl‑2‑pyrrolidone; or
(b) N‑(N‑dodecyl)‑2‑pyrrolidone except in preparations containing 25% or less of designated solvents.
OLEANDOMYCIN in animal feed premixes for growth promotion.
OMETHOATE in pressurised spray packs containing 0.2% or less of omethoate.
ORANGE OIL (BITTER) except:
(a) when steam distilled or rectified; or
(b) in preparations for internal use; or
(c) in preparations containing 1.4% or less of orange oil (bitter); or
(d) in soaps or bath or shower gels that are washed off the skin; or
(e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or
(f) in other preparations when packed in containers labelled with the statement:
Application to the skin may increase sensitivity to sunlight.
OXADIARGYL.
OXADIXYL.
OXANTEL EMBONATE for the treatment of animals.
OXFENDAZOLE for the treatment of animals.
OXIBENDAZOLE for the treatment of animals.
OXYCARBOXIN.
OXYTETRACYCLINE in preparations:
(a) for topical application to animals for ocular use only; or
(b) containing 40% or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
OXYTHIOQUINOX.
PACLOBUTRAZOL.
PENCONAZOLE.
PENDIMETHALIN.
PENFLUFEN.
PENTHIOPYRAD except in preparations containing 20% or less of penthiopyrad.
PERACETIC ACID in concentrations of 10% or less of peracetic acid.
PERMETHRIN (excluding preparations for human therapeutic use):
(a) in preparations containing 25% or less of permethrin; or
(b) in preparations for external use, for the treatment of dogs, containing 50% or less of permethrin when packed in single use containers having a capacity of 4 mL or less;
except in preparations containing 2% or less of permethrin.
PETROL except preparations containing 25% or less of petrol.
PHENAZONE for the external treatment of animals.
PHENISOPHAM.
PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15% or less of such substances, except in preparations containing 1% or less of phenol and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol.
PHENYL METHYL KETONE except in preparations containing 25% or less of designated solvents.
o‑PHENYLPHENOL except in preparations containing 5% or less of o‑phenylphenol.
PHOSPHONIC ACID (excluding its salts and derivatives) except in preparations containing 10% or less of phosphonic acid (H3PO3).
PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35% or less of phosphoric acid (H3PO4) except:
(a) in preparations containing 15% or less of phosphoric acid (H3PO4); or
(b) in solid or semi‑solid preparations; or
(c) in professional dental kits.
o‑PHTHALALDEHYDE in preparations containing 1% or less of o‑phthalaldehyde.
PICARIDIN except in preparations containing 20% or less of picaridin.
PINE OILS in preparations containing 25% or less of pine oils when packed and labelled as a herbicide.
PINOXADEN in preparations containing 10% or less of pinoxaden.
PIPERAZINE for animal use.
PIRIMICARB in preparations containing 0.5% or less of pirimicarb.
POLIXETONIUM SALTS in preparations containing 60% or less of polixetonium salts except in preparations containing 1% or less of polixetonium salts.
POLYETHANOXY (15) TALLOW AMINE.
POLYOXIN D ZINC SALT.
POLY(OXY‑1,2‑ETHANEDIYL), α ‑[2‑[(2‑HYDROXYETHYL)AMINO]‑2‑OXOETHYL]‑ α ‑HYDROXY‑,MONO‑C13‑15‑ALKYL ETHERS.
POTASSIUM CHLORATE except:
(a) when included in Schedule 2; or
(b) in preparations containing 10% or less of potassium chlorate.
POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of potassium hydroxide being:
(a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
(b) liquid or semi‑solid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.
POTASSIUM METABISULPHITE when packed for domestic use except in preparations containing 10% or less of potassium metabisulphite.
POTASSIUM NITRITE in preparations containing 1% or less of potassium nitrite except:
(a) in preparations containing 0.5% or less of potassium nitrite;
(b) when present as an excipient in preparations for therapeutic use; or
(c) in aerosols.
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:
(a) solid preparations, the pH of which in a 10 g/L aqueous solution is less than 2.5; or
(b) liquid or semi‑solid preparations, the pH of which is less than 2.5.
POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.
PRALLETHRIN (cis:trans=20:80) in preparations containing 10% or less of prallethrin except in insecticidal mats containing 1% or less of prallethrin.
PROFOXYDIM except in preparations containing 20% or less of profoxydim.
PROGESTERONE:
(a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or
(b) in implant preparations for growth promotion in cattle.
PROHEXADIONE CALCIUM.
PROMETRYN.
PROPAMOCARB.
PROPANIL.
PROPAQUIZAFOP.
PROPICONAZOLE in preparations containing 20% or less of propiconazole.
PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80% or less of propionic acid, except:
(a) in preparations containing 30% or less of propionic acid; or
(b) for therapeutic use.
PROPOXUR:
(a) when impregnated in plastic resin strip material containing 10% or less of propoxur; or
(b) in dust preparations containing 3% or less of propoxur; or
(c) in granular sugar‑based fly baits containing 1% or less of propoxur, a dark colouring agent and a separate bittering agent; or
(d) in pressurised spray packs containing 2% or less of propoxur; or
(e) in printed paper sheets for pest control containing 0.5% or less of propoxur and in any case not more than 100 mg of propoxur per sheet.
n‑PROPYL ALCOHOL in preparations containing 10% or less of n‑propyl alcohol except:
(a) in preparations containing 5% or less of n‑propyl alcohol; or
(b) in preparations for cosmetic or therapeutic use other than in spray form.
PROPYZAMIDE.
PROTHIOCONAZOLE‑DESCHLORO except in preparations containing 0.5% or less of prothioconazole‑deschloro.
PROTHIOCONAZOLE‑TRIAZOLIDINETHIONE except in preparations containing 0.5% or less of prothioconazole‑triazolidinethione.
PYMETROZINE.
PYRACLOSTROBIN.
PYRAFLUFEN‑ETHYL.
PYRASULFOTOLE.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except:
(a) in preparations for human therapeutic use; or
(b) in preparations containing 10% or less of such substances.
PYRIDABEN in preparations containing 25% or less of pyridaben.
PYRIFENOX.
PYRITHIOBAC SODIUM.
PYRITHIONE ZINC in paints containing 0.5% or less of pyrithione zinc calculated on the non‑volatile content of the paint except in paints containing 0.1% or less of pyrithione zinc calculated on the non‑volatile content of the paint.
PYRIOFENONE in preparations containing 30% or less of pyriofenone.
QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20% or less of quaternary ammonium compounds except:
(a) when separately specified in these Schedules; or
(b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
(c) in preparations containing 5% or less of such quaternary ammonium compounds.
QUINCLORAC.
QUININE in preparations for veterinary use containing 1% or less of quinine.
QUINTOZENE.
QUIZALOFOP‑p‑ETHYL in aqueous preparations containing 40% or less of
quizalofop‑p‑ethyl.
RACTOPAMINE in animal feed premixes containing 10% or less of ractopamine.
RESMETHRIN in preparations containing 10% or less of resmethrin.
RIMSULFURON.
ROBENIDINE except in preparations containing 20% or less of robenidine.
ROSIN when packaged for use as a soldering flux or in flux‑cored solder.
SAFLUFENACIL in water dispersible granules or a water‑based suspension concentrate.
SALICYLANILIDE.
SAROLANER for veterinary use in divided preparations each containing 120 mg or less of sarolaner per dosage unit.
SEDAXANE.
SELAMECTIN except in preparations containing 12% or less of selamectin.
SETHOXYDIM.
SIDURON.
SILICOFLUORIDES in preparations containing 3% or less of fluoride ion except:
(a) barium silicofluoride when separately specified in this Schedule; or
(b) in preparations containing 15 mg/kg or less of fluoride ion.
SINBIOALLETHRIN in preparations containing 10% or less of sinbioallethrin except in preparations containing 1% or less of sinbioallethrin.
SODIUM BROMIDE except when included in Schedule 4.
SODIUM CHLORATE except in preparations containing 10% or less of sodium chlorate.
SODIUM DIACETATE except in preparations containing 60% or less of sodium diacetate.
SODIUM DODECYLBENZENE SULFONATE except in preparations containing 30% or less of sodium dodecylbenzene sulfonate.
SODIUM HYDROGEN SULFATE except in preparations containing 10% or less of sodium hydrogen sulfate.
SODIUM HYDROSULFITE when packed for domestic use except in preparations containing 10% or less of sodium hydrosulfite.
SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of sodium hydroxide being:
(a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
(b) liquid or semi‑solid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.
SODIUM LAURETH‑6 CARBOXYLATE except in preparations containing 1% or less of sodium laureth‑6 carboxylate.
SODIUM METABISULPHITE when packed for domestic use except in preparations containing 10% or less of sodium metabisulphite.
SODIUM NITRITE in preparations containing 1% or less of sodium nitrite except:
(a) in preparations containing 0.5% or less of sodium nitrite; or
(b) when present as an excipient in preparations for therapeutic use; or
(c) in aerosols.
SODIUM PERCARBONATE (CAS No. 15630‑89‑4) in preparations containing 35% or less of sodium percarbonate except in preparations containing 15% or less of sodium percarbonate.
SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use except in preparations containing 10% or less of sodium polystyrene sulphonate.
SODIUM STANNATE except in preparations for cosmetic use containing 1% or less of sodium stannate.
SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.
SPINETORAM.
SPINOSAD except in aqueous suspensions containing 25% or less of spinosad.
SPIROMESIFEN for agricultural use.
STAR ANISE OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 50% or less of star anise oil.
STYRENE (excluding its derivatives).
SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFADIAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFADIMIDINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFAMERAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of sulfamic acid (H3NO3S).
SULFATHIAZOLE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFOMETURON‑METHYL.
SULFOXAFLOR in preparations containing 25% or less of sulfoxaflor.
SYMPHYTUM spp. (Comfrey) for dermal therapeutic or dermal cosmetic use.
2,3,6‑TBA.
TDE (1,1‑dichloro‑2,2‑bis[4‑chlorophenyl]ethane) in preparations containing 10% or less of TDE.
TEBUCONAZOLE.
TEBUFENOZIDE.
TEFLUTHRIN in preparations containing 2% or less of tefluthrin.
TEMEPHOS:
(a) in liquid preparations containing 10% or less of temephos; or
(b) in powders containing 2% or less of temephos; or
(c) in preparations containing 40% or less of temephos when packed in single use containers having a capacity of 2 mL or less.
TEPRALOXYDIM.
TERBUTRYN.
TETRACHLOROETHYLENE in preparations containing 5% or less of tetrachloroethylene except:
(a) when included in Schedule 2; or
(b) in preparations for the treatment of animals; or
(c) when absorbed into an inert solid.
TETRACHLORVINPHOS except in animal feeds containing 0.2% or less of tetrachlorvinphos.
TETRACONAZOLE in preparations containing 20% or less of tetraconazole.
TETRACYCLINE in preparations:
(a) for topical application to animals for ocular use only; or
(b) containing 40% or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
TETRAMETHRIN [(R, cis): (R, trans) = 20:80] except in pressurised spray packs.
TETRANILIPROLE except in preparations containing 20% or less tetraniliprole.
THIABENDAZOLE:
(a) for the treatment of animals; or
(b) when packed and labelled for use as a fungicide except in preparations containing 50% or less of thiabendazole.
THIAMETHOXAM in preparations containing 60% or less of thiamethoxam.
THIAZOPYR.
THIFENSULFURON.
THIOBENCARB.
THIODICARB in pelleted preparations containing 1.5% or less of thiodicarb.
THIOPHANATE‑METHYL in preparations containing 25% or less of thiophanate‑methyl.
THYME OIL except:
(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or
(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c) in preparations containing 50% or less of thyme oil.
TIGOLANER in preparations containing 10% or less of tigolaner.
TIOCARBAZIL.
TOLCLOFOS‑METHYL.
TOLTRAZURIL.
TOPRAMEZONE
TRALKOXYDIM.
TRENBOLONE in implant preparations for growth promotion in animals.
TRIADIMEFON in wettable powders containing 25% or less of triadimefon.
TRIADIMENOL.
TRI‑ALLATE.
TRIBENURON‑METHYL.
TRICHLOROACETIC ACID, alkali salts of.
1,1,1‑TRICHLOROETHANE except:
(a) in preparations packed in pressurised spray packs; or
(b) in preparations containing 25% or less of designated solvents; or
(c) in preparations, other than writing correction fluids or thinners for writing correction fluids in containers having a capacity of 50 mL or less; or
(d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:
(i) the word “Trichloroethane” written in letters not less than 1 mm in height and in distinct contrast to the background; and
(ii) the expression:
WARNING – DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;
written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.
TRIDIPHANE.
TRIETAZINE.
TRIFLOXYSTROBIN.
TRIFLUDIMOXAZIN except in preparations containing 12.5% or less.
TRIFLUMIZOLE.
TRIFLUMURON.
TRIISOPROPANOLAMINE LAURYL ETHER SULFATE except in preparations containing 30% or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:
(a) Avoid contact with eyes and skin; and
(b) Wash hands after handling.
TRINEXAPAC‑ETHYL except:
(a) when packed in a sealed water‑soluble measure pack; or
(b) in solid preparations containing 25% or less of trinexapac‑ethyl in packs of 50 g or less.
3,6,9‑TRIOXAUNDECANEDIOIC ACID except in preparations containing 5% or less of 3,6,9‑trioxaundecanedioic acid, the pH of which is 3.5 or greater.
TRITICONAZOLE.
TROLAMINE (excluding its salts and derivatives) except:
(a) when in Schedule 4; or
(b) in preparations containing 5% or less of trolamine.
TURPENTINE OIL except in preparations containing 25% or less of turpentine oil.
VIRGINIAMYCIN in animal feed additives containing 1% or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.
VERNOLATE.
WARFARIN in rodent baits containing 0.1% or less of warfarin.
ZINEB.
Schedule 6—Poisons
Note: See section 16, subsection 46(2), section 49, subsection 54(3) and sections 55 and 61.
ABAMECTIN:
(a) in preparations for pesticidal use containing 4% or less of abamectin except when included in Schedule 5; or
(b) in slow‑release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.
ACEPHATE.
ACETAMIPRID except in preparations containing 1% or less of acetamiprid.
ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) except when included in Schedule 2.
ACETIC ANHYDRIDE excluding its derivatives.
ACIFLUORFEN.
ACINITRAZOLE except in preparations containing 20% or less of acinitrazole.
ACLONIFEN.
ALBENDAZOLE for the treatment of animals except:
(a) when included in Schedule 5; or
(b) in intraruminal implants each containing 3.85 g or less of albendazole.
ALDRIN.
ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non‑domestic use:
(a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
(b) in liquid or semi‑solid automatic dishwashing preparations, the pH of which is more than 12.5.
ALKOXYLATED FATTY ALKYLAMINE POLYMER except:
(a) when included in Schedule 5; or
(b) in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.
ALLETHRIN except:
(a) when included in Schedule 5; or
(b) in insecticidal mats containing 20% or less of allethrin; or
(c) in other preparations containing 1% or less of allethrin.
ALLYL ESTERS (excluding derivatives) being:
(a) ALLYL CYCLOHEXANEACETATE (CAS No. 4728‑82‑9); or
(b) ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705‑87‑5); or
(c) ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142‑19‑8); or
(d) ALLYL HEXANOATE (CAS No. 123‑68‑2); or
(e) ALLYL ISOVALERATE (CAS No. 2835‑39‑4); or
(f) ALLYL NONANOATE (CAS No. 7493‑72‑3); or
(g) ALLYL OCTANOATE (CAS No. 4230‑97‑1); or
(h) ALLYL PHENYLACETATE (CAS No. 1797‑74‑6); or
(i) ALLYL TRIMETHYLHEXANOATE (CAS No. 68132‑80‑9);
in preparations containing 0.1% or less of free allyl alcohol by weight of allyl ester except in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl esters.
ALPHA‑CYPERMETHRIN:
(a) in aqueous preparations containing 30% or less of alpha‑cypermethrin; or
(b) in other preparations containing 10% or less of alpha‑cypermethrin;
except when included in Schedule 5.
AMICARBAZONE.
AMIDITHION.
AMIDOPROPYL BETAINES except:
(a) in cosmetic wash‑off preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines when labelled with a warning to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER;
in cosmetic leave‑on preparations containing 1.5% or less of amidopropyl betaines; or
(b) in other preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines, when labelled with warnings to the following effect:
(i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
(ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.
2‑AMINO‑6‑CHLORO‑4‑NITROPHENOL in hair dye and eyebrow/eyelash colouring preparations, except:
(a) in preparations containing 2% or less of 2‑amino‑6‑chloro‑4‑nitrophenol when applied directly to the hair, or containing 2% or less of 2‑amino‑6‑chloro‑4‑nitrophenol after mixing and when the immediate container and primary pack are labelled with the following statements:
(i) KEEP OUT OF REACH OF CHILDREN; and
(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;
(b) in eyelash and eyebrow tinting products containing 1.5% or less of 2‑amino‑6‑chloro‑4‑nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statement:
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;
written in letters not less than 1.5mm in height.
4‑AMINO‑m‑CRESOL in hair dyes and eyebrow/eyelash colouring preparations except:
(a) in hair dye preparations containing 1.5% or less of 4‑amino‑m‑cresol after mixing for use when the immediate container and primary pack are labelled with the following statements:
(i) KEEP OUT OF REACH OF CHILDREN; and
(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;
written in letters not less than 1.5mm in height; or
(b) in eyelash and eyebrow tinting products containing 1.5% or less of 4‑amino‑m‑cresol after mixing for use when the immediate container and primary pack are labelled with the following statement:
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;
written in letters not less than 1.5mm in height.
2‑AMINO‑5‑ETHYLPHENOL in hair dye preparations except in preparations containing 1% or less of 2‑amino‑5‑ethylphenol when the immediate container and primary pack are labelled with the following statements:
(a) KEEP OUT OF REACH OF CHILDREN; and
(b) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes and eyebrows; to do so may be injurious to the eye;
written in letters not less than 1.5 mm in height.
4‑AMINO‑2‑HYDROXYTOLUENE in hair dyes and eyebrow/eyelash colouring products except:
(a) in hair dye preparations containing 1.5% or less of 4‑amino‑2‑hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statements:
(i) KEEP OUT OF REACH OF CHILDREN; and
(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;
written in letters not less than 1.5mm in height; or
(b) in eyelash and eyebrow tinting products containing 1.5% or less of 4‑amino‑2‑hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statement:
WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;
written in letters not less than 1.5mm in height.
AMINOCARB in preparations containing 25% or less of aminocarb.
AMINOETHOXYVINYLGLYCINE except in preparations containing 15% or less of aminoethoxyvinylglycine.
1‑AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.